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Obesity can be defined as an excess of body weight due to an imbalance between food intake and energy 
expenditure1, leading to an accumulation of white adipose tissue (WAT) with adipocytes hypertrophy and 
hyperplasia2. Nowadays, obesity represents one of the most common issues of the public welfare in the 
majority of developed countries, and epidemiologic data about the high incidence and prevalence of this 
pathological condition are alarming. Indeed, obesity was defined by the World Health Organization (WHO) 
as a global epidemic1, and as much as 9,8% of the world population is currently obese3. Obesity is generally 
classified by the body mass index (BMI)1, a simple calculation developed by a Belgian statistician, Adolphe 
Quetelet, in 1871: it represents the ratio between a subject’s weight and his height squared (kg/m2). The 
classification according to the BMI is therefore the following: under-weight: ≤ 18.0 kg/m2; normo-weight: 
18,1-25,0; over-weight: 25,1-30,0; obese: 30,1-35,0; severe obesity: > 35,1.  
The BMI, however, does not take into account the precise fat distribution and for this reason other 
measurements such as the hip-waist ratio or body fat percentage are useful to clinically define the obesity 
grade. The excess of body weight is associated in general with a reduction of life expectancy4 since it leads 
to several pathologies, such as diabetes mellitus type II, cardiovascular diseases, different types of cancer, 
obstructive sleep apnea and many more4. There are several causes leading to obesity: an imbalanced diet, 
sedentary life and genetic predisposition are all factors participating to body weight gain5-6. Particularly 
interesting is the opinion by which obesity can be a maladaptation to environmental stress, which would 
lead to an imbalance of the neuro-endocrine axis7. Although imbalances of several hormonal systems have 
been described as critical in the pathophysiology of obesity, it is still unclear which alteration represents a 
cause and which an effect.  
The identification of precise circulating biomarkers of obesity and their involvement in its pathophysiology 
could be essential to early diagnose potential co-morbidities and especially to better address the 
development of future therapeutic strategies. Currently, it is well known that several hormonal signals, 
such as for instance leptin8, ghrelin9 or adiponectin8 among others, are altered in obese subjects. Some of 
these changes are secondary to obesity, while others could play an important role in its pathogenesis. 
Furthermore, published evidence also shows that other molecules, such as endocannabinoids (ECs) or 
steroid hormones might have a role in the physiopathology of obesity10-11. However, while alterations of 
several hormones have been well characterized in the obese population, a precise and reliable 
quantification of steroid hormones, in particular the androgens sub-group, and of the ECs is still lacking. 
Indeed, in most cases, it is not easy to perform an accurate measurement of these molecules: often, these 
analytes circulate at very low concentrations and their intra-group different chemical natures make the 
development of multi-analytes quantification methods an analytical challenge.  
The most significant revolution in the recent history of analytical chemistry concerning quantification of 
bio-molecules is represented by the development of techniques based on mass spectrometry. These new 
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analytical tools allow us to have reliable and trustworthy results essential for both clinical analyses and 
scientific research, representing an authentic turning point for the entire scientific progress. In the last 
twenty years, the development of chromatography coupled with mass spectrometry is making possible the 
quantification of an increasing number of different molecules, which are not suitable to be measured with 
traditional techniques, such as for instance immunoassays12. This new technique joins the accurate 
separation of biological matrices components typical of chromatography with the specific identification and 
quantification of each molecule performed by the mass spectrometry13. Initially, quantification methods 
were developed using gas chromatography coupled with mass spectrometry (GC/MS); more recently, the 
quantification of a wide range of chemically different molecules has been made possible by coupling the 
mass spectrometry with the more versatile liquid chromatography13. The advent of these new technical 
devices performing accurate, sensitive and rapid analyses, has allowed discovering new markers, screening 
entire populations and increasing the number of molecules that can be measured and related with 
different pathophysiological mechanisms. The discovery or the better characterization of circulating 
biomarkers could lead, among others, to important progress in the field of obesity research.  
In this context, I have been interested in improving the quantification of two types of circulating markers 
involved in obesity: steroid hormones and ECs, since the unavailability of sensitive and specific quantitative 
methods for these two classes of compounds has limited their investigation. My thesis will be therefore 
divided in two parts, to illustrate the studies that I carried out with chromatography tandem mass 
spectrometry for the measurement of these two groups of molecules.  
In the first part of the present thesis (chapter two), which was carried out at the Center of Applied 
Biomedical Research (CRBA) in Bologna, we developed a sensitive, specific and accurate quantification 
method for nine steroid hormones using a liquid chromatography tandem mass spectrometry (LC-MS/MS) 
system. After the validation, the developed method was used first for a comparative study with 
immunometric methods, routinely used in the Laboratorio Centralizzato of the Policlinico Sant’Orsola 
Malpighi in Bologna to measure circulating steroids in patients. After the correlation study, we performed 
steroid measurements in a healthy population (179 males and 177 females), redefining circulating 
reference intervals. Indeed, steroids circulating reference intervals that have been used so far were 
established more than 50 years ago using radioimmunoassays (RIA); since our correlation study highlighted 
several limitations of this quantitative method, a redefinition of the reference intervals was needed. 
Afterwards, to test the involvement of steroid hormones in obesity, the developed method was used to 
define differences in circulating steroid hormones concentrations in three populations: normo-weight 
subjects (BMI: 18,1 – 25,0), over-weight subjects (BMI: 25,1 – 30,0) and obese subjects (BMI≥ 30,1). Indeed, 
among other alterations, visceral obesity, which is characterized by the accumulation of adipose mass in 
the visceral cavity, is associated with a hyper-activation of the hypothalamic-pituitary-adrenal axis (HPA) 
18 
 
and the impairment of the hypothalamic-pituitary-gonadal axis (HPG), leading to an altered production of 
steroid hormones, in particular glucocorticoids and androgens10. Our study had therefore as aim to better 
elucidate the real role of these molecular alterations in obesity. 
In the second part of the project (chapter three), which was developed at the Neurocentre Magendie 
INSERM U862 in Bordeaux, we evaluated another class of circulating molecules whose levels are altered in 
obese subjects: the ECs. In the last twenty years, the relationship between ECs and obesity has been object 
of extensive research11-14. Since the beginnings of 90s an increasing number of studies have attempted to 
clarify the involvement of the endocannabinoid system (ECS) in the context of food intake and energy 
balance14. While, however, alterations of the ECS in obesity animal models have been extensively 
documented15-16, the role of this system in the pathophysiology of human obesity is still poorly defined. The 
first methods to quantify ECs in plasma were developed almost twenty years ago, and an imbalance of 
these circulating molecules in humans was highlighted17-19. Nowadays we know that plasma ECs are higher 
in obese patients compared to normo-weight subjects and that these levels correlate with parameters 
related to obesity19-20, despite the fact that the physiological role of these molecules is still unclear. 
Furthermore, it was shown that after a diet-induced weight loss, circulating ECs tend to decrease21, further 
confirming that this alteration is strictly related to the obesity condition. In addition, it was also recently 
demonstrated that the plasma EC anandamide (AEA) levels are strongly related to the feeding status22, 
increasing during fasting and decreasing after a meal, thus showing a profile of a meal initiator signal. 
Based on this evidence, we decided to carry out a project aimed at deifying alterations of circulating ECs in 
obese patients after a weight loss induced by bariatric surgery, currently the most effective long-term 
treatment for obesity. We measured basal and dynamic ECs plasma levels in 12 patients with severe 
obesity (BMI > 40 kg/m2 or BMI > 35 kg/m2 with obesity associated complications) before, one month after 
and six months after the Roux-en-Y gastric bypass (RYGB) intervention, currently one of the most 
performed types of bariatric surgery23.  
Moreover, to assess the recovery of circulating normal levels after a weight loss and a potential link with 
the ECS, we measured also androgens, the group of steroids involved particularly in male sexual functions, 
in our male patients undergoing RYGB. Indeed, data from animal studies have showed a link between the 
ECS and androgens, including the presence of the ECS on all the three levels of the HPG and the 
involvement of both ECs and androgens in the same biological functions, such as for instance 
reproduction24. 
In particular, we measured testosterone and dehydroepiandrosterone (DHEA) to assess whether after RYGB 
and the consequent weight loss, the HPG functionality and normal circulating levels of androgens are 
recovered. The eventual changes of circulating ECs and androgens could be then correlated to 
anthropometric parameters, such as the BMI, and between each other to determine if these two plasma 
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molecules altered by obesity can have a direct relationship. In humans, this link has never been tested, 
especially in relation to this pathology. 
 
All together the findings illustrated in this thesis project will help better define the role of steroid 
hormones, in particular the androgen sub-group, and ECs in the framework of obesity in humans and the 
role that each type of molecule might have in its pathophysiology. 
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INTRODUCTION TO LIQUID CHROMATOGRAPHY TANDEM 
MASS SPECTROMETRY 
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I. Chromatography 
Ia. Historical Notes  
 
“I decided to build a machine equivalent to an array of about 200 separating funnels”. 
(Archer John Porter Martin) 
 
Chromatography is an analytical technique used to separate a complex matrix in single components, 
determining the separation on different characteristics of the molecules.  
The origin of chromatography dates back to the late 19th century. The first “chromatography-like” 
technique is attributed to a Russian botanist, Mikhail Tsvet, that in 1890 had used a liquid-adsorption 
column containing calcium carbonate to separate plants components based on their different colors25: 
green for the chlorophyll, orange for the carotenes and yellow for the xanthophylls (figure 1.1), giving to 
this technique the name chromatography, literally “color writing”.  
 
 
 
 
Figure 1.1: first chromatography developed by Tsvet. 
 
 
In 1922 LS Palmer used the principles developed by Tsvet to separate carotenoids present in milk, butter 
and other matrices26. During the first half of the 20th century, the separation principle based on different 
characteristics of the material components was used to analyze the composition of other natural products. 
In 1943 Archer John Porter Martin and Richard Laurence Millington Synge developed the partition 
chromatography that was used for the first time to separate different amino-acids27, obtaining for this 
innovation the Nobel Prize in chemistry in 1952. Since then, the technology advanced rapidly. In 1947, Fritz 
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and Cremer developed the first type of gas chromatography28 (GC), characterized by a gaseous mobile 
phase, while the first high pressure liquid chromatography (HPLC), using a liquid solution as mobile phase, 
was built by Csaba Horvath in 1970, achieving the analytical separation also for biological compounds which 
could not be vaporized. After that, HPLC quickly improved with the development of new column packing 
materials. The history of chromatography is represented in figure 1.2. 
Nowadays chromatography is an indispensable analytical technology used worldwide in every branch of 
physical and biological science to separate chemical compounds for any type of qualitative and quantitative 
analysis. This technique is constantly improving, allowing the separation of increasingly greater number of 
molecules.  
 
                         
Figure 1.2: Chromatography time-line. 
 
23 
 
Ib. Technical Notes  
The separation of mixture constituents using chromatography is achieved by their different distribution 
between two different phases over time (figure 1.3). Every chromatographic system is characterized by:  
- Stationary phase: is the phase immobilized on the support particles, or on the inner wall of 
column tubing. Its interaction with the analytes determines the separation.  
- Mobile phase: is the phase carrying the analytes through the stationary phase, moving in a specific 
direction. It can be a gas (GC) going through the stationary phase under pressure, or a liquid (liquid 
chromatography, LC) going through the stationary phase by gravity or using a pump system. 
 
 
 
Figure 1.3: Analytes repartition between stationary and mobile phase.  
 
 
The choice of the suitable stationary and mobile phase depends on the physical-chemical proprieties of the 
analytes to separate. 
There are different types of chromatography based on the attractive force used for the separation: 
 Normal phase: for polar compounds. The stationary phase is polar while the mobile phase is non-
polar. The separation is based on the analyte adsorption on the polar surface of the stationary 
phase. 
 Reversed phase: for non-polar compounds. The stationary phase is non-polar while the mobile 
phase is polar. The separation is based on analyte partitioning between the mobile and stationary 
phase through hydrophobic interactions.  
 Ion Exchange: for ionic compounds. The separation is  based  on ionic  interactions of  the  analyte  
with  the  ionic  group  on  the  stationary  phase. 
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 Size Exclusion: is a physical separation process. The stationary phase is a porous matrix and the 
separation is based on the different size and shape of analytes. 
The result of a chromatographic analysis, as visual output, is the chromatogram, in which every peak 
corresponds to a different analyte. On the x-axis there is the time and on the y-axis there is the intensity of 
the signal obtained by the detector. 
 
Ic. Chromatographic parameters  
The chromatographic analysis performance is characterized by different parameters:  
- Retention time: is the characteristic time that each analyte spends to pass through the 
chromatographic system under determinate conditions.  
- Capacity factor: is the relative time that the analyte spends to go out from the column compared to 
an analyte that hasn’t affinity for the stationary phase. This parameter is relevant because, unlike 
the retention time, it is independent of the column dimension and the mobile phase flow, so it can 
be used to compare analytes performance in different chromatographic systems.  
- Efficiency: it evaluates peaks sharp shape and symmetry. Usually, it can be estimated with the 
“theorical plate theory”. The plate model supposes that the chromatographic column contains a 
large number of separate layers, called theoretical plates. They represent the hypothetical zone in 
which the analyte establishes an equilibrium between stationary and mobile phase moving down 
the column from one plate to the next. Giving that, having many of them increases the efficacy of 
the separation. 
- Selectivity factor: it is the difference in retention time of one molecular band relative to another. It 
is an indicator of the ability of the chromatographic system to separate two different analytes. 
- Resolution: it shows the separation efficiency between two peaks in relation to their width. It is 
calculated as the ratio between the difference of retention time between two peaks and their 
width on average. 
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Id. High Pressure liquid chromatography  
High pressure liquid chromatography is one of the most used analytical chemistry tool. It can have medical 
applications, detecting different analytes concentration in the blood; legal application, detecting drugs in 
urine; and it allows analyzing drugs composition and identifying components in complex mixtures. The 
HPLC technique is powerful and versatile and has many advantages compared to other types of 
chromatography, thanks to excellent reproducibility, high sensitivity, better resolution and furthermore it 
can be easily automatized.  
The typical HPLC system consists of different devices (figure 1.4): 
 
 
 
 
Figure 1.4: The HPLC system. 
 
 
1. Mobile phase reservoir: the choice of the mobile phase depends on the required level of 
separation. Solvents should be of high purity and degassed, not corrosive, with a low 
viscosity and they must not alter analytes proprieties.  
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2. Pump system: this device is generating the mobile phase gradient. Depending on the analytes to 
separate, two types of gradients can be used: the isocratic gradient, in which mobile phase is 
constant during the overall chromatographic run, and the elution gradient, in which separation is 
achieved modulating the composition of mobile phase. The pump system must be able to work 
with very high pressure and to provide a constant and reproducible flow, guarantying the 
repeatability of analytes retention times. 
3. Autosampler: the correct sample injection is a very important factor during a chromatographic 
analysis. The injection system has to provide injection volume repeatability and a good versatility in 
samples handling. The modern autosamplers use mostly Rheodyne injector valve technology (figure 
1.5), to be simultaneously connected with all the HPLC devices, and a temperature controller for 
the samples tray. 
 
 
 
 
Figure 1.5: Rheodyne System. 
 
 
4. Guard column: it is a very short column with the same characteristics of the analytic column (e.g. 
composition of stationary phase and diameter). The guard column is positioned between the 
injector and the analytic column and it is essential to restrain contaminant materials. It has to be 
replaced more often than the analytic column.  
5. Analytic column: the column contains the stationary phase and it is the heart of every 
chromatographic system. Nowadays there are many types of column, which are different for the 
stationary phase composition, diameter and length; the pick depends on the analytes to separate. 
The column resolution power must be periodically evaluated: it is the main column life indicator. 
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6. Detection system: after the separation, the chromatographic system needs a detector to reveal the 
nature of the analytes. The detector must have high sensitivity, since the analytes volume after the 
separation is usually very small; it has to be fast and it has to give quantitative and qualitative 
interpretations. The most common revelation systems are UV detectors and mass spectrometers, 
their use depends on the nature of the analyzed compounds.  
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II. Mass spectrometry 
 
IIa. Historical Notes 
 
“The future of mass spectrometry looks to be as exciting as its past” 
(Jennifer Griffiths, “A brief history of mass spectrometry”, 2008) 
 
The mass spectrometry analytical technique has origin in the physics field. In 1897 J.J. Thomson and his 
laboratory assistant E. Everett developed the first “spectrometer-like” apparatus to measure particles 
mass-to-charge ratio. While they were studying the transmission of electricity through gases, they 
identified the first subatomic particles: the electron29. For this great discovery, Thomson received in 1906 
the Nobel Prize in physics. Afterwards, in 1919, Francis Aston built what later was recognized as the first 
authentic mass spectrometer, using it to measure masses of charged atoms. In the first half of the 20th 
century Aston improved the resolution power of his instrument and used it to identify the elemental 
isotopes30, receiving the Nobel Prize in physics in 1922. In the same half of the century, Alfred Nier, an 
electrical engineer, built several revolutionary instruments31, and promoting the use of this technique to 
scientists outside the restricted physicists community. In the 1940s, mass spectrometers were 
commercially available, but at that time, their use was limited to quantitative analysis. A group of three 
chemists, Fred McLafferty, Klaus Biemann and Carl Djerassi, through systematic mass spectrometry 
experiments, noticed that every class of organic molecules had a different and specific fragmentation 
pattern29. In this way, they could determine the structures of unknown molecules, placing the basis of the 
current qualitative-quantitative use of mass spectrometry. In 1946 William Stephens presented the concept 
of the mass spectrometer “time of flight” (TOF)32. At the beginnings of 1980s small organic molecules were 
routinely analyzed, but not the macromolecules, more difficult to ionize. A big turning point for this issue 
was in the 1984, when Franz Hillenkamp and Michael Karas developed the “matrix-assisted laser 
desorption/ionization” (MALDI)33 building up a ionization technique also for macromolecules, and 
simultaneously John Fenn developed the “electrospray ionization” (ESI)34, receiving for this technical 
discovery the Chemistry Nobel Prize in 2002. The mass spectrometry main historical events are represented 
in figure 1.6. 
 
 
29 
 
 
 
 
Figure 1.6: Mass spectrometry time-line 
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IIb. Technical Notes  
The mass spectrometer is an analytical technique used to measure the mass of charged molecules (ions) 
evaluating their mass-to-charge ratio (m/z), generally using electromagnetic fields. It is a key analytic tool 
for qualitative analysis, elucidating molecular structures, and for quantitative analysis, determining the 
amount of unknown compounds.  
When the sample is loaded into the mass spectrometer, its molecules are ionized usually through the 
expulsion (“negative mode”) or the gain (“positive mode”) of a proton and then separated according to 
their m/z. Afterwards, the ions are detected and the visual output obtained is a mass spectrum, where on 
the x-axis there is the m/z and on the y-axis there is the relative intensity of each ion. Furthermore, to 
improve the analysis specificity, modern mass spectrometers use a “double” selection of charged ions, and 
this highly specific technique is called tandem mass (MS/MS). After the ionization, there is a first analyzer in 
which the ions (precursor ions) are selected according to their m/z (MS analysis) followed by another 
spectrometer region, called “collision chamber”, in which the ions collide with an inert gas breaking their 
original structure in some smaller ions, called product ions. After the collision chamber there is another 
analyzer, similar to the first one, that selects the product ions according to their m/z (second MS analysis). 
In this way, the specificity is extremely high because there are three levels of selection: the precursor ion 
m/z, the fragmentation pattern, distinctive for each molecule, and the product ion m/z. The fragmentation 
pattern is used especially in qualitative analysis, because breaking molecules can give important 
information about the compound structure.  
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IIc. Structure of a mass spectrometer  
Almost all the mass spectrometers have a recurring structure. They are mainly constituted by an ionization 
source, an analyzer and a detector (figure 1.7). 
 
 
 
 
Figure 1.7: Structure of a mass spectrometer. 
 
 
i. The ionization source  
The source is the key component of a mass spectrometer: here takes place the ionization, the basic process 
of every mass spectrometry analysis. There are different kinds of ionization techniques: some of them are 
“hard ionization”, using high energy and high power, often causing a partial molecule fragmentation; other 
ionization techniques, mainly used, are defined “soft ionization”, since they involve a smaller amount of 
energy. Among all the soft ionization techniques, the most used are the electrospray ionization (ESI) and 
the atmospheric pressure chemical ionization (APCI) for liquid samples (e.g. mass spectrometry coupled 
with HPLC or micro-injector); the choice depends on the molecule type to analyze (figure 1.8). Furthermore, 
the MALDI ionization technique is the only one suitable for analytes with a very high molecular weight 
(>100.000 Da), like peptides and polymers.  
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Figure 1.8: Ionization type suitability according to analytes polarity and molecular weight. 
 
 
1. The electrospray ionization, ESI 
ESI is probably the most diffused ionization technique, since it is suitable for a large number of molecules. It 
is a soft ionization used for analytes with a medium – high polarity and a molecular weight up to 150.000 
Da. Usually, the sample is dissolved in a mixture of water and organic solvent, such as methanol or 
acetonitrile, and introduced in an high-voltage capillary (that can be heated to facilitate the solvent 
evaporation) and then nebulized with the help of an inert gas, for instance nitrogen or carbon dioxide. The 
nebulization allows the formation of charged droplets in the first vacuum region of the spectrometer, 
where the solvent evaporates and the droplets form a charged jet (through a process called Coulomb 
fission) that is carried in the mass spectrometer analyzer (figure 1.9). This ionization technique is perfectly 
compatible with an HPLC system and has some advantages as the possibility to analyze macromolecules 
and a good sensitivity. The disadvantages are the incompatibility with saline solutions and high HPLC flow: 
for a good performance the HPLC flow should be < 0,5 ml/min. There could be also some issues related to 
the detection of the exact mass of the molecules because of the formation of adducts (the precursor ion 
can bind sodium molecules during the ionization process) or multiply charged ions; this can however be 
avoided by adding a small percentage of weak acid (e.g. acetic acid) to the HPLC mobile phase. 
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Figure 1.9: ESI ionization. 
 
 
2. The Atmospheric Pressure Chemical Ionization, APCI 
APCI is the best ionization technique when working with high HPLC flow (typically between 0.5 and 2 
ml/min) and it is suitable for analytes having low molecular weight (<1000 Da) and low polarity. It is a soft 
ionization technique, but it has a stronger fragmentation power than ESI. The eluting analyte is carried 
through a capillary from the chromatographic system to a heated nebulizer needle, typically working at 
very high temperatures (usually >400°C), and it is sprayed with a high-flow rate of nitrogen (chemical 
ionization). The solvent evaporates and the spray is then subjected to a high potential corona discharge 
needle that creates ions (figure 1.10). With this type of ionization is very rare to find adducts or multiply 
charged ions. 
 
 
Figure 1.10: APCI ionization. 
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ii. The mass analyzer  
The mass analyzer is the spectrometer region in which the ions coming from the source are sorted and 
separated according to their m/z ratio. There are several parameters that can be used to evaluate a mass 
analyzer: 
  The mass resolution power: the measure of the analyzer ability to discriminate two peaks of slightly 
different m/z.    
  The mass range: the range of m/z measured by the analyzer. 
  The mass accuracy: the ratio between the m/z measurement obtained by the analyzer and the true 
analytes m/z. 
Among different types of mass analyzer, the quadrupole mass filter and the TOF are definitely the most 
diffused. TOF analyzer is usually coupled with MALDI ionization source; the MALDI-TOF system allows 
analyzing high masses over 1000 KDa. Ion m/z is determined via a time measurement: ions are accelerated 
in a flight tube and the time spent by each ion to reach the detector, depending on the ion m/z, is 
measured. 
 
Almost all mass spectrometry instruments coupled with a chromatographic system use the quadrupole as 
mass analyzer. Indeed, it is completely compatible with ESI and APCI ionizations and it is the easiest 
analyzer to use with a wide range of applicability and high specificity.   
The quadrupole is basically constituted by four parallel metal rods (length approximately of 20 cm), which 
define the ions path using oscillating electrical fields, stabilizing or destabilizing them through 
a radiofrequency (RF) (figure 1.11). This way, only the ions in the selected m/z range can pass through the 
system and arrive to the detector; other ions with a non corresponding m/z have unstable trajectories and 
will collide with the rods. 
 
 
Figure 1.11: Typical quadrupole structure. 
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A common variation of the classic single quadrupole instrument is the triple quadrupole. These instruments 
have three linear quadrupole stages: the first quadrupole (Q1) acts as a mass filter to sort and let pass the 
precursor ions in the selected m/z range; the second quadrupole (Q2) is a collision chamber in which ions 
collide with an inert gas, breaking their original structure and producing specific fragments also called 
product ions; the third quadrupole (Q3), equal to the first, transmits to the detector product ions in the 
selected m/z range (figure 1.12). Frequently, between the ionization source and Q1, there is another 
quadrupole (Q0) that is not acting as a mass filter, but is only stabilizing the ions trajectories.  
 
 
Figure 1.12: Triple quadrupole arrangement. 
 
 
 
There are two MS/MS operative modes: 
- Single reaction monitoring (SRM): both mass analyzers (Q1 and Q3) are set to a selected mass. This is a 
very selective analysis mode. 
- Multiple reaction monitoring (MRM): in this analysis mode the operator can sort more than one product 
ion (usually two) with the Q3 increasing the specificity of the analysis (figure 1.13). 
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Figure 1.13: SRM and MRM operative modes. 
 
 
 
 
 
iii. The detector  
A detector, the final part of a mass spectrometry instrument, must identify and quantify ion signals. In large 
part of mass spectrometry experiments, there is a small ions amount reaching the detector, so it is 
necessary to amplify the signal. The most commonly used detector is an electron multiplier, a vacuum tube 
in which the incident charges signal is multiplied through a series of sequential electrodes called dynodes. 
The result is a huge signal amplification that can be elaborated by the calculator obtaining the classical 
mass spectrum. 
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III. Liquid chromatography tandem mass spectrometry 
 
IIIa. Historical and Technical Notes 
 
“The next time that you run an LC-MS instrument, or sit down with others to review some LC-MS 
data, just spend a short time and reflect on all the groundbreaking work and all the heartache that 
went into the development of this technique by a few pioneers who had the dogged resolve to 
overcome what was seen at the time to be an insolvable problem.” 
(Frank Pullen, “The fascinating history of the development of LC-MS; a personal perspective”, 2010) 
 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a technique that combines the 
advantages of two complementary methods: the separation skills of liquid chromatography, which can 
fractionate complex samples in single analytes, with the mass analysis capabilities of mass spectrometry, 
which can precisely measure or accurately identify small analytes amount. From the historical point of 
view, LC-MS/MS development was not easy: the problem was to combine two techniques of which the 
former works with high liquids volume and pressure, and the latter works with high vacuum (approximately 
10-7 torr in the source). In 1968 the first kind of interface between the two instruments was proposed by a 
Russian scientist, Victor Tal’Roze, who tried to spray a very small amount of liquid into a conventional mass 
spectrometer35 with a simple approach. In 1974 Baldwin and MacLaferty tried the same experiment but 
increasing the liquid amount36, developing a DLI LC-MS (direct liquid injection liquid chromatography mass 
spectrometry), but the amount of liquid efficiently ionized was still too small. In 1975 three scientists, 
Horning, Dziric and Carroll, developed the first atmospheric pressure ionization (API)37; however the spectra 
produced with this ionization were not so clear for the presence of cluster ions35. In 1980 Vestal and 
Blackley built up the first Thermospray interface, which allowed the direct liquid ionization also for low 
volatile molecules, but this approach was still presenting some limits as the necessity to have ammonium 
acetate in the mobile phase to drive the ionization38. The real decisive moment was in the first half of 
1980s, when the APCI ionization source and the ESI ionization source were developed, coupling finally 
together the liquid chromatography and the mass spectrometry without limits of mobile phase composition 
or analytes chemical characteristics. The APCI was developed by Bruce Thomson39, who was working in the 
mass spectrometry company Sciex, while the ESI was developed by John Fenn at Yale University34, as 
mentioned before. Afterwards, LC-MS/MS improved rapidly thanks to new commercially available 
instruments, better pre-analytic techniques and new materials for LC columns stationary phases.  
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The LC-MS/MS development represents a turning point in the analytical chemistry history. Since its 
technical features and the quantitative-qualitative analysis spectrum, it can offer an endless range of 
applications, as for instance newborns screening (in particular for metabolic disorders), drug composition 
analysis or development, pharmacokinetic studies, bimolecular analysis, protein identification, forensic 
medicine, doping detection in sport, and many more. Nowadays this technique represents one of the most 
diffused within analytical chemistry laboratories. The history of LC/MS is represented in figure 1.14. 
 
 
 
Figure 1.14: LC/MS time-line.  
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CIRCULATING STEROID HORMONES MEASUREMENT IN 
HEALTHY AND OBESE PATIENTS 
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Quantitative circulating molecules measurements have always been an important tool for endocrinology. 
The development of the first RIA aimed at insulin measurement in the 50s allowed for the first time the 
measurement of a hormone in the blood40. Soon after insulin, quantitative techniques based on RIA were 
developed for steroid hormones13. This wide hormone class has been always extensively studied since 
steroid hormones are involved in many physiological and pathological processes essential for the human 
body. The steroid class includes a great number of molecules, some of which have been very well 
characterized as for instance glucocorticoids or sexual steroids. The precise and accurate measure of 
circulating steroid hormones is essential for carrying out diagnoses and follow-up of many endocrine 
pathologies13. Nowadays, in the clinical practice, steroid hormones are quantified using immunoassays. This 
technique has a very good sensitivity, but the specificity is considered a limit, since it is critically depends on 
the antibody used. Indeed, many discrepancies among measurements carried out in different laboratories 
have been evidenced12, especially for steroid hormones circulating with very low concentrations, such as 
testosterone in women41. With the advent of GC/MS, new quantification methods for steroids were 
developed, increasingly sensitive and specific giving accurate and precise results. The limit of GC/MS is the 
derivatization step: steroids are not volatile molecules and consequently they are not suitable to be 
analyzed with this technique; to elude this problem, analytes moieties are chemically modified to make 
compounds more volatile and thermostable. This step has been considered the limit of this technique 
because the pre-analytical sample preparation becomes laborious and time-consuming42, making 
complicated the introduction of the GC/MS as routine technique in clinical laboratories.  
The introduction of LC-MS/MS in endocrinology has been considered an epochal revolution. This technique 
put together the RIA practicality and the GC/MS reliable technical features, providing fast and effortless 
multi-analyte measurements13. In the last years, always more quantitative multi-analytes methods with this 
technique have been developed for several molecules, and also for steroid hormones43-44.    
In this part of the thesis, carried out at the Center for Applied Biomedical Research (CRBA) in Bologna we 
chose this technique to develop a sensitive, accurate and specific method for the quantification of nine 
steroid hormones: cortisol, corticosterone, 11-deoxycortisol, androstenedione, deoxycorticosterone (DOC), 
testosterone, 17OH-progesterone, DHEA and progesterone. These steroids were chosen for their biological 
relevance and their involvement in several pathological states but also for chemical common 
characteristics, thus allowing the development of a fast multi-analytes technique. 
This method has been validated following the Food and Drug Administration (FDA)45 guidelines for the 
validation of bioanalytical methods. After the validation we used this method to carry out a comparative 
study with immunoassay, currently used at the Laboratorio Centralizzato of the Policlinico Sant’Orsola 
Malpighi in Bologna to quantify these molecules.  
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The reference intervals in healthy population for steroid hormones were defined in the 50s performing a 
healthy population sera screening with RIA. Since reference intervals are fundamental to diagnose 
pathologies and to establish diagnosis criteria, and since our comparative study evidenced the already well 
known limits of immunoassays, a review of these normality ranges was urgently needed. We measured the 
nine steroid hormones included in our analytical method in 179 healthy males and 177 healthy females to 
redefine their circulating normal range with LC-MS/MS.  
Once established new steroids reference intervals in healthy subjects, we decided to measure these 
analytes in over-weight and obese patients. Obesity is a worldwide diffused pathological condition in which 
there is an imbalance between food intake and energy expenditure. This pathology has been intensely 
studied and an imbalance of several different physiological endocrine systems has been found. As well as 
other endocrine axes, steroids production and functionalities are altered in obesity, in particular the HPA 
axis and the HPG axis. The impairment of these two axes leads to important changes in circulating 
concentrations of some steroid hormones: glucocorticoids concentrations result typically increased and sex 
steroids are altered in a sex dependent manner10. Since among the steroids included in our analytical 
method there are some of the principal glucocorticoids (cortisol and 11-deoxycortisol) and androgens 
(testosterone, DHEA and androstenedione) and also an intermediate of both glucocorticoids and androgens 
synthesis (17OHprogesterone), we carried out these measurements to obtain circulating profiles in subjects 
with different BMI and verify the alterations of circulating levels in these subjects. 
The precise quantitative assessment of steroid hormones imbalance in obese patients can help to elucidate 
the mechanisms underlying these altered concentrations, since they are still poorly understood. 
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I. Steroid Hormones 
 
Ia. Biosynthesis and Transport  
Steroid hormones are a wide hormone class including a large number of molecules. These hormones have a 
key role in body physiology, growth and energy balance, regulating many basic processes46.   
In general, all the steroid hormones have a very similar chemical structure; indeed, they are all derived 
from cholesterol, from which they take the characteristic basic structure with four cicloalkane rings (three 
cyclohexan and one cyclopentan) connected to each other (figure 2.1). 
 
Figure 2.1: Characteristic steroids structure, the cicloalkane rings. 
 
The different functional groups linked to the cicloalkane rings structure confer to every steroid the 
characteristic biological proprieties. The steroidogenesis, the biological process by which all the steroid 
hormones are generated from the cholesterol, is a complex multistep cascade regulated by a large number 
of different enzymes47 (figure 2.2) located in mitochondria and smooth endoplasmic reticulum (SER). The 
cytochrome P450c11a1, located in mitochondria, catalyses the first, slower and therefore rate limiting step 
for the whole steroidogenesis cascade: the conversion of cholesterol in pregnenolone47. 
These hormones are synthesized mostly by the adrenal cortex, testicles, ovary and brain (neurosteroids) but 
a small part is produced also in some peripheral tissues, like the adipose tissue. Steroid hormones can be 
divided in three main functional classes: mineralocorticoids produced in the zona glomerulosa, the 
outermost layer of the adrenal cortex, glucocorticoids, produced in the zona fascicolata of the adrenal 
cortex and sexual hormones, produced mainly by testicles and zona reticularis of the adrenal cortex 
(androgens) and ovary (estrogens)46 (figure 2.3).  
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Figure 2.2: Steroidogenesis. 
 
 
 
Figure 2.3: Adrenal layers and relative steroids production.  
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Steroid hormones biosynthesis is not directly dependent on transcription: the regulation of steroidogenesis 
involves the control of enzymes which modify cholesterol in the steroid hormone of interest and the 
production of single hormones is stimulated and regulated by other hormones upstream, as for instance 
adrenocorticotropic hormone (ACTH) for cortisol synthesis and follicle-stimulating hormone (FSH) for 
estradiol synthesis48.  
Unlike peptide hormones, steroid hormones are not stored but secreted as soon as they are produced and 
their secretion rate is directly dependent on the synthesis. In various biological fluids they exist at three 
different states: free, bound to transport proteins and conjugates. The free fraction, the less abundant in 
the blood (1-8%), represents the biologically active fraction. Because of their lipophilic nature, they are 
generally carried in the blood bound to specific glycoprotein such as albumin or the more specific sex 
hormone-binding globulin (SHBG), carriers for sexual steroids, or corticosteroid-binding globulin (CBG); 
furthermore, this fraction represents a “circulating reserve” of these hormones, providing free active 
hormones when the production rate decreases. Lastly, the conjugated part is the fraction linked to 
hydrophilic moieties, to facilitate their excretion through the liver and kidneys48. 
 
Ib. Receptors and genomic effects  
Since their lipophilic nature, steroid hormones can easily enter in the cytosol trough the plasma membrane, 
binding intracellular or nuclear receptors, expressed only in target tissues49. The structural organization of 
steroids receptors is well preserved, consisting of four distinct parts (figure 2.4): a variable domain that can 
interact with other transcription factors (1) at the NH2 terminal, DNA zinc finger binding domain (2), a 
dimerization domain (3) and the hormone binding domain (4) at the COOH terminal, which is different in 
every type of steroids receptor. Once the steroid binds the specific receptor, it causes a conformational 
change that allows the receptor to bind highly specific DNA sequences, called hormone responsive elements 
(HRE)49. The HRE sequences are very similar in every tissue for length and structure, but they have different 
hormone binding region depending on the target steroid they can bind and the target tissue in which they 
are expressed. The hormone-receptor complex acts as a transcription factor, which regulates gene 
transcription49. After the transcription, the messenger RNA (mRNA) is translated into specific protein by 
ribosomes, carrying out functions in target cells (figure 2.5). This genomic steroid mediated effect is a “long 
term effect” because it is directly influencing proteins synthesis and therefore it is slower than other kinds 
of hormonal actions.  
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Figure 2.4 : Structural organization of a steroid receptor. 
 
 
 
 
 
Figure 2.5 : Steroids receptor mechanism of action. 
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Ic. Physiology  
As told before, steroid hormones can be grouped in different categories characterized by a wide spectrum 
of physiological actions. 
 
1. Mineralocorticoids 
The primary mineralocorticoids function is the control of salt-water balance. The most important hormone 
in this category is the aldosterone, which plays an important role maintaining extracellular fluid volume by 
conserving body sodium.   
Aldosterone is produced in the zona glomerulosa of the adrenal glands by the enzyme CYP11B2, after the 
conversion of the C18 methyl group of the corticosterone, another mineralocorticoid hormone, in an 
aldehyde. Aldosterone is largely secreted in response to signals arising from the kidney when a reduction in 
circulating fluid volume is detected. The principal aldosterone regulator is the renin-angiotensin system: 
hypovolemia or hypotension sensed by the kidneys stimulates the justaglomerulal cells to produce renin; 
renin acts on angiotensin, a protein secreted by the liver, to form angiotensin I which is further cleaved by 
angiotensin converting enzyme (ACE), secreted by the lungs, to angiotensin II, a powerful vasoconstrictor, 
which lastly acts on the adrenal zona glomerulosa to stimulate aldosterone production48 (figure 2.6). 
Aldosterone acts on kidneys to promote active re-absorption of sodium and passive reabsorption of water; 
furthermore, it provides excretion of potassium, which stimulates aldosterone biosynthesis, providing a 
feedback control mechanism. Viceversa, potassium low levels directly decrease aldosterone production.  
Following the general mechanism described above, aldosterone binds the nuclear mineralocorticoids 
receptors (MR) in target cells, mainly in kidneys, causing transcriptional changes typical of steroid hormones 
action50.  The physiological aldosterone concentration in the blood is very low and, like the majority of 
steroid hormones, its circulating concentration follows a physiological circadian rhythm: the highest 
concentration is around 8 a.m. and the lowest is around 11 p.m48.  
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Figure 2.6: Aldosterone production induced by rennin-angiotensin system. 
 
 
2. Glucocorticoids 
Glucocorticoids are the steroid hormones in general responsible for the glucose metabolism, but they have 
several other different functions. The primary and most powerful hormone of this group is cortisol. 
Glucocorticoids synthesis is regulated by the HPA axis, mostly trough ACTH, a 39 amino acids peptide that is 
synthesized within the anterior pituitary gland from the 241 amino acids precursor called pro-
opiomelanocortin (POMC), in response to the corticotropin-releasing hormone (CRH) produced by the 
paraventricular nucleus of the hypothalamus (PVN), mainly in response to stress situations51. ACTH acts on 
the zona fasciculata of the adrenal cortex inducing glucocorticoids production through ACTH receptors on 
the adrenal cells surface, stimulating the cholesterol delivery to mitochondria to start the steroidogenesis. 
As told before, glucocorticoids are responsible for a wide range of physiological effects generally in 
response to stress situations, binding tissues specific intracellular receptors (glucocorticoids receptors, GR) 
and following the general steroids mechanism of genomic actions described above49.  
Like aldosterone, also cortisol is secreted with a circadian rhythm, following the ACTH secretion: its blood 
concentration is higher on wakening in the morning and it decreases throughout the day, reaching the 
lowest point in late evening (figure 2.7 adapted by Williams Textbook of endocrinology, 12th edition48). 
Individual ACTH and consequently cortisol secretion rhythm depends on subject’s sleep-awake cycle, and 
also food intake is a stimulus for ACTH production. Important changes in the glucocorticoids daily secretion 
could be due to pathologies, such as the Cushing syndrome48. 
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Figure 2.7: Cortisol circadian rhythm in healthy subjects. 
 
 
Metabolic effects. Glucocorticoids have catabolic effect inducing mobilization of energy resources48.  They 
stimulate gluconeogenesis in the liver, glucose de novo production, and inhibit glycogenolysis, the glycogen 
breakdown51; they inhibit glucose uptake in peripheral tissues, like the adipose tissue or the muscle, 
increasing the glucose blood concentration contrasting insulin action.  Glucocorticoids can also stimulate 
proteins catabolism in extra-hepatic tissues, stimulate lipolysis in the adipose tissue, free fatty acids 
formation trough triglycerides hydrolysis and stimulate the adipocyte differentiation inducing adipogenesis, 
through the transcriptional activation of key genes51.   
Immune effects. Glucocorticoids have in general an anti-inflammatory effect52, up-regulating the 
expression of anti-inflammatory molecules and down-regulating the expression of pro-inflammatory 
molecules, suppressing inflammatory responses and showing a regulatory role to prevent destructive 
reactions of the immune system, dangerous for the organism52. Glucocorticoids inhibitory effect on the 
immune system is exerted at different levels. In the blood, they can decrease the lymphocytes number, 
inducing their apoptosis; also the immunoglobulin production is decreased. They can inhibit cytokines 
synthesis inhibiting the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells), an important 
transcription activator of cytokines genes48. Glucocorticoids can further reduce the local inflammatory 
response by preventing actions of histamine and down-regulate the prostaglandin synthesis. 
Because of this inhibitory effect on the immune system, they are used for the treatment of pathological 
states caused by immune system hyper-activation, such as allergies and autoimmune diseases53.  
Central nervous system.  It was shown that GRs are expressed in some key areas of rodents’ brain such as 
hippocampus, hypothalamus, cortex and cerebellum54. Indeed glucocorticoids have various effects on the 
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mood in humans that can range from depression to euphoria55. It was also shown that high levels of 
glucocorticoids can cause neuronal death, especially in the hippocampus56, impairing learning function.  
Other effects. In general glucocorticoids increase the blood pressure, potentiating the action of vasoactive 
substances and acting on the kidneys and the vasculature. In the endocrine system, they suppress the 
secretion of various hormones, such as the thyroid-stimulating hormone (TSH), the gonadotropin-releasing 
hormone (GnRH), the FSH and the luteinizing hormone (LH)48.  
 
3. Sexual steroids 
Sexual steroids are mainly produced by gonads, ovary, testicles and by the zona reticularis of the adrenal 
cortex. Similarly to glucocorticoids, the production of these steroids is regulated by the HPG axis through 
the production of the peptide hormone GnRH by neurons in the hypothalamus48. GnRH then acts on 
gonadotropin-producing cells of the anterior pituitary gland stimulating the production of LH and FSH, 
which can directly act on the gonads with a positive feedback mechanism inducing the sexual steroids 
production. The effect of sexual steroids can be mediated by intracellular and intranuclear receptors 
(androgen receptors, AR; estrogen receptors, ER; progesterone receptors, PR) inducing the slow genomic 
effect described before, or through plasma membrane G protein-coupled receptors inducing a fast non-
genomic effect48. Sexual steroids are generally responsible for sexual characteristics development, but they 
are also involved in several other functions. These steroids can be divided in two main groups depending on 
their actions: androgens, sexual steroids class more abundant in males, and estrogens, more abundant in 
females. 
Androgens. The primary steroid hormone of this class is the testosterone; its production occurs in Leydig 
cells of the testicles under the control of the LH, on which testosterone has a negative feedback, inhibiting 
the GnRH production in the hypothalamus48. Other androgens are the dihydrotestosterone (DHT), 
androstenedione and the DHEA. One of the primary functions of testosterone and other androgens is the 
development of the sexual male characteristics; during the embryogenesis, androgens production is 
essential for the normal male genital differentiation (primary sexual characteristics). The increase of 
circulating testosterone concentration during the puberty (figure 2.8 adapted by Williams Textbook of 
endocrinology, 12th edition48) is responsible for the normal development of secondary sexual 
characteristics, such as for instance the hair facial growth, and it is especially essential for the 
spermatogenesis and seminal fluid production. During the adult life, normal circulating testosterone levels 
are required to maintain many of the changes induced during the puberty48. Among other functions it was 
recently showed that androgens can also have a regulatory role decreasing fat deposits through the 
inhibition of adipocytes differentiation57.    
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Figure 2.8: Testosterone levels during life. 
 
 
 
Estrogens. In the steroidogenesis, these sexual steroids are directly derived from androgens 
androstenedione and testosterone. Estrogens are generally produced by the ovary, and like for androgens, 
also their production is under LH and FSH direct control and estrogens have a negative regulatory feedback 
on GnRH production. The primary hormones of this class are the estradiol (E2), secreted by the granulosa 
cells of the dominant follicle, and progesterone, while other estrogens are estrone and estriol. The primary 
function of estrogens is the development of female sexual characteristics like endometrial and uterine 
growth, regulatory mechanism on the menstrual cycle and the oocytes maintaining in the ovary, all 
functions essential for the reproduction48. Indeed, in the luteal phase of the menstrual cycle estradiol and 
progesterone are necessary to prepare the endometrium for the implantation. Progesterone is the most 
important hormone during the pregnancy48: it allows the embryo implantation, it decreases the mother 
immune response against the fetus and it decreases contractility of the uterus muscles cells. Estradiol has 
also a role in male reproduction, preventing the sperm cells death58. Among other, non reproductive 
functions, estrogens have an important role in preserving appropriate bone metabolism59. Indeed during 
the menopause, when ovary production of estradiol and progesterone ceases, there is a higher risk of 
osteoporosis that leads to an increased risk of bone fracture. 
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Id. Steroid hormones related diseases  
Since the great number of key functions that steroid hormones carry out in the body, a deregulation of 
their normal production or mechanism of action leads to a wide range of diseases.   
 
1. Mineralocorticoids disorders 
Two principal disorders involve mineralocorticoids production: hyperaldosteronism and hypoaldosteronism. 
Hyperaldosteronism is a pathological condition in which there is an increased aldosterone production in the 
adrenal cortex60. The first consequences of this over-production are hypertension and reduction of 
potassium blood levels, also called hypokalemia, due to the increased aldosterone action on the kidneys60. 
The hyperaldosteronism can be primary, direct consequence of hyper-production by adrenal glands, or 
secondary, indirect consequence of other pathological conditions. The primary is usually caused by an 
adrenal adenoma, called Conn’s syndrome, or by an idiopathic adrenal hyperplasia61 (75% of clinical cases). 
The discrimination between these two pathological conditions is essential because the treatment for each 
is different: for Conn’s syndrome the most effective therapy is the surgery intervention, while in the case of 
idiopathic adrenal hyperplasia the treatment is a medical therapy with aldosterone antagonists62. The 
secondary hyperaldosteronism is due mainly to over-activation of the renin-angiotensin system, as for 
instance in the presence of a renin secreting tumor, which leads to an increased aldosterone production. 
Recent evidences have shown an increased function of the renin-angiotensin-aldosterone system in 
obesity63. An increased aldosterone production was found in obese patients64 and it may contribute to 
obesity-related hypertension and the increased risk of cardiovascular disease. Further evidences 
highlighted a possible role of adipokines, cytokines-like molecules produced by the adipose tissue, as 
stimulus for the increase of aldosterone production65. 
Hypoaldosteronism, on the other hand, is the pathological condition in which aldosterone production is 
decreased60. The causes of primary hypoaldosteronism can be a general adrenal insufficiency or genetic 
causes like several enzymatic disorders resulting from mutations in genes coding for enzymes responsible 
for the steroidogenesis. In particular for aldosterone the most important enzyme lacking is the aldosterone 
synthase (or 18 hydroxylase) that catalyses the conversion of corticosterone in aldosterone66. The 
hypoaldosteronism causes hypotension due to hypovolemia and hyperkalemia, the increase of blood 
potassium.  
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2. Glucocorticoids disorders 
One of the most diffused disease involving glucocorticoids is the Cushing’s syndrome that can be defined as 
the pathological state due to prolonged exposure to elevated levels of circulating glucocorticoids67. It can 
be caused by endogenous increased production of glucocorticoids or it can be iatrogenic when it is due to 
long term therapies with glucocorticoids drugs. The most diffused form of Cushing’s syndrome with an 
endogenous cause has a pituitary origin, often the result of the presence of a benign pituitary adenoma 
secreting ACTH in excess67, which stimulates continually glucocorticoids production by the adrenal gland. 
Another endogenous cause can be an adrenal adenoma secreting glucocorticoids or an ectopic production 
of ACTH, for instance in presence of lung cancer68. The symptoms are mostly gonadal dysfunctions with 
menstrual irregularity in women, depression and lethargy, and a marked obesity with diabetes in most of 
the cases69. Accurate cortisol and ACTH levels determination is indispensable to identify this syndrome; 
especially the deregulation of their circadian rhythms can be an important clue. Also some asymptomatic 
tumors, called incidentalomas because detected by coincidence, can secrete glucocorticoids in excess (30% 
of adrenal incidentalomas)70 giving rise to a subclinical Cushing’s syndrome, defined as a glucocorticoids 
abnormal production without specific Cushing’s syndrome symptoms. Another disease involving the 
glucocorticoids production is the Addison’s disease, an autoimmune pathology characterized by 
adrenocortical insufficiency and therefore glucocorticoids (and mineralocorticoids in some cases) 
deficiency71. The primary adrenocortical insufficiency can be caused by different metastatic tumors and 
ACTH resistance syndrome48. Interestingly, Cushing’s syndrome and Addison’s disease are characterized by 
opposite modification of the metabolic phenotype: while marked obesity is a primary trait of Cushing 
disease and therefore of the glucocorticoids excess, Addison’s disease is characterized by weight loss and 
hypoglycemia; both these conditions evidenced the critical involvement of glucocorticoids in energy 
balance72. The secondary adrenocortical insufficiency, on the other hand, can be due to hypopituitarism or 
sudden interruption of glucocorticoids therapies (iatrogen).  
The congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders characterized by 
mutations of the genes coding for enzymes involved in the steroidogenesis73. In almost every case of CAH 
there is a defective cortisol production73 and, depending on the steroidogenesis pathway involved, there 
could be also a mineralocorticoids or androgens subnormal production. Usually, there is a hyper-production 
of the steroid hormone upstream the defective enzyme and a deficit of all the steroid hormones 
downstream. The most diffused enzyme lacking is the CYP21 also known as 21 hydroxylase (95% of all the 
CAH74) located in the SER of adrenal cells, that catalyzes the conversion of progesterone in DOC in the 
mineralocorticoids pathway and the conversion of 17OH-progesterone in 11-deoxycortisol in the 
glucocorticoids pathway (figure 2.9). This results in a decreased aldosterone and cortisol production that 
leads to hyperplasia of the adrenal cortex and elevated ACTH levels, due to the absence of cortisol negative 
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feedback. There could be also an increased androgens production, because the excess of 17OH-
progesterone that cannot be converted in the glucocorticoids pathway is converted to androstenedione74 
(figure 2.9). The principal signs for a 21 hydroxylase deficiency diagnosis in newborns are salt wasting, 
hypotension, hypoglycemia and genital ambiguity in females due to the androgens excess. In every case of 
CAH, a correct steroids circulating profile determination is essential to determinate the diagnosis and the 
lacking enzyme73.  
 
 
 
 
Figure 2.9: 21-hydroxylase deficiency: effects on steroidogenesis. 
 
 
3. Sexual steroids disorders 
Among pathological conditions concerning the sexual steroids, the hypogonadism can be defined as the 
clinical syndrome that results from a decreased functional activity of the gonads and therefore a reduced 
sex steroids biosynthesis48. More specifically, hypoandrogenism in men is the clinical syndrome that results 
in a decreased testosterone, and consequently sperm production by testicles48. The consequences of the 
androgen deficiency are different depending on the onset age and the severity of the deficit. In fetal 
androgens deficiency, usually caused by congenital lack of testosterone biosynthesis enzymes, the 
phenotype may range from a normal female to a male with ambiguous genitalia, depending on the degree 
of androgens production. During the pre-pubertal age, testosterone levels rise allowing secondary sexual 
characteristics development and during the adulthood is necessary to maintain all the sexual functions; in 
presence of androgens deficit these processes are impaired, resulting in patients with impotence, infertility, 
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gynecomastia and poor muscle mass strength48. Non congenital hypoandrogenism may have different 
causes like tumors, autoimmunity, drugs and many others48. Furthermore, a relationship between obesity 
and decreased androgens circulating levels has been extensively documented75 but molecular mechanisms 
underlying this decreased production are still not well defined. 
Hypoestrogenism is the clinical syndrome consisting in a decreased estradiol production in the ovary. It is 
physiologic in post-menopausal age, when estrogens production falls, but it can be also associated to drugs 
treatments against endometriosis, like GnRH antagonists76; also in this case the consequences are similar to 
normal menopause symptoms, like for instance hot flashes and lower libido. The hypergonadism is the 
opposite condition, in which there is a hyper-functionality of the gonads and therefore increased levels of 
circulating sexual steroids48. Commonly, the hyperandrogenism in women is usually one of the primary 
symptom of the polycystic ovary syndrome (PCOS) frequent in post-pubertal age and associated with 
irregularity of the menstrual cycle and, as long term consequences, dyslipidemia and insulin resistance77, 
whereas the hyperestrogenism in most of the cases is due to secreting ovarian tumors78. Furthermore in 
both sexes, dysfunction of the enzyme aromatase (CYP19) can cause abnormalities in sexual hormones 
circulating levels: this enzyme catalyzes the conversion of testosterone in estradiol and the conversion of 
androstenedione in estrone in many tissues.  As a consequence, the aromatase excess syndrome (AEXS) 
causes an excess of estrogens resulting in gynecomastia and adult hypogonadism in males and menstrual 
irregularity and enlarged uterus in females79  , while aromatase deficiency can lead to virilization in females 
and osteopenia or osteoporosis in men due to low levels of estrogens80.  
 
 
Ie. Glucocorticoids, androgens and obesity  
In addition to all the pathologies described so far, also obesity can alter steroid hormones production. 
Visceral obesity is associated, among other alterations, with a hyper-activation of the HPA axis, leading to 
an altered glucocorticoids action, and a sex specific impairment of the HPG axis10.  
The cause of the HPA axis hyper-activation is still unclear; a hypothesis is represented by the fact that 
obesity can be assumed as a chronic stress condition, leading to a chronic activation of this neuro-
endocrine axis81. On the other hand, this hyper-activation could represent also a compensatory mechanism 
for an increased clearance of cortisol due to an altered function of the enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11βHSD) in the adipose tissue75.  
However, the direct relationship between circulating cortisol levels and visceral obesity can be explained by 
the human pathophysiological models of the Cushing’s syndrome and the Addison’s disease72. As explained 
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before, Cushing’s syndrome is characterized by increased cortisol levels and the visceral obesity is a 
distinctive tract of the Cushing phenotype, whereas the Addison’s disease presents decreased cortisol 
production due to adrenal insufficiency and anorexia and weight loss are characteristics of this pathology72.  
Although increased circulating concentrations of cortisol have been found in obese patients82-84, the fact 
that the hyper-cortisolism is a direct consequence of increased visceral fat is not as evident. In some studies 
it has been found a direct correlation between cortisol circulating levels and waist circumference85-86, 
whereas in others this association was lacking83. Further knowledge is therefore required to elucidate this 
intricate link between the hyper-activation of the HPA and obesity. 
The impairment of the HPG axis is different according to the gender10. In men, increase of body weight and 
visceral adiposity are associated with decreased levels of testosterone, reduced SHBG and increase in 
estrogens levels, impairing the sexual functions75. The cause-effect relationship is still not clear; obesity and 
testosterone low levels seem to have a bidirectional link: low testosterone levels predict development of 
visceral obesity while high BMI and central adiposity lead to decreased circulating testosterone87.  
In general, obesity is one of the main chronic pathologies associated with testosterone deficit in men88, and 
the molecular reasons underlying this mechanism are still poorly understood89. Androgens levels decrease 
proportionally to the increase of BMI90, suggesting that this decline is a direct consequence of increased 
visceral fat accumulation. Interestingly, a direct inverse correlation was found between circulating leptin 
and circulating testosterone in men with different obesity degree90. Since obese patients have higher levels 
of circulating leptin8, it is possible that this leptin excess can contribute to the reduction of testosterone, 
also because leptin receptors are present in Leydig cells, responsible of testosterone production90. 
Moreover, several studies found normal levels of gonadotropin in obese patients, suggesting that the 
inhibition of testosterone production is not due to central mechanisms90. Further studies are however 
required to confirm these hypotheses and to elucidate this obesity-related impairments. 
In contrast, in women obesity is associated with increased secretion rates of testosterone and DHT2. 
Moreover, in obese women SHBG concentration is inversely correlated with the increase of body weight91; 
this determines an increase of free testosterone and DHT available in tissues10. However, only few studies 
were performed so far to determine the relationship between androgens increase and obesity in women; 
furthermore, results in the literature are not consistent92. 
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II. Steroid Hormones measurement: state of the art 
Since an accurate measurement of circulating steroid hormones is essential to correctly address the 
diagnoses of each pathological condition described in the former section, the development of suitable and 
reliable quantitative methods for these molecules has been since long time the aim of many analytical 
chemistry researchers. Steroids represent a wide class of hormones in which molecules are structurally very 
similar to each other and furthermore the most part of these analytes circulate in the blood at very low 
concentration; for this reason the analytical method of choice has to be sensitive, specific, precise and 
accurate. 
So far, there are three main analytical methods used in the research and clinical practice to quantify steroid 
hormones: RIA, GC/MS and LC-MS/MS. Here I will review one by one these techniques, in order to evaluate 
the best to develop a quantification method for steroid hormones. 
 
IIa. Radioimmunoassay and Immunoassay  
Radioimmunoassay is an analytical quantification method developed by Rosalyn Sussman Yalow and 
Solomon Aaron Berson in 1960 for the first time to measure insulin in human plasma40. For this discovery 
they received the Nobel Prize in medicine in 1977. In the 1969 the first RIA for steroid hormone was 
developed by Abraham, measuring estradiol in serum13. Since its discovery, RIA has been the most used 
technique for hormones circulating concentration measurements; indeed, this technique joints the 
specificity of an immunologic reaction (antigen-antibody complex) with sensitivity of a radiochemistry 
method and at the moment is the most used technique for steroids quantification in the clinical routine. 
The two key components of this assay are: a known amount of mixture containing the radioactive antigen 
(usually labeled with 125I or 131I that can be easily introduced into protein tyrosine residues) and a known 
amount of highly specific antibody to bind the antigen. The radiolabeled antigen and the correspondent 
antibody are then mixed and the formation of the complex antigen-antibody occurs. An amount of this 
mixture is then added to pre-purified blood samples: the “cold” (unlabeled) antigen from the serum 
competes with the radiolabeled one for the binding site of the antibody (figure 2.10). The bound 
radiolabeled antigen is then separated from the unbound one adding a secondary antibody and the 
radioactivity of the latter is measured. By building a calibration binding curve with pure standard analytes, 
it is possible to calculate the concentration of analytes in the serum sample. The primary RIA advantage is 
the sensibility due to the radioactivity. The limits of this technique are the cost of the kits and of the 
radioactive waste disposal and especially the specificity lack: commercially available antibody can present 
cross-reactivity, binding also molecules structurally similar to the analyte, leading to an overestimation of 
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the analyte concentration12. In particular, the specificity lack is a dramatic issue for molecules with a very 
low concentration, such as testosterone in women. In 2003, Herold and Fitzgerald in a Clinical Chemistry 
editorial clearly titled “Immunoassays for testosterone in women: better than a guess?”41 affirming that 
concentrations obtained using some commercially available RIA kits measuring testosterone in women 
were always inaccurate missing a lot the target values. Also estrogens levels in post-menopausal women, 
an important clue to predict the breast cancer risk, are currently determined using RIA, achieving unreliable 
results in most of the cases, due to their very low concentration. In a review of 2010, the authors explained 
that RIA results for these analytes presented inter-individual differences in specificity causing significant 
problems when used for epidemiologic studies of breast cancer93. Furthermore, another limit of this 
analytical technique is the impossibility for the commercially available kits to measure different analytes 
simultaneously: the classical RIA kit approach is to measure each steroid using individual aliquot of serum 
analyzed with an assay made for a single analyte42. Therefore, to evaluate a whole steroid pattern for a 
complex endocrine disease is necessary to use some different kits, making the procedure costly and time 
consuming. To overcome the RIA time-consuming issue in the clinical routine, laboratories are currently 
using immunometric platforms, a completely automatized system that requires a small sample volume 
(approximately 0.1-0.2 ml) to measure multiple steroids from a single serum aliquot, using 
chemiluminescence or electrochemiluminescence instead of the radioactivity. However, these platforms 
also have serious advantages due to the specificity lack: the sample purification is not performed leading 
sometimes to an overestimation of the analyte concentration when the antibody binds structurally similar 
molecules and to an underestimation when matrix interferents compete with the analyte binding the 
antibody.  
 
 
Figure 2.10: The Radioimmunoassay. 
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IIb. Gas chromatography - mass spectrometry  
GC/MS is currently one of the most reliable quantification techniques for circulating steroid hormones and 
as such it is considered the reference method also called gold standard. It was used during 60s to elucidate 
the structures and the biosynthesis pathway of this class of hormones94. The GC/MS offers a high 
comparable level of sensitivity and specificity to LC/MS, basing the analysis on the same technical principles 
but with different features. In brief, the mixture of analytes is separated on a silica capillary column with a 
very small diameter (< 0.50 mm) and a length not lower than 10 m containing the stationary phase; the 
mobile phase is an inert gas that pass through the column dragging out the analytes at different times 
depending on the physical characteristics of the analytes and on the chemical nature of the stationary and 
mobile phase of choice, following the traditional chromatography principles. Afterwards, the sample is 
introduced in the mass spectrometry and then ionized, allowing the ions corresponding to the molecules of 
interest to reach the detector where they can be identified and quantified. The most important difference 
between the GC/MS and LC/MS, representing also the limit of this technique, is that the chemical nature of 
the analyte can be a limit to analyze it, since only volatile and thermo-stable compounds are completely 
suitable for this kind of chromatography. Most analytes, including also steroids, are not intrinsically volatile 
and as such not analyzable with GC/MS. In these cases, it is used the derivatization procedure42: analytes 
moieties are chemically modified to make compounds more volatile and thermo-stable. This procedure has 
some disadvantages: the pre-analytical sample preparation is more time consuming and hard working42 
making the introduction of GC/MS complicated in clinical routine laboratories. Furthermore, some different 
moieties added to analytes by the derivatization procedure could bind the analyte at different sites, 
generating from the same molecule compounds of different molecular weight complicating analyte 
identification. The advantage of the GC/MS compared to LC/MS is the more elevated resolution of the 
peaks also for molecules with minimal structure differences and the more accurate qualitative analysis: 
some kind of derivatizations, such as the methyloxime-trimethylsilyl ether (MO-TMS), allow a rapid 
structural characterization of the molecule, easily predicting the number of C=O and C-OH groups94. 
Particularly interesting is the opinion of same authors affirming that in the steroid hormones analysis field 
LC/MS and GC/MS can become complementary technique rather than competitive, since LC/MS is more 
suitable for steroids clinical routine quantification, while GC/MS is more useful for the structural analysis in 
the research field94.  
 
IIc. Liquid chromatography tandem mass spectrometry  
Since all the analytical methods used so far for steroid hormones quantification have some significant 
limits, in the past decade LC-MS/MS development has been a turning point in the field of steroid hormones 
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quantification95. This technique represents the best compromise between RIA applicability and GC/MS 
advanced reliability, having high sensitivity and specificity parameters values and avoiding the time 
consuming derivatization procedure, since there are not chemical limits for molecules analysis94. The LC-
MS/MS is capable to quantify different steroid hormones in a single chromatographic run from a single 
serum aliquot, introducing the revolutionary ability to achieve high throughputs with the minimum time-
consuming sample preparation, consisting in simple and fast sample purification without the derivatization 
step13. In the past decade, a large number of steroids quantification methods were developed, becoming 
always more sensitive and fast, satisfying the needs of clinical laboratories43-44. However, the limits for a 
wide use of this technique in the clinical practice still are the great initial investment for the equipment and 
requirement of staff with specialized expertise.  
 
IId. Analytical techniques comparison 
As explained in the previous paragraphs, the three analytical techniques used so far for steroids 
quantification RIA or immunoassay, GC/MS and LC-MS/MS have different features.  
The requirement of specific chemical characteristics of analytes is one of the main disadvantages of GC/MS: 
as told before, only volatile molecules can be analyzed with this technique and when molecules do not 
have this propriety, such as steroids, a derivatization step has to be performed to chemically modify analyte 
moieties. On the contrary, LC-MS/MS has no limitations about chemical nature of the analytes of interest 
because of the versatility of the liquid chromatography. Furthermore, LC-MS/MS can be easily automatized, 
while GC/MS, requiring the derivatization step, cannot. While the sensitivity of all the three discussed 
methods is excellent, specificity represent the most important limit of RIA, critically linked to the specificity 
of the antibody commercially available. Mass spectrometry techniques offer a great specificity, increased 
with the MS/MS analysis. Furthermore, since the possibility to develop multi-analytical methods, the daily 
potential throughput is significantly higher with mass spectrometry techniques; certainly, LC-MS/MS offers 
shorter analysis time compared to GC/MS: after a simple and fast purification the sample can be directly 
injected into the system without additional steps. Additionally, RIA cost per sample is definitely higher, 
whereas for LC-MS/MS the cost per sample is related to common solvents and consumables, once afforded 
the initial instrument cost. Different technical features of RIA, GC/MS and LC-MS/MS are summarized in 
table 2.1. 
Giving the high sensitivity and specificity, wide applicability, reduced time-consuming, high productivity and 
reduced cost per sample, we decided to employ LC-MS/MS to develop a new fast, multi-analytic, sensitive 
and specific method for the quantification of steroid hormones in blood. 
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  Task RIA GC/MS LC-MS/MS 
Applicability Molecular weight 
limit 
No limit Linked to instrumental 
features 
Linked to instrumental 
features 
  Chemical analyte 
nature 
No limit Analytes volatile and 
thermostable 
No limit 
Pre-analytic Sample preparation Sample purification Sample purification Sample purification 
  Derivatization Not needed Necessary Generally not needed 
  Use of radioactivity Yes No No 
  Automatized? Yes No Yes 
Analytic Method development Industrial (kits) "Home-made" with 
technical experience 
"Home-made" with 
technical experience 
  Sensitivity Generally good Generally good Generally good 
  Specificity Limited Generally good Generally good 
  Speed of the analysis Long Medium Short 
Post-analytic Maintenance Quite easy Quite easy with 
technical experience 
Quite easy with 
technical experience 
  Daily throughput 100 measurements 
of the same analyte 
50 measurements 
multi-analyte 
50 measurements 
multi-analyte 
  Cost per sample High Low Low 
  Cost of the 
equipment 
High (detector) 
Medium (kits) 
High High 
 
Table 2.1 : Different features of RIA, GC/MS and LC-MS/MS 
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III. Aim of the project  
Steroid hormones are a wide class of molecules carrying out many essential functions in human physiology. 
An impairment of their circulating levels, given by alterations of their synthesis or mechanisms of action can 
lead to a wide class of severe pathologies. We have been interested in the quantification of these 
molecules, developing an analytical method and establishing new reference intervals in normal and obese 
subjects. A precise and accurate quantification of these circulating molecules is indispensable to diagnose 
steroid-related pathologies, such as enzymatic deficit or adrenal insufficiency, and to monitor patients 
follow-up.  
So far, quantification methods for these molecules were carried out with RIA, immunoassays or GC/MS. 
Making a careful comparison of these two techniques with LC-MS/MS we decided to use the latter to 
develop a new quantification method for steroid hormones. Indeed, as told in the previous section, LC-
MS/MS represents the best compromise between RIA applicability and GC/MS specificity. The MS/MS 
analysis provides a superior specificity level. Therefore we developed a fast, sensitive and specific method 
for nine steroid hormones, chosen for their biological relevance, but also for common chemical 
characteristics that allowed us to develop a multi-analytic method. Separation and quantification of 
cortisol, corticosterone, 11-deoxycortisol, androstenedione, testosterone, DOC, 17OH-progesterone, DHEA 
and progesterone was achieved in 21 minutes. The method has been then validated following the FDA 
guidelines for the validation of bioanalytic methods45 evaluating sensitivity and linearity, specificity, 
accuracy and precision, matrix effect and consequent analytes recovery.    
Once obtained the values from the validation, we decided to carry out a comparative study with the 
immunoassay approach, currently used at the Laboratorio Centralizzato of the Policlinico Sant’Orsola in 
Bologna to measure steroid hormones in the clinical routine. A comparison study was carried out for six out 
of nine analytes, since corticosterone, 11-deoxycortisol and DOC at the time of the study were not 
measured at the Laboratorio Centralizzato. Circulating values of cortisol (n = 159), testosterone (n = 162) 
progesterone (n = 85), androstenedione (n = 137), DHEA (n = 143) and 17OH-progesterone (n = 99) were 
measured by LC-MS/MS and obtained results were compared with values obtained by immunoassays.  
Results of our comparative study confirmed the already known limits of the immunoassay, especially 
regarding analytes circulating at low concentrations, such as testosterone in women or progesterone < 1 
ng/ml. Giving that, we decided to perform a screening on a healthy population, to redefine steroids 
reference values in normal population. Currently, reference intervals used in the clinical practice were 
made with RIA in 50s; because of the well-identified limits of these immunometric techniques, it is urgent a 
review of these reference values. We recruited 179 healthy males and 177 healthy females grouped by age, 
among the blood donors in the Centro Trasfusionale of the Policlinico Sant’Orsola. The redefinition was 
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made for eight out of nine steroid hormones, since in the majority of the population DOC circulating values 
were below the limit of quantification of our method.  
Once established circulating ranges in the healthy population, we decided to measure circulating steroids 
levels in an overweight population (n= 88, BMI: 25.1 – 30.0 kg/m2) and in an obese population (n=93, BMI > 
30 kg/m2). A group of healthy control subjects, matched with obese and overweight subjects by age and 
anthropometric characteristics, was extrapolated from the healthy population recruited for the steroids 
reference interval study.  
The relationship between obesity and steroid hormones is long known. Obesity leads to impairment of both 
the HPA axis and the HPG axis, causing altered functionalities and altered circulating concentrations of 
steroids, especially regarding glucocorticoids and androgens14. The direct link between this deregulation 
and the obesity condition is still poorly understood. Since among molecules included in our method are 
present some of the principal glucocorticoids (cortisol and 11-deoxycortisol) and androgens (testosterone, 
DHEA and androstenedione) and also an intermediate of both glucocorticoids and androgens synthesis 
(17OHprogesterone), we decided to use this method to find differences in steroid profiles among subjects 
with different BMI. Our findings will be useful to better understand the changes induced by obesity in the 
HPA axis and HPG axis, and the relationship between circulating steroids impairment and the development 
of obesity co-morbidities. 
 
 
 
 
Figure 2.11: Steroid hormones included in the quantification method (in red). 
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IV. Materials and methods 
 
IVa. Chemicals  
Pure standard of cortisol, corticosterone, 11-deoxycortisol, androstenedione, DOC, testosterone, 17OH-
progesterone, DHEA, progesterone, 21-deoxycortisol, epitestosterone, DHEA-sulphate (DHEA-S) and 
cortisone were from Steraloids, Newport, RI. Pure standard of deuterated compounds such as d4-cortisol, 
d8-corticosterone, d2-11deoxycortisol, d5-testosterone, d8-17OHprogesterone, d2-DHEA and d9-
progesterone were from CDN Isotopes, Pointe Claire, Canada while C2-testoterone was from Cambridge 
Isotopes Laboratories, Andover, MA. Bovine serum albumin (BSA) and pure standard of prednisone and 
prednisolone were from Sigma-Aldrich, St. Louis, MO; pure standards of betamethasone, dexamethasone 
21phosphate disodium salt, methylprednisolone acetate and triamcinolone acetonide were respectively 
from Defiante Farmaceutica, Madeira, Portugal; Visufarma, Rome, Italy; Pfizer, New York City, NY; Bristol-
Myers Squibb, New York City, NY.  Gradient grade methanol and zinc sulphate hepta-hydrated were 
purchased from Merck, Darmstadt, Germany; ultra-pure water was produced by MilliQ Gradient A10 
system (Millipore, Volketswill, Switzerland). Steroid-free serum was from MP Biomedicals, Solon, OH. The 
solid phase extraction (SPE) cartridges were IST Isolute C18 100mg, 1cm3 from Biotage, Uppsala, Sweden. 
Reference material was from the Reference Institute for Bioanalytics, Bonn, Germany. 
 
IVb. Steroids immunometric measurements  
For the method comparison study, we evaluated immunometric methods routinely used in the clinical 
routine by the Laboratorio Centralizzato of the Policlinico Sant’Orsola Malpighi in Bologna. Cortisol, 
testosterone and progesterone were measured by electro-chemiluminescence immunoassay on the 
Modular Analytics ElecsysE170 by Roche Diagnostics (Mannheim, Germany); androstenedione by the solid-
phase, competitive chemiluminescent enzyme immunoassay Immulite2000; DHEA by DSL-9000 RIA and 
17OHprogesterone by 17OHP Bridge RIA. 11deoxycortisol, corticosterone and DOC were excluded from the 
comparative study, since there are no immunoassays performed for this analytes in the Laboratorio 
Centralizzato. 
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IVc. Biochemical and blood parameters measurements 
Circulating triglycerides (CV intra-assay: <1.5%; CV inter-assay: 1.8%), total cholesterol (CV intra-assay: 
1.0%; CV inter-assay: 2.7%), cholesterol high density lipoprotein (HDL) (CV intra-assay: 0.95%; CV inter-
assay: 1.3%), insulin (CV intra-assay: 1.5%; CV inter-assay: 4.9%) and uric acid (CV intra-assay: 0.5%; CV 
inter-assay: 0.7%) measurements were performed by the Laboratorio Centralizzato at the Policlinico 
Sant’Orsola Malpighi in Bologna. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
determined using a sphygmomanometer Gamma G5 (Heine, Herrsching, Germany); glycemia was measured 
with a glucose meter Breeze 2 Bayer (Leverkusen, Germany). 
 
IVd. Subjects and statistics 
Patients recruitment has been made in different hospital facilities; indeed, different groups of subjects 
participated to each study. For the comparison study, we analyzed de-identified sera from the Laboratorio 
Centralizzato. For the steroids reference intervals redefinition, healthy subject were recruited among blood 
donors. Some of these healthy subjects were included in the control normoweight group then compared 
with overweight and obese volunteers in the last study. 
 
i. Samples for quantification methods comparison study  
De-identified serum samples were collected for the method comparison study among sera from the 
Laboratorio Centralizzato of the Policlinico S.Orsola-Malpighi. The LC-MS/MS method was compared with 
immunoassay measurements for analytes cortisol (n = 159), testosterone (n = 162) progesterone (n = 85), 
androstenedione (n = 137), DHEA (n = 143) and 17OHprogesterone (n = 99). All the results below the LOQ 
of both methods were excluded. Non-normally distributed variables were compared by the Mann–Whitney 
test and all data are expressed as median and interquartile range (IQR). To assess the imprecision of both 
the quantification methods was used the Deming Regression96. Bland Altman plots97 were used for the 
methods agreement estimation, representing the percentage difference between the methods against the 
mean.  
 
ii. Subjects recruitment for estimation of steroids reference intervals  
The subjects were recruited among healthy blood donors at the Centro Trasfusionale of the Policlinico 
Sant’Orsola in Bologna and among healthy volunteers at the local health service of the town of Massa 
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Lombarda for the project Regione Emilia Romagna, after their informed consent. 179 adult males and 177 
adult females were selected and grouped by age; for pre-menopausal females there are two subgroups 
depending on the menstrual cycle phase (follicular, day 1 - 11 or luteal). Subjects were normoweight (BMI 
18 – 25) with a waist circumference lower than 88 cm for women and lower than 102 cm for males and free 
from any kind of drugs during the period of the study. All the inclusion and exclusion criteria are 
summarized in table 2.2. The blood withdrawal was performed between 8:00 and 10:00 a.m. after ten 
minutes of saline solution infusion. Data analysis was performed on MedCalc v9.3.7.0 (Mariakerke, 
Belgium).  
 
INCLUSION CRITERIA  EXCLUSION CRITERIA 
Age: 18-90 years Any kind of drug in the last 4 weeks 
BMI: 18-25 kg/m
2
 Drug or alcohol addiction 
Body weight stability in the last 3 months Endocrine diseases 
Normal sexual development Kidney or liver diseases 
  Heritable disorders 
  Current or previous cancer 
  Current or previous autoimmune diseases 
  Current or previous cardiovascular diseases 
  Current or previous neurological diseases 
  Current or previous psychiatric diseases 
  Chronic intestinal diseases 
  Allergy 
  Sleeping disorders 
 
Table 2.2: Inclusion and exclusion criteria for the redefinition of steroids reference intervals. 
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iii. Obese subjects recruitment for assessment of steroids profiles 
Among the healthy volunteers recruited at the local health service of the town of Massa Lombarda for the 
project Regione Emilia Romagna, 34 males and 58 females obese (BMI>30.1) were selected. They were not 
diabetic and they were not taking any kind of drug at the moment of the study. This obese population was 
compared to 34 males and 54 females overweight (BMI: 25.1 – 30.0) and to 34 males and 59 females 
normoweight (BMI: 18.0 – 25.0) of the same age. All the characteristics of the three populations were 
compared using the Kruskall Wallis test. Significant differences in circulating steroids were then analyzed 
with Dunn’s multiple comparison test. 
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V. Results 
The quantification method was developed by first identifying the best mass spectrometry and 
chromatography condition to obtain the best signal from all the nine analytes: cortisol, corticosterone, 11-
deoxycortisol, androstenedione, DOC, testosterone, DHEA, 17OH-progesterone and progesterone. The 
extraction was optimized allowing the best recovery percentage and sensitivity. First, we validated the 
quantification method following the FDA guidelines45 by calculating sensitivity and linearity, specificity, 
accuracy and precision, matrix effect and recovery percentage.  
The quantification method was then used to measure steroid hormones in approximately 300 de-identified 
sera to carry out a comparative study with immunometric techniques currently used in the clinical routine 
to quantify these hormones. After this, we used our method to redefine circulating ranges of these nine 
steroids in healthy subjects, since the reference intervals used so far are at this point obsolete.  
Once obtained circulating ranges in healthy subjects, we measured steroids in an overweight and an obese 
population, to test the differences induced by a different BMI class or obesity condition. 
 
 
Va. Quantification method development 
 
1a. Mass spectrometry parameters assessment 
i. Mass spectrometer: API 4000QTrap instrument 
The mass spectrometer used for this part of the project is a triple quadrupole API 4000QTrap AB Sciex 
(Toronto, Canada). This instrument is equipped with an interchangeable ionization source that can operate 
in two different ionization modes: ESI (TurboIonSprayTM) and APCI (Heated NebulizerTM). Ions generated in 
the source at atmospheric pressure are then introduced in the quadrupole region through an orifice 
located in the middle of a metallic plate, called curtain plate. The curtain gas, a nitrogen stream with an 
opposite direction respect to the ions flow, allows only charged molecules to go through the orifice, 
removing interference molecules while the exhaust gas, connected to a waste flask, eliminates liquid 
excess in the source. Both these gas streams protect the high vacuum spectrometer region. After the 
curtain plate there is a ceramic plate, called orefice plate, with a further smaller orifice allowing the ions 
entrance in the quadrupole region. Ions are here accelerated by a voltage, called declustering potential 
(DP), applied between the orifice plate and a lens called skimmer: high DP values correspond to ions that 
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need high energy to detach themselves from solvent and water molecules. The entrance potential (EP) then 
drives the ion beam through the Q0, an accessory quadrupole used to stabilize the ions trajectories. The 
interface is summarized in figure 2.12. The Q0 is a region in which there is a medium vacuum, 8x10-3 torr, 
while the operative three quadrupoles are in a region with high vacuum, 3x 10-5 torr. Before each 
quadrupole there is a quadrupolar lens and a pre-filter called stubbies (ST), essential to preserve the voltage 
and to focus the ion beam.  
In the second quadrupole-collision chamber occurs the ions fragmentation, also called collision activated 
dissociation (CAD); this “special” quadrupole is therefore equipped with an inert gas flow, such as nitrogen, 
also called CAD gas essential for the fragmentation. The API 4000QTrap collision chamber, the LINACTM has 
particular inclined rods, which allow acceleration of the ion beam. In this way, the collision chamber can be 
emptied from the generated fragments in 5msec and be rapidly ready for the following analysis, avoiding 
the overlap of different parent ions fragments. It is possible to set two compound dependent parameters 
for the Q2: the collision energy (CE) is the voltage between Q0 and Q2 that determines the kinetic energy 
used by the ions to collide with nitrogen molecules generating fragments and the cell exit potential (CXP), 
the voltage between Q2 and Q3, which determines the speed of the ions entering in the Q3. 
 
 
 
 
Figure 2.12: API 4000QTrap interface. 
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ii. Optimization of syringe pump parameters 
For each analyte and deuterated internal standards (ISTD) two specific transitions were characterized, a 
“quantifier” for the quantitative measurement and a “qualifier” to further confirm the identity of the 
analyte, using the MRM mode. The electric parameters “compound dependent” were assessed in this 
phase, infusing standard solutions of each analyte directly in the source at concentrations ranging from 
100ng/ml to 10ug/ml through an infusion pump (Harvard Apparatus, Holliston, MA) and a Hamilton 1001 
TLL 1ml syringe (Supelco, Bellefonte USA) providing a constant flow of 10ul/min.  
There are different stages of the syringe pump analysis: 
Q1 scan: identification of the parent ion observing all the ions included in a certain range of m/z. 
Q1 multiple ions: increasing values of DP and EP were applied to the analyte m/z value previously found in 
Q1; for both the parameters, the value giving the higher analyte intensity was chosen. 
Q2 product ions: The parent ion was fragmented in the collision chamber. The whole fragmentation mass 
spectrum was evaluated and the two most abundant and characteristic fragments were chosen 
(“quantifier” and “qualifier”), to obtain the higher sensitivity and specificity. Afterwards, increasing values 
of CE and CXP were applied and the values giving the highest fragment intensity were chosen. 
At the end, optimized m/z, DP, EP, CE and CXP of every analyte and ISTD were included in the final MRM 
experiment used to set the chromatographic parameters. All the parameters are summarized in the table 
2.3. 
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Table 2.3: Analytes and ISTD compound-dependent parameters. 
 
 
 
 
 
Analyte MW Tr Transition m/z Q1 m/z Q3 DP CE CXP IR 
Cortisol 362.46 7.4 Quantifier 363.2 121.2 60 45 3 4.3 
   Qualifier 363.2 267.4 60 35 5  
d4-cortisol 366.46 7.4 IS 367.3 97.1 50 45 3  
Corticosterone 346.46 9.5 Quantifier 347.1 121.0 76 45 9 2.1 
   Qualifier 347.1 97.1 76 45 5  
d8-corticosterone 354.46 9.4 ISTD 355.4 125.4 88 45 5  
11Deoxycortisol 346.46 9.9 Quantifier 347.2 109.1 82 45 5 1.1 
   Qualifier 347.2 97.0 82 45 5  
d2-11 Deoxycortisol 348.46 9.9 ISTD 349.4 97.1 75 45 3  
Androstenedione 286.41 11.3 Quantifier 287.4 97.0 78 30 3 1.4 
   Qualifier 287.4 109.0 78 40 5  
DOC 330.50 11.6 Quantifier 331.4 109.1 80 40 4 1.1 
   Qualifier 331.4 97.0 80 30 4  
Testosterone 288.42 11.8 Quantifier 289.2 97.1 78 35 3 1.0 
   Qualifier 289.2 109.1 78 35 5  
13
C2-testosterone 290.41 11.8 ISTD 291.4 111.1 74 35 5  
17OHProgesterone 330.46 12.0 Quantifier 331.1 97.0 70 40 3 0.9 
   Qualifier 331.1 109.3 70 45 5  
d8-17OHprogesterone 338.46 11.9 ISTD 339.5 100.1 50 45 7  
DHEA 288.42 12.1 Quantifier 271.3 197.2 55 25 3 3.0 
   Qualifier 271.3 213.3 55 25 4  
Progesterone 314.46 12.8 Quantifier 315.6 97.1 80 30 3 1.1 
   Qualifier 315.6 109.1 80 40 4  
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iii. Optimization of flow injection analysis parameters 
At this stage of method development, physical source parameters are optimized to maximize the ionization 
efficiency of each analyte and ISTD. Since these parameters are used for all the analytes and ISTD, they 
were chosen according to a compromise in terms of different ionization efficiency of each compound. Small 
analytes amounts were repeatedly injected through the autosampler; the experiment was repeated with 
both the ionization sources, ESI and APCI. The parameters giving the maximum signal were chosen, 
evaluating the signal-noise ratio (S/N) of every peak. The best values were obtained with the APCI 
ionization with positive ion mode. All the parameters selected are in the table 2.4.    
 
 
Nebulizer Current 3µA 
Temperature  400°C 
Curtain Gas 30 psi 
Nebulizer Gas 30 psi 
CAD Gas (nitrogen) 10mTorr 
 
Table 2.4: Ion source parameters. 
 
 
 
2a. Chromatography development 
i. Chromatography system: HPLC Serie 200 
The HPLC system was a Serie 200 PerkinElmer (PerkinElmer, Waltham, MA) equipped with two micro 
pumps, a quaternary pump, column oven, autosampler with samples tray, injector and a peltier 
temperature controller. The analytic column was a reverse phase Luna RP-C8, 100x4.6mm, 5µm, 100 Å 
suitable for low polarity analytes such as steroids; the guard column was RP-C8 4x2mm, 5µm both from 
Phenomenex (Torrance, CA, USA). As mobile phases methanol and water gradient grade were used, since 
they have the polarity suitable to achieve the separation of these analytes. 
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ii. LC analytes separation results 
All the steroids included in the method were structurally very similar; some of them 
(11deoxycortisol/corticosterone; DOC/17OHprogesterone; testosterone/DHEA) were isobar sharing the 
same molecular weight. Frequently, isobar molecules can produce fragments with the same m/z: the only 
way to avoid the overlap of different fragments originated from a different parent ion is to separate them 
modulating the chromatography gradient, allowing to reach the revelator at different moments. 
Chromatographic resolution was achieved for all the isobaric steroid pairs and even for the steroids, like 
testosterone and androstenedione, which differ by only 2 atomic mass unit (amu) in their molecular 
weight.   
 
iii. Analytic gradient development 
The mobile phase A was 20% methanol and the mobile phase B was 100% methanol. The total flow rate 
was set at 750µl/min, suitable for APCI ionization and to reduce back-pressure with that kind of analytic 
column, and the column compartment temperature was 40°C. We optimized a gradient modulating the 
flow rate and composition; a good resolution for all the nine compounds included in the method was 
achieved in 21 minutes, paying particular attention to the separation of the isobar compounds. The elution 
was performed using increasing percentage of the organic phase. The gradient is represented in table 2.5 
and the chromatogram in figure 2.13. 
 
 
 
 
 
 
 
 
 
Table 2.5: Chromatography gradient. 
Time 
(min) 
Flow 
(µl/min) 
Solvent 
A (%) 
Solvent 
B (%) 
0 750 98.0 2.0 
2.3 750 98.0 2.0 
2.4 750 55.1 44.9 
8.5 750 55.1 44.9 
12.5 750 0.0 100.0 
14.5 750 0.0 100.0 
14.6 750 98.0 2.0 
21.0 750 98.0 2.0 
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Figure 2.13: The chromatogram. (1: cortisol; 2: corticosterone; 3: 11deoxycortisol; 4: androstenedione; 5: DOC; 6: 
testosterone; 7: 17OHprogesterone; 8: DHEA; 9: progesterone) 
 
 
iv. On-line purification assessment 
To further improve the chromatographic process eliminating interfering substances, an on-line purification 
system was developed using a perfusion column POROS R1/20 2.1mmx30mm by Applied Biosystems 
(Foster City, CA). The POROS preparative column was placed before the analytic column thus obtaining a 
two-dimensional chromatography. To purify the sample at the preparative column, a flow from two lines of 
the quaternary pump was used: the solvent A of the quaternary first line was H2O with 10% of methanol, 
while the flow of the second line B was 100% methanol. The sample was first loaded in the POROS column 
with a flow rate of 3ml/min of solvent A: the analytes were adsorpted by the internal POROS polymer while 
the high flow removed interfering samples molecules carrying them to the waste. After 1 minute, the micro 
pumps back-flush allowed the analytes elution from the POROS to the analytic column. The different flow 
coordination is organized through a ten-port switching valve (VICI, Houston, TX) connected with all the 
devices. The valve can assume two different positions: in the initial position A (figure 2.14-A) the flow of the 
quaternary pump goes into the valve from the port 3 loading the sample into the POROS (port 2) and going 
then to the waste through the port 8 and 9. After the first minute, the valve changes the position (position 
B, figure 2.14-B): the quaternary pump flow is directed to the waste while the flow of the micro pumps 
carries the analytes from the POROS (port 9 and 10) to the analytic column (port 1 and 2) allowing their 
chromatographic separation. After 16 minutes, the valve switch to the A position allowing the POROS 
cleaning by the quaternary solvent B and the re-equilibration of the analytic column by the micro pumps for 
the last 5 minutes. 
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Figure 2.14: VALCO A and B position 
 
 
3a. Pre-analytical phase: optimization of samples preparation 
i. Blood withdrawals  
The blood was collected in Vacuum Z serum beads clot activator. The samples were centrifuged soon after 
the withdrawal at 2000 x g for 10 minutes at room temperature and then sera were stored in 1.5 ml 
polypropylene tubes and frozen at -20°C until the analysis. 
Subjects were saline-infused for 10 min before blood withdrawal to avoid stress-related alterations in the 
glucocorticoids cascade. 
 
ii. Standard solutions, internal standard and calibrators  
Stock solutions were prepared in methanol for each standard and ISTD at different concentrations in the 
mg/ml range. Working solutions were prepared at 100µg/ml for cortisol, progesterone and all the ISTD 
while for the other analytes were prepared 10µg/ml standard solutions. A stock calibrator was prepared by 
mixing all the analytes obtaining a solution with the following concentrations: cortisol, 500 ng/ml; DHEA 
and progesterone, 50 ng/ml; corticosterone, androstenedione and testosterone, 20 ng/ml; 11deoxycortisol, 
DOC and 17OHprogesterone, 10 ng/ml. The BSA 4% in H2O was chosen as matrix for an eight-point 
calibration curve prepared by serial dilution from the stock calibration solution described above. The pure 
BSA solution represented the “zero point”. A working ISTD solution was prepared obtaining the following 
concentrations: d4-cortisol 50 ng/ml, d8-corticosterone and d2-11deoxycortisol 5 ng/ml, d2-DHEA 3 ng/ml, 
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13C2-testosterone 2 ng/ml and d8-17OHprogesterone 1 ng/ml, d9-progesterone 10 ng/ml. All the stock 
solution, working solution and calibrators were stored at -20°C.  
 
iii. In-house and European quality controls  
For the method validation three in-house quality controls (QCs) were created by generating serum pool 
mixing male serum, female serum and mixed sera adding pure standards to achieve three different 
concentration ranges for each analyte: low, medium and high. Aliquots of 1 ml of each pool were then 
frozen and three aliquots for every concentration range were thawed at room temperature and analyzed at 
the beginning, in the middle and at the end of every analysis batch to test the repeatability of the method 
intra and inter assay. To verify the accuracy of the analytic method, European certified sera (previously 
measured using GC/MS by the manufacturer company) were analyzed as unknown samples in each analysis 
batch. 
 
iv. Samples purification optimization 
After some tests, we developed a SPE method finding a compromise between sample washing, to avoid 
contaminants and analytes recovery percentage. For each curve calibrator, QCs and serum sample 900µl 
were transferred into a 12x75mm glass tube. To each tube was then added 1ml of deproteinization 
solution, prepared as follow:  
- Solution A: water with 8,9% of ZnSO4 (H2O)7 
- Solution B: Solution A with methanol 1:5 
For each ml of final solution 1µl of ISTD stock solution was added, containing the following concentrations 
of each ISTD: d4-cortisol, 50ng/ml; d8-corticoterone 5ng/ml; 11deoxycortisol, 5ng/ml; 13C2-testosterone, 
2ng/ml; d8-17OHprogesterone, 1ng/ml.  The tubes were then vortexed for 3 minutes and centrifuged at 
2000 x g for 10 minutes at room temperature: supernatants were transferred into the SPE cartridge 
previously activated for the extraction. The SPE procedure was performed as follow: 1ml of methanol to 
activate the C18 cartridge then conditioned with 1ml of H2O; samples loading; washing with 3ml of H2O and 
then elution with 1ml of methanol 100%. The eluted samples were collected in the 12x75mm glass tubes 
and then dried under a gentle stream of nitrogen. The samples were then reconstituted with 150µl of water 
and 150µl of methanol and transferred into autosampler vials and 200µl were injected in the LC-MS/MS 
system. 
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4a. LC-MS/MS quantification by isotopic dilution  
The software used for the quantification of the mass spectrometry analysis and data processing was 
Analyst 1.5 by AB Sciex. The isotopic dilution quantification method by linear regression was the chosen 
quantification mode. This kind of quantification is based on the use of an internal standard (IS), a chemical 
compound added in known and constant amount to each calibrator, QC and sample. It must have the same 
physical and chemical characteristics of the analyte to measure; indeed, it is used to correct analytes loss 
during the sample preparation and sample injection, minimizing the analytes quantification variability. 
Since the IS must to be very similar but not identical to the analyte, the deuterated corresponding 
molecules are the most used. The minimum difference of molecular weight, depending on the number of 
substituted hydrogens, allows distinguishing the two compounds during the LC-MS/MS analysis.  
The calibration curve was therefore built using the ratio between the pure standard and their 
correspondent IS on the y axis and the theoretic concentrations of the calibrators on the x axis. The 
concentration of each analyte was calculated by interpolation on the respective regression curve. Since the 
specific ISTD was not available for each analyte, the quantification was performed as follow: d4-cortisol for 
cortisol quantification; d8-corticosterone for corticosterone quantification; d2-11deoxycortisol for 
11deoxycortisol quantification; 13C2-testosterone for testosterone, androstenedione and DHEA 
quantification; d8-17OHprogesterone for 17OHprogesterone, DOC and progesterone quantification. The 
ISTD d5-testosterone, d2-DHEA and d9-progesterone were finally not used for the quantification because of 
their deuterium instability during the APCI ionization.  
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Vb. Assessment of quantification method validation 
i. How to validate a quantitative analytical chemistry technique  
There are some parameters that must be assessed for the validation of a quantitative analytical chemistry 
method defined by FDA45. Of course, they strictly depend on the compatibility between the analyte to 
measure and the technique/instrument of choice, and for this reason are completely different among 
laboratories. 
- Sensitivity: the smallest concentration of a substance that can be reliably measured by the analytical 
method. For instrumental analysis, to define mathematically the sensitivity is used the limit of detection 
(LOD), the lowest analyte amount that can be distinguished from the absence of that substance (a blank 
value) and the limit of quantification (LLOQ), the lowest analyte amount that can be reasonably quantified 
with statistic certainty. Moreover, another parameter evaluated for the sensitivity of each peak can be the 
S/N, commonly used in mass spectrometry analysis. It is the ratio between the analyte signal and the 
background, representing how much the peak is distinguished from the basal noise. 
- Specificity: the method capability to distinguish unequivocally the analyte among other substances 
present in the sample. The specificity is an important value especially when the quantification is in a 
complex biological matrix, such as plasma. 
- Accuracy and precision: the accuracy is the proximity degree of a measured analytes amount to the true 
analytes amount in the matrix and is expressed as the ratio between the found value and the true value in 
percentage; the precision, also called repeatability, is the evaluation of how much repeated measurements 
under the same conditions show the same results. It can be calculated “intra-assay” when the repeated 
measurements are made during the same day and the same analytical session and “inter-assay” when they 
are made in different days. 
All these parameters together, carefully evaluated during the method validation, can provide significant 
information to drive the method development and eventual targeted technical improvements. 
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ii. Determination of LC-MS/MS sensitivity and linearity  
Linearity was achieved for three or four orders of magnitude, depending on the analyte. The LOD was 
calculated as the lowest concentration exhibiting a S/N above 3, while the LLOQ was calculated as the 
lowest quantifiable concentration with a S/N higher than 10, an accuracy between 80 and 120% of the true 
value and a CV (coefficient of variation) lower than 20%. The LOD and LLOQ evaluation was made on five 
replicates of the same injection. The sensitivity was also investigated adding known low amount of the 
analytes to the steroid-free serum. All the data obtained are summarized in the table 2.6. 
 
 
 Linearity r
2
 LLOQ                                                         
(pure std) 
LOD     
(pure std) 
Serum 
Sensitivity  
 ng/ml  ng/ml S/N CV% Accuracy % pg  ng/ml 
Cortisol 0.244 – 500.0 0.9997 0.2440 49 9.0 99.3 4.8 0.244 
Corticosterone 0.039 – 20.0 0.9995 0.0391 13 3.4 95.9 4.0 0.313 
11Deoxycortisol 0.019 – 10.0 0.9993 0.0195 14 15.3 94.1 2.0 0.078 
Androstenedione 0.019 – 20.0 0.9998 0.0195 14 13.2 100.7 2.3 0.039 
DOC 0.019 – 10.0 0.9994 0.0195 11 9.6 107.8 2.5 0.078 
Testosterone 0.019 – 20.0 0.9993 0.0195 11 6.2 94.2 2.8 0.019 
17OHProgesterone 0.010 – 10.0 0.9996 0.0098 11 8.9 107.5 1.7 0.078 
DHEA 0.195 – 50.0 0.9995 0.1953 10 11.2 97.4 29.2 0.781 
Progesterone 0.024 – 50.0 0.9999 0.0244 29 9.3 103.4 1.2 0.049 
 
 
Table 2.6: Method sensitivity and linearity. 
 
iii. Specificity assessment 
As mentioned before, endogenous and exogenous steroid hormones are compounds structurally very 
similar. The potential interference of the following compounds was therefore evaluated: 21deoxycortisol, 
epitestosterone, DHEA-S, cortisone, prednisone and prednisolone, triamcinolone acetonide, 
methylprednisolone, dexamethasone and betamethasone. The absence of these compounds interference 
was confirmed: some of these molecules had the same m/z and fragmentation pattern of analytes included 
in the method but they were separated with chromatography. The specificity was further evaluated with 
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the analyte ion ratio (IR): the ratio between the quantifier and qualifier ion peak area was calculated for 
each analyte in each sample and if the ratio differed more than 20% from the respective pure standard IR, 
the measurement was considered not validable. 
 
iv. Determination of accuracy and precision  
The accuracy was calculated as described before and accepted between the 80 and 120%. It was evaluated 
through European certified sera measurements for the analytes cortisol, testosterone, 17OHprogesterone 
and progesterone. For the others European certified sera were not commercially available, therefore the 
accuracy was evaluated by in-house validation, spiking gravimetrically determined quantities of pure 
standards in steroid-free serum. We calculated a low, medium and high range different for each analytes, 
based on physiological ranges. The accuracy obtained for each analyte at low, medium and high 
concentration range is reported in table 2.7. 
The intra-assay precision (accepted <15%) was estimated by measuring six replicates of serum samples with 
low, medium and high concentration range. The inter-assay precision (accepted <20%) was calculated 
evaluating six replicates of the three concentration ranges of six different days in six different weeks. The 
results are in table 2.7. 
 
  Low Range Medium Range High Range 
  Accuracy 
% 
Intra-assay 
CV% 
Inter-assay 
CV% 
Accuracy  
% 
Intra-assay 
CV% 
Inter-assay 
CV% 
Accuracy 
% 
Intra-assay 
CV% 
Inter-assay 
CV% 
Cortisol 94.9 3 8 103.7 3 7 93.6 2 5 
Corticost. 92.5 2 10 98.3 6 5 98.5 3 7 
11Deoxycor. 106.2 8 8 99.1 4 5 102.3 3 2 
Androst. 86.3 10 11 97.9 10 10 100.6 7 11 
DOC 100.7 5 6 100.0 6 9 104.1 6 9 
Testost. 99.9 4 7 97.4 4 7 99.6 3 4 
17OHProg. 104.4 5 9 102.1 4 5 101.4 4 5 
DHEA 94.6 8 8 101.8 7 9 98.2 8 10 
Prog. 83.7 8 11 92.4 5 6 92.0 5 6 
 
Table 2.7: Method accuracy at three different concentration ranges  
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v. Evaluation of matrix effect  
Even after several purification steps, the presence of other molecules in the sample can alter the ionization 
efficiency of the analytes either enhancing or decreasing the signal. In mass spectrometry analyses, this 
effect is called matrix effect. The typical matrix effect consists in a decrease of the signal through a 
mechanism called ion suppression, due to the competition between the analyte and other molecules for 
the ionization. Good sample purification and the use of ISTD minimize consequences of the eventual matrix 
effect, avoiding a sensitivity decrease. 
The matrix effect during the development of this method was evaluated at two levels. First, known 
amounts of pure analytes were added to the steroid-free serum and BSA after the extraction; the samples 
were then injected in the LC-MS/MS system and the ratio between the signal and the signal obtained by 
injecting pure analyte was calculated, to verify whether the presence of the matrix was altering the analyte 
signal. Second, a mix of the nine pure analytes was injected directly in the ionization source while a blank 
matrix sample was injected from the HPLC system. Thus, the stable signal given by the pure analytes 
injected in the source can be enhanced or decreased by the matrix. Alterations of the analytes signal were 
not observed. All the results concerning the matrix effect experiments are in table 2.8. 
 
 
  Matrix Effect       
in BSA   
 (recovery %) 
Matrix Effect       
in serum 
(recovery %) 
Cortisol 84.8 87.4 
Corticosterone 96.8 95.5 
11Deoxycortisol 92.8 96.1 
Androstenedione 98.3 99.0 
DOC 97.4 96.5 
Testosterone 97.3 99.1 
17OHProgesterone 98.3 100.9 
DHEA 101.2 103.8 
Progesterone 100.2 100.6 
 
Table 2.8: Evaluation of matrix effect. 
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Vc. Results of quantification methods comparison study: immunoassay vs LC-MS/MS 
The comparison study has been carried out for six of the nine steroid hormones included in our 
quantification method, since corticosterone, 11deoxycortisol and DOC were not measured by the 
Laboratorio Centralizzato. 
First, the sensitivity of the two quantification methods was compared (table 2.9). For cortisol, testosterone, 
progesterone, androstenedione and 17OHprogesterone the LC-MS/MS method achieved the best 
sensitivity, whereas for DHEA the best sensitivity value was achieved by immunometric assays. By Mann-
Whitney comparison, there were no statistically significant differences for testosterone in males and 
progesterone above 1 ng/ml. Lower median values were obtained by LC-MS/MS for cortisol (-16%, p = 
0.0052), testosterone in females (-26%, p = 0.0080) and progesterone below 1 ng/ml (-84%, p < 0.0001). 
Lower measurements (p < 0.0001) were provided by LC-MS/MS also for the analytes androstenedione, 
DHEA and 17OHprogesterone. A good correlation, with a correlation coefficient (r) above 0,9, was obtained 
for cortisol, male testosterone, progesterone above 1 ng/ml, androstenedione and DHEA; lower correlation 
grade was obtained for females testosterone (r=0.773), progesterone below 1 ng/ml (r=0.637) and 
17OHprogesterone (r=0.874). In figure 2.15 are represented the Deming regression graphs, in which results 
obtained with LC-MS/MS are plotted on the x-axis and results obtained with immunometric assays are on 
the y-axis. The dotted line represents the perfect correspondence between the two quantitative methods, 
with a theoretical slope and intercepts values respectively of 1 and 0, while the black line represents the 
real obtained correspondence. The perfect methods correspondence (slope=1; intercept=0) was obtained 
for testosterone in males. Slope values higher than 1 were achieved for cortisol and progesterone >1ng/ml 
(confidence interval, CI 95%: 1.119 – 1.233; 1.077 – 1.378 respectively).   Testosterone in females and 
progesterone below 1 ng/ml showed elevated slope coefficients (95%CI: 1.311–2.137 and 0.253–6.149, 
respectively) and testosterone in females had also a negative intercept coefficient (95%CI: −0.326 to 
−0.036). Significantly elevated slopes were obtained also for androstenedione, DHEA and 
17OHprogesterone (95%CI: 2.068–2.530; 2.348–3.068; 0.870–1.589, respectively).  
A Bland Altman analysis of the data was performed: on the y-axis is shown the percentage difference 
between results obtained by immunoassay and LC–MS/MS on average; on the x-axis the average results of 
the two methods. All the obtained data are in figure 2.16. An acceptable mean difference was achieved for 
males and females testosterone, cortisol and progesterone >1ng/ml. Among them, only for males 
testosterone the difference was not different from 0% (95%CI: -6.6% to 1.5%). Mean differences 
significantly different from 0, ranging between 80.2% and 133.2%, were obtained for androstenedione, 
17OHprogesterone, DHEA and progesterone <1ng/ml. Furthermore, for these analytes the agreement 
intervals were located in the positive part of the graphs. These data indicated a good accuracy and 
calibration of the immunometric platform ElecsysE170, used for the determination of cortisol, testosterone 
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and progesterone. However, the data showed a possible cross-reactivity at low concentrations for 
testosterone and progesterone.  
Concluding the comparative analysis, calibrators of 17OHP Bridge, Immulite2000 and DSL9000 were 
measured with the LC-MS/MS method as unknown samples. Results showed a good accuracy for 17OH 
Bridge calibrators (92.8 – 101.6%) confirming that the low correlation between the two methods for the 
17OHprogesterone measurement is due to a low specificity of the immunoassay. A calibration problem was 
found for the DSL9000 used for DHEA measurement: the calibrator’s accuracy was between 46.2 and 
55.5%, explaining the overestimation of this analyte. For the androstenedione measurement, Immulite2000 
calibrators showed an accuracy of 133.1% for low levels (0.5ng/ml), and 82.5% for high levels (5ng/ml), 
explaining, also in this case, the analyte overestimation.  
 
 
SENSITIVITY LC-MS/MS 
in serum (ng/ml) 
Immunoassays 
(ng/ml) 
Cortisolo 0.244 1.000 
Androstenedione 0.039 0.300 
Testosterone 0.019 0.100 
17OHProgesterone 0.078 0.100 
DHEA 0.781 0.200 
Progesterone 0.049 0.100 
 
Table 2.9: RIA and LC-MS/MS sensitivity comparison. 
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Figure 2.15: Deming regression analysis: cortisol (A: m=1.176±0.029; q=−3.093±3.147; r=0.968), males testosterone (B: 
m=1.004±0.062; q=−0.097±0.283; r=0.938), females testosterone (C: m=1.724±0.208; q=−0.181±0.073; r=0.773), progesterone 
>1ng/ml (D: m=1.227±0.074; q=−0.587±0.573; r=0.946), progesterone <1ng/ml (E: m=3.201±1.466; q=0.270±0.166; r=0.637), 
androstenedione (F: m=2.299±0.117; q=0.042±0.093; r=0.906), DHEA (G: m=2.708±0.182; q=1.478±0.800; r=0.929) and 
17OHprogesterone (H: m=1.230±0.181; q=0.769±0.152; r=0.874); m: slope; q: intercept. 
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Figure 2.16: Bland Altman analysis: A – cortisol; B – males’ testosterone; C – females testosterone; D – progesterone >1ng/ml; E – 
progesterone <1ng/ml; F – androstenedione. Y axis: percentage of the difference between RIA result and LC-MS/MS result 
compared to the average; x axis: average of the two methods results. 
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Vd. Estimation of steroids reference intervals  
356 healthy adults were grouped according to sex and age, obtaining five groups for males (18-29, 30-39, 
40-49, 50-59, ≥60 years old) and five groups for women (18-29, 30-39, 40-49, 50-59, ≥60 years old). 
Anthropometric subjects characteristics are reported in table 2.10; reference intervals are reported in table 
2.11.  
Kruskal Wallis analysis showed results significantly different among the age groups for BMI and waist 
circumference, with higher values in the groups 50-59 and >60 for both genders (females: p=0.036 and 
p=0.018; males p=0.0009 and p<0.0001 respectively). Similarly, higher values of cholesterol (p<0.0001 for 
both genders), PAD (p=0.0065 for females and p=0.0063 for males) and PAS (p<0.0001 for females and 
p=0.0004 for males) were found in the older people group for both genders while higher value of HDL was 
found for males (p=0.0006) and higher value of triglycerides was found in women (p<0.0001). Furthermore, 
different characteristics of females in luteal and follicular phase are reported in table 2.12: significant 
differences were not observed for anthropometric characteristics in these two groups.   
The LC-MS/MS method was sensitive enough to determine circulating levels in the healthy adult population 
of eight analytes: cortisol, corticosterone, 11deoxycortisol, androstenedione, testosterone, DHEA, 
17OHprogesterone and progesterone. Most of the samples showed a concentration lower than the 
sensitivity in serum matrix for the DOC (0.078 ng/ml) therefore the reference range was not calculated for 
this analyte. One value of corticosterone, testosterone and 17OHprogesterone, two of DHEA, four of 
11deoxycortisol and 28 of progesterone were discarded because the IR values were not accurate. Values 
below the sensitivity limit were found for some analytes: one for corticosterone, androstenedione and 
DHEA, 13 for 11deoxycortisol, 3 for 17OHprogesterone and 65 for progesterone (71% of them in the post-
menopausal subgroup) in the female group and 4 measurements of 11deoxycortisol and 39 of 
progesterone in males group.  
Analyzing the steroid profile with Kruskal Wallis analysis, we found significant differences for DHEA and 
progesterone among the different age groups for both males (p<0.0001) and women (p<0.0001), showing 
an age-dependent tendency to decrease. The same tendency was observed for androstenedione 
(p<0.0001), testosterone (p<0.0001) and 17OHprogesterone (p<0.0001) in women. Males testosterone 
showed a not significant (p=0.086) tendency to decrease with age. Among women in different menstrual 
cycle phases, 17OHprogesterone and progesterone were significantly higher in luteal phase (p<0.0001). A 
non significant tendency to increase in the luteal phase was found for cortisol and corticosterone. 
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 A F 18-29 n=31 F 30-39 n=41 F 40-49 n=56 F 50-59 n=36 F ≥60 n=13 
  Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P 
Age (years) 27.0 18.0 - 29.0 35.0 30.5 - 39.0 45.0 40.0 - 50.0 55.0 51.0 - 59.0 64.0 60.0 - 90.0 
BMI (kg/m2) 21.2 18.8 - 24.8 21.2 18.8 - 24.6 21.7 18.1 - 24.8 22.8 19.4 - 25.0 23.1 18.1 - 24.7 
Waist Circum. 
(cm) 
76.0 65.6 - 83.72 76.0 64.5 - 86.9 76.0 63.7 - 87.0 79.5 66.4 - 87.2 83.0 67.0 - 87.0 
SBP (mmHg) 70.0 60.0 - 80.0 77.5 60.2 - 80.0 80.0 60.0 - 90.0 80.0 70.0 - 90.0 80.0 70.0 - 85.0 
DBP (mmHg) 110.0 95.0 - 120.0 110.0 100.0 - 129.5 115.0 95.3 - 140.0 120.0 105.0 - 140.0 135.0 110.0 - 160.0 
Total cholesterol 
(mg/dl) 
149.5 
108.0 -
 202.2 
170.0 129.5 - 254.2 188.5 148.9 - 279.1 193.5 138.1 - 285.8 204.0 155.0 - 260.0 
HDL (mg/dl) 59.5 22.0 - 87.8 50.0 29.6 - 87.2 57.5 33.7 - 103.2 59.5 32.4 - 88.6 63.0 45.0 - 89.0 
Triglycerides 
(mg/dl) 
49.5 27.3 - 90.6 56.0 35.9 - 108.6 60.0 38.5 - 113.2 66.0 28.9 - 130.8 110.0 57.0 - 137.0 
Glycemia 
(mg/dl) 
75.5 44.2 - 98.4 78.5 59.4 - 107.4 82.0 49.9 - 103.3 82.0 61.0 - 100.3 79.0 61.0 - 105.0 
Insulin (µU/ml) 6.10 3.35 - 13.45 5.05 2.29 - 12.44 4.10 1.89 - 13.21 5.70 3.24 - 9.55 4.40 2.80 - 14.00 
 
 
B M 18-29 n=49 M 30-39 n=44 M 40-49 n=38 M 50-59 n=23 M ≥60 n=26 
 Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P 
Age (years) 24.0 18.0 - 29.0 36.0 30.0 - 39.0 44.5 40.0 - 49.0 52.0 50.0 - 59.0 66.0 60.0 - 87.7 
BMI (kg/m2) 22.3 18.8 - 24.9 23.2 19.2 - 25.0 23.6 19.2 - 25.0 23.9 20.7 - 25.0 24.0 21.2 - 25.0 
Waist Circum. 
(cm) 
79.0 68.2 - 92.6 84.0 69.4 - 92.4 85.5 74.7 - 96.1 91.0 78.0 - 97.0 88.0 77.1 - 98.9 
SBP (mmHg) 80.0 70.0 - 90.0 75.0 65.0 - 90.0 80.0 65.0 - 100.0 85.0 75.0 - 90.0 80.0 60.1 - 89.9 
DBP (mmHg) 120.0 100.0 - 130.0 120.0 100.0 - 140.0 110.0 105.0 - 130.0 125.0 110.0 - 150.0 130.0 120.0 - 150.0 
Total cholesterol 
(mg/dl) 
148.5 108.9 - 261.5 182.0 139.4 - 261.1 181.0 142.6 - 257.7 194.0 157.7 - 262.9 198.5 99.8 - 235.0 
HDL (mg/dl) 38.0 25.7 - 93.5* 43.0 28.7 - 71.6 41.5 26.6 - 63.0 48.5 30.1 - 81.5 56.0 25.1 - 95.8 
Triglycerides 
(mg/dl) 
67.0 33.4 - 179.8 62.0 36.9 - 168.1 76.3 48.5 - 155.9 79.0 52.2 - 141.6 71.0 46.5 - 165.1 
Glycemia 
(mg/dl) 
77.0 56.4 - 102.0 81.5 64.0 - 102.0 81.0 61.2 - 99.0 88.0 63.2 - 101.9 85.5 59.3 - 98.9 
Insulin (µU/ml) 6.40 2.50 - 14.62 5.00 2.25 - 11.66 5.57 2.05 - 12.67 6.10 2.56 - 9.78 4.65 2.31 - 10.83 
 
Table 2.10: Anthropometric and metabolic characteristics of the healthy subjects: females (A) and males(B). 
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A F 18-29 n=31 F 30-39 n=41 F 40-49 n=56 F 50-59 n=36 F ≥60 n=13 
 Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P 
Cortisol 109.7 62.3-256.4 108.6 57.8-189.3 100.5 52.0-198.1 121.5 57.4-186.3 120 56.9-180.8 
Corticosterone 3.59 0.52-14.38 3.320 0.93-11.01 2.88 0.67-17.71 3.64 0.66-9.91 3.47 0.62-8.96 
11Deoxycorisol 0.301 <1.015 0.211 <1.085 0.251 <0.998 0.3 <0.786 0.311 0.118-0.782 
Androstenedione 0.849 0.376-2.070 0.760 0.434-1.722 0.572 0.200-1.068 0.349 0.137-0.791 0.222 0.039-0.632 
DOC 0.078 0.078-0.142 0.078 0.078-0.091 0.078 0.078-0.178 0.078 0.078-0.114 0.078 0.078-0.101 
Testosterone 0.267 0.111-0.411 0.251 0.116-0.490 0.213 0.105-0.409 0.160 0.081-0.414 0.166 0.045-0.634 
17OHProgesterone 0.816 0.156-2.958 0.642 0.240-2.193 0.501 0.110-2.273 0.242 0.079-1.534 0.209 0.121-1.356 
DHEA 6.35 2.25-26.74 4.670 1.58-17.49 3.470 1.09-15.03 2.685 1.06-7.27 1.800 <8.11 
Progesterone 5.278 <20.302 0.699 <19.165 0.182 <15.360 <0.049 <7.419 <0.049 0.049-0.081 
 
 
B M 18-29 n=49 M 30-39 n=44 M 40-49 n=38 M 50-59 n=23 M ≥60 n=26 
 Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P Median 2.5 - 97.5 P 
Cortisol 137.5 65.8-194.8 137.3 54.9-208.3 119.4 53.3-196.7 136.2 53.8-189.5 118.6 87.3-171.3 
Corticosterone 4.33 0.92-12.29 4.17 0.64-17.68 2.94 0.72-16.68 3.89 1.58-9.62 3.99 0.96-9.15 
11Deoxycorisol 0.432 0.079-1.188 0.373 <1.053 0.298 0.087-0.938 0.357 0.082-0.995 0.309 0.095-1.038 
Androstenedion
e 
0.627 0.353-1.345 0.595 0.229-1.321 0.596 0.311-1.108 0.549 0.395-1.188 0.449 0.278-0.753 
DOC <0.078 <0.147 <0.078 <0.138 <0.078 <0.159 <0.078 <0.078 <0.078 <0.144 
Testosterone 5.439 
1.452-
10.174 
5.623 3.075-8.299 4.878 2.134-7.177 5.231 2.264-7.896 4.292 2.635-7.205 
17OHProgestero
ne 
1.246 0.295-3.310 1.154 0.539-2.807 1.173 0.357-2.346 1.058 0.471-1.965 0.975 0.441-1.834 
DHEA 7.76 2.93-16.33 5.76 2.03- 3.98 4.040 1.53-11.57 3.51 1.68-9.70 2.21 <6.66 
Progesterone 0.093 <0.207 0.094 <0.225 0.084 <0.164 0.058 <0.116 0.051 <0.132 
 
Table 2.11: Median and reference intervals of steroids levels in healthy subjects (ng/ml): females (A) and males(B). 
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 Follicular Phase, n=45 Luteal Phase, n=21 
Characteristics Median 2.5 - 97.5 P Median 2.5 - 97.5 P 
Age (years) 41.0 21.9 - 49.4 37.0 18.0 - 52 
BMI (kg/m2) 21.8 18.9 - 24.7 21.8 17.9 - 24.1 
Waist Circum. (cm) 76.0 66.9 - 86.4 76.0 65.0 - 86.0 
SBP (mmHg) 80.0 60.0 - 90.0 80.0 60.0 - 80.0 
DBP (mmHg) 110.0 100.0 - 133.6 110.0 90.0 - 140.0 
Total cholesterol (mg/dl) 179.0 130.2 - 235.4 176.0 133.2 - 246.0 
HDL (mg/dl) 58.0 31.7 - 95.4 56.0 35.3 - 88.9 
Triglycerides (mg/dl) 56.0 36.6 - 91.2 60.0 40.0 - 100.8 
Glycemia (mg/dl) 79.0 46.9 - 100.3 80.0 53.0 - 92.0 
Insulin (µU/ml) 4.10 2.20 – 9.84 6.20 3.10 - 11.90 
Steroids Median 2.5 - 97.5 P Median 2.5 - 97.5 P 
Cortisol (ng/ml) 98.7 51.1 - 195.1 114.5 62.9 - 281.4 
Corticosterone (ng/ml) 2.77 0.66 - 14.25 4.61# 1.16 - 15.80 
11Deoxycortisol (ng/ml) 0.224 0.084 - 1.025 0.342 0.079 - 0.744 
Androstenedione (ng/ml) 0.594 0.267 - 1.970 0.739 0.337 - 2.111 
DOC (ng/ml) <0.078 <0.088 0.078 <0.142 
Testosterone (ng/ml) 0.210 0.108 - 0.421 0.245 0.102 - 0.401 
17OHProgesterone (ng/ml) 0.382 0.139 - 1.100 1.587## 0.235 - 2.959 
DHEA (ng/ml) 4.20 1.15 - 17.63 4.48 1.68 - 18.29 
Progesterone (ng/ml) 0.103 <1.707 10.394## 0.052 - 25.830 
 
 
Table 2.12: Anthropometric and metabolic characteristics of females in luteal and follicular phase and relative steroids reference 
intervals. (
#
 p<0.05; 
##
 p<0.0001). 
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Ve. Evaluation of steroid profile in obese subjects  
Steroids levels were then determined in three subgroups of subjects : normalweight subjects (NW), 
overweight subjects (OW) and obese subjects (OB). The anthropometric characteristics of these subjects 
are summarized in table 2.13. In both genders, overweight and obese subjects showed higher waist 
circumference, PAD and PAS, insulin, glycemia and triglycerides and lower HDL compared to the 
normalweight subjects.  
Concerning the circulating steroids profile (table 2.14), in females cortisol levels were significantly lower 
(p=0.0032) in the obese population; corticosterone levels decreased progressively from the normalweight 
to the obese group (p=0.0081). Significant differences were not found for other steroids. In males, on the 
contrary, significant differences were not found for glucocorticoids. The differences were found for 
17OHprogesterone and testosterone (p=0.0022 and p<0.0001 respectively), both decreased in the obese 
group compared to overweight and normal weight population. Dunn's multiple comparison tests were 
performed to evaluate the specific significant differences among the three groups of subjects (figure 2.17-
18). 
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 A NW n=59 OW n=54 OB n=58 Kruskal-Wallis 
Characteristics Median IQR 25 - 75 P Median IQR 25 - 75 P Median IQR 25 - 75 P p 
Age (years) 48.0 41.0 - 58.0 48.0 42.0 - 60.0 48.0 40.0 - 58.0 n.s. 
BMI (kg/m2) 22.1 21.1 - 23.3 27.1 25.9 - 27.9 33.3 30.9 - 37.9 <0.0001 
Waist Circum. (cm) 79.0 74.0 - 83.0 91.0 84.0 - 95.0 104.5 99.5 - 113.0 <0.0001 
SBP (mmHg) 80.0 75.0 - 85.0 80.0 80.0 - 90.0 80.0 80.0 - 90.0 0.0109 
DBP (mmHg) 120.0 110.0 - 130.0 130.0 120.0 - 142.5 130.0 120.0 - 142.5 0.0001 
Total cholesterol (mg/dl) 5.30 3.80 - 6.90 6.85 6.00 - 8.80 11.65 8.40 - 14.60 <0.0001 
HDL (mg/dl) 80.0 72.2 - 90.8 84.0 78.0 - 92.5 92.0 82.2 - 99.0 0.0003 
Triglycerides (mg/dl) 193.0 169.7 - 225.2 200.0 178. 0 - 224.0 191.0 176.0 - 216.0 n.s. 
Glycemia (mg/dl) 63.0 57.0 - 70.5 58.0 49.0 - 67.0 53.0 44.0 - 60.0 0.0003 
Insulin (µU/ml) 65.0 51.2 - 82.5 78.5 58.0 - 111.0 82.5 65.0 - 121.0 0.0044 
 
 
 B NW n=59 OW n=54 OB n=58 Kruskal-Wallis 
Characteristics Median IQR 25 - 75 P Median IQR 25 - 75 P Median IQR 25 - 75 P p 
Age (years) 51.0 44.0 - 61.0 50.5 44.0 - 61.0 50.5 44.0 - 61.0 n.s. 
BMI (kg/m2) 23.3 22.1 - 24.2 27.1 25.7 - 28.7 32.8 31.2 - 36.2 <0.0001 
Waist Circum. (cm) 87.0 83.0 - 90.0 98.5 95.0 - 102.0 112.0 108.0 - 119.0 <0.0001 
SBP (mmHg) 80.0 80.0 - 85.0 85.0 80.0 - 90.0 90.0 80.0 - 100.0 0.0002 
DBP (mmHg) 120.0 120.0 - 130.0 130.0 120.0 - 140.0 145.0 133.7 - 152.5 <0.0001 
Total cholesterol (mg/dl) 5.10 3.80 - 6.60 8.10 6.00 - 11.00 15.0 10.40 - 21.30 <0.0001 
HDL (mg/dl) 88.0 81.2 - 96.0 90.0 75.5 - 98.0 92.5 80.0 - 97.5 n.s. 
Triglycerides (mg/dl) 201.5 180.0 - 221.0 208.5 191.0 - 228.0 202.5 183.0 - 240.0 n.s. 
Glycemia (mg/dl) 56.5 43.0 - 63.0 48.5 40.0 - 54.0 40.5 36.0 - 47.0 0.0002 
Insulin (µU/ml) 73.0 55.0 - 114.0 105.0 76.0 - 156.0 139.5 109.0 - 190.0 0.0001 
 
 
Table 2.13: Anthropometric and metabolic characteristics of normo-weight (NW), over-weight (OW) and obese (OB) populations. 
Females (A) and males(B). (n.s. : not significant) 
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A Median IQR  
25 - 75 P 
Median IQR  
25 - 75 P 
Median IQR 
25 - 75 P 
p 
Cortisolo (ng/ml) 112.0 97.4 - 146.2 111.1 83.5 - 143.5 92.0 72.8 - 108.9 0.0032 
Corticost. (ng/ml) 3.43 1.66 - 6.78 2.79 1.74 - 5.86 2.03 1.27 - 3.86 0.0081 
11Desoxycor. (ng/ml) 0.317 0.187 - 0.500 0.338 0.204 - 0.461 0.251 0.184 - 0.400 n.s. 
Androst. (ng/ml) 0.550 0.316 - 0.705 0.483 0.405 - 0.760 0.485 0.324 - 0.672 n.s. 
DOC (ng/ml) <0.078 <0.078 <0.078 <0.078 <0.078 <0.078 n.s. 
Testost. (ng/ml) 0.198 0.135 - 0.253 0.194 0.147 - 0.256 0.190 0.137 - 0.238 n.s. 
17OHProg. (ng/ml) 0.378 0.211 - 0.500 0.423 0.253 - 0.665 0.322 0.203 - 0.666 n.s. 
DHEA (ng/ml) 3.87 1.82 - 6.24 4.06 2.26 - 5.37 3.10 2.03 - 6.13 n.s. 
Prog. (ng/ml) 0.060 <0.910 0.091 <1.059 0.049 <1.357 n.s. 
 
B Median IQR  
25 - 75 P 
Median IQR  
25 - 75 P 
Median IQR 
25 - 75 P 
p 
Cortisolo (ng/ml) 125.4 105.7 - 149.6 128.3 105.9 - 150.0 112.4 102.1 - 143.9 n.s. 
Corticost. (ng/ml) 3.90 2.87 - 5.58 4.62 2.03 - 6.29 3.15 2.28 - 5.39 n.s. 
11Desoxycor. (ng/ml) 0.385 0.232 - 0.545 0.415 0.278 - 0.551 0.409 0.272 - 0.562 n.s. 
Androst. (ng/ml) 0.530 0.457 - 0.678 0.637 0.442 - 0.771 0.561 0.371 - 0.761 n.s. 
DOC (ng/ml) <0.078 <0.078 <0.078 <0.078 <0.078 <0.078 n.s. 
Testost. (ng/ml) 4.981 3.974 - 6.055 4.979 3.937 - 5.789 2.898 2.363 - 4.281 <0.0001 
17OHProg. (ng/ml) 1.078 0.884 - 1.527 1.031 0.868 - 1.269 0.811 0.640 - 1.063 0.0022 
DHEA (ng/ml) 3.64 2.77 - 5.74 4.17 2.32 - 7.54 4.04 2.50 - 5.73 n.s. 
Prog. (ng/ml) 0.061 <0.103 0.067 <0.095 0.056 <0.071 n.s. 
 
Table 2.14: Circulating steroid hormones of normal weight (NW), overweight (OW) and obese (OB) populations respectively. 
Females (A) and males(B). (n.s. : not significant) 
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Figure 2.17: Dunn's Multiple Comparison Test performed for testosterone and 17OH progesterone in males. 
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Figure 2.18: Dunn's Multiple Comparison Test performed for cortisol and corticosterone in females. 
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VI. Discussion and conclusion 
The introduction of LC-MS/MS is the most important advance in endocrinology laboratories since the 
development of the immunoassays95. Since the well known limits of immunoassays and, on the other hand, 
the fast technical improvements of the liquid chromatography and mass spectrometry in the last decade, 
LC-MS/MS has improved the worth and the credibility of hormones quantification13, offering sensitive, 
specific and multi-analytes measurements, reducing analysis time and cost per sample. For this reason, 
nowadays an increasing number of laboratories have started using this technology for routine clinical 
diagnostic measurements98.   
In this context, we developed a sensitive, specific and accurate multi-analytes quantification method for 
the quantification of nine serum steroids: cortisol, corticosterone, 11deoxycortisol, androstenedione, DOC, 
testosterone, DHEA, 17OHprogesterone and progesterone. These hormones have been chosen for their 
clinical relevance and, since our aim was to develop a multi-analytes method, chemical compatibility: other 
important steroids such as aldosterone, DHT, pregnenolone and the estrogens were not included in this 
method because they require a different kind of ionization and a different polarity. With a single 
chromatographic run of 21 minutes, we obtained the panel of nine circulating steroids, offering to the 
clinician a powerful tool for the diagnosis of steroids-related pathologies. By using a higher serum volume 
(900 µl) than those reported in other published multi-analyte methods99-101, we were able to provide a 
general better sensitivity determined during method validation in a complex matrix. Although such good 
sensitivity was not enough to determine DOC circulating reference intervals in our healthy population, the 
inclusion of this hormone in the quantification method is however important for the diagnosis of some 
pathological conditions such as the 21-hydroxilase or 11-hydroxylase deficit that cause an increased 
concentration of this hormone. Moreover, using this high serum volume, also noise and interferences can 
increase; to avoid contaminations we developed the double purification: the SPE and the on-line 
purification with a perfusion column. The chromatographic gradient gave a good resolution for all the 
analytes, and especially for isobaric compounds, such as corticosterone and 11-deoxycortisol, DOC and 
17OH-progesterone.  
Once validated following the FDA guidelines45 and verified by using certified products of the Reference 
Institute for Bioanalytics, the LC-MS/MS method has been compared with routine immunoassays employed 
in the Laboratorio Centralizzato of the Policlinico Sant’Orsola Malpighi in Bologna. The results of this study 
showed a good immunoassays performance concerning steroid hormones circulating at physiological high 
concentrations, such as cortisol, men testosterone and progesterone >1ng/ml, while problems due to the 
calibration of the immunoassays were highlighted for androstenedione and DHEA. Poor specificity of the 
immunoassays, extensively supported by literature data and documented in one of the previous 
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paragraphs13-40, was found for women testosterone, 17OHprogesterone and progesterone <1ng/ml. In the 
first case, the poor specificity causes a low accuracy, as much as testosterone concentrations in some 
samples result in the pathologic range if analyzed with immunoassay and in the healthy range if analyzed 
with LC-MS/MS. On the other hand, the poor accuracy caused a systematic overestimation for 
17OHprogesterone and a proportional overestimation for progesterone <1ng/ml. As told before, for the 
analytes corticosterone, 11deoxycortisol and DOC was not possible to perform the comparative study, 
since they are not currently measured at the Laboratorio Centralizzato.  
Since the clear limits of the immunoassays were confirmed, we used the method to redefine the reference 
intervals in a healthy population composed of 356 subjects (179 adult males and 177 adult females). This 
thesis work, recently published (Annexes), has been one of the first work in which an LC-MS/MS multi-
analytes quantification method of a wide steroids profile is used for the definition of reference intervals. 
Our data showed a strong androgens tendency to decrease proportionally with age in both men and pre-
menopausal women. While testosterone and androstenedione are stable in post-menopausal women, 
DHEA tends to decrease in all the groups. In addition, post-menopausal women presented an age-
dependent decrease also for glucocorticoids, both cortisol and 11-deoxycortisol.  
In general our values of cortisol and corticosterone are lower than those reported in previous studies101-104. 
The explanation could be the saline infusion performed to our patients to avoid stress-related alterations in 
the glucocorticoids cascade. However further wide population screening are required to better establish 
steroids circulating reference intervals, grouping the population for decades.  
Afterwards, steroids circulating concentrations were determined in an overweight population and an obese 
population. We compared then the results obtained in these two cohorts with a group of normal weight 
people extracted from our healthy population, matching the three subjects groups by age. Concerning the 
women, we found significantly lower cortisol levels in the obese group compared to overweight and normal 
weight women: these data could be apparently in contrast with data literature, since obesity presents an 
hyper-activation of the HPA axis that should lead an increased production of glucocorticoids. To better 
understand these data, a determination of the circadian rhythm of this hormone is necessary, since single-
time cortisol measurements are inadequate to determine the activation status of the HPA axis105. 
Furthermore, also a measurement of cortisone, the inactive metabolite of the cortisol, can elucidate better 
the meaning of this controversial result.  
Concerning men, we found highly significant lower levels of testosterone in the obese population, in 
agreement with what reported in literature from other authors. Indeed, these data concerning 
testosterone are not surprising: obesity in adult males is associated with hypogonadotropic 
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hypogonadism106 and it is well known that infertility can be an obesity consequence, supported by low 
testosterone levels and an altered androgen-to-estrogens ratio. 
In conclusion, the great technical approach provided by the LC-MS/MS for endocrine measurements of 
different hormones classes can be used to provide a rapid, simultaneous and reliable quantification 
indispensable for diagnoses and monitoring of a wide range of pathologies. The introduction of this 
technique in the clinical routine can contribute to more accurate diagnoses based on more precise 
laboratory data.  
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CIRCULATING ENDOCANNABINOIDS QUANTIFICATION IN 
OBESE PATIENTS BEFORE AND AFTER GASTRIC BYPASS 
SURGERY 
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The endocannabinoid system (ECS), principally consisting of cannabinoid receptor type 1 (CB1), cannabinoid 
receptor type 2 (CB2) and their endogenous ligands, the fatty acid derivatives endocannabinoids (ECs), is 
involved in a plethora of physiopathological processes, some of which are not fully understood107. Since the 
ECS is ubiquitously located, many key regulatory actions have been attributed to ECs, but several studies 
during the last twenty years have highlighted the prominent role of this system in the framework of food 
intake and energy balance14. ECs, in this context mainly acting through CB1 receptors108, seem to have 
principally an anabolic function increasing food intake, promoting fat storage and decreasing energy 
expenditure, generally contributing to visceral fat accumulation in animals14. These ECs actions are exerted 
via both central109 and peripheral110 mechanisms. For instance, CB1 in the central nervous system (CNS) is 
highly expressed in hypothalamic nuclei involved in the control of energy balance and food intake and in 
neurons of the mesolimbic system involved in the regulating reward processes associated to food intake. 
Also in the periphery CB1 expression has been found in organs involved in the maintenance of the energy 
homeostasis, such as the white adipose tissue, the liver and the gastro-intestinal tract.  
While in animals ECs functions have been extensively characterized15-16, fewer studies in humans have been 
carried out. The evidence obtained from the ECS characterization in murine models led some years ago to 
develop a CB1 antagonist molecule as anti-obesity drug, which was called Rimonabant14. Despite 
encouraging results obtained from phase III clinical trials, Rimonabant was withdrawn from the market 
because of important psychiatric side effects such as depression and mood disorders. This disappointing 
clinical experience has shown how little we know about the ECS in humans. 
To better understand the role of this system in the context of human obesity, less than ten years ago 
circulating levels of ECs started to be measured in human plasma using chromatography coupled with mass 
spectrometry. Nowadays, it is well known that an up-regulation of plasma ECs exists in obese subjects17-19, 
despite the precise role of these circulating molecules is still unclear. Moreover, a correlation between ECs 
levels and anthropometric parameters related to obesity was found by several authors19-20, as well as 
alterations of ECs circulating levels depending on the feeding status22 or a diet-induced weight loss21.  
Based on the evidence found so far concerning higher circulating levels of plasma ECs in obese patients and 
the decrease of these levels after a weight loss21, we decided to carry out a project aimed at evaluate ECs 
circulating levels in obese patients before and after a particular type of bariatric surgery intervention, the 
Roux-en-Y gastric bypass (RYGB), currently the most effective long-term anti-obesity therapy, achieving not 
only the best weight-loss percentage, but also inducing important metabolic improvements, including 
better control of type 2 diabetes111-112. This part of the thesis project was carried out at the Neurocentre 
Magendie INSERM U862 in Bordeaux. 
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This project consists of the evaluation of basal levels of circulating ECs at three stages of the study, before 
the surgery, one month after the surgery and six months after the surgery; the estimation of variations of 
plasma ECs values before and after the consumption of a controlled meal at the same three stages and the 
possible relationship between ECs changes and alterations of metabolic and anthropometric parameters 
resulting from the weight loss induced by the surgery.  Our data could lead to better understand the role of 
circulating ECs in energy balance regulation and their role in possibly mediating weighloss and metabolic 
effects induced by the bariatric surgery. 
Moreover, it was shown that 40% of obese non-diabetic men and 50% of obese diabetic men have 
decreased circulating concentrations of testosterone113. As explained in the former chapter, obesity is one 
of the chronic pathological conditions more frequently associated with hypogonadism, the decreased 
functionality of the gonads that leads to reduced circulating levels of sex steroids. The reasons underlying 
this deregulation are still poorly understood114 and some data from clinical studies evidenced a recovery of 
normal plasma testosterone concentrations after a weight loss induced by RYGB115-117. In this context, we 
want to evaluate the recovery of normal androgens circulating concentrations, in particular testosterone 
and DHEA, in our obese patients undergoing RYGB. Moreover, since we measured fasting androgens 
before, one month after the surgery and six months after the surgery, we could analyze androgens 
concentrations in relation to different percentage of weight loss.  
In addition, early evidence highlighted a connection between these two biological systems in animals: first, 
several constituents of the ECS are present on the HPG axis; second, ECs are involved in biological functions 
controlled by sex steroids, such as reproduction and sexual arousal118. Even if there are some discrepancies 
between different studies, several investigations carried out in 70s showed also that chronic marijuana 
smokers have decreased levels of testosterone119-120. As well as Δ9-tetrahydrocannabinol (THC), AEA 
injections reduced testosterone levels in male wild-type mice but not in CB1 knock-out mice, suggesting 
that this effect is CB1 mediated121. Despite a consistent number of studies carried out in animals, the 
relationship between circulating levels of ECs and androgens in humans has been poorly investigated. Once 
assessed the alterations that may occur in plasma concentrations of both types of analyzed molecules in 
our obese patients, it will be possible to evaluate whether a correlation exists between circulating levels of 
ECs and androgens related to different obesity conditions. These data could provide a better understanding 
of the link between these two systems in humans. 
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I. The endocannabinoid system 
 
Ia. Historical notes  
The wide recreational, medical and religious use of the Cannabis Sativa has been documented since ancient 
times with medicinal benefits encompassing anesthetic, airway opening, anti-hypertensive as well as anti-
emetic actions122. Despite this, the underlying physiological and molecular mechanisms were unknown. The 
first scientific turning point concerning the physiological characterization of the cannabis effects was in 
1964 when Gaoni and Mechoulam first isolated and described the chemical structure of the terpenoid 
derivative Δ9-THC123, the main psychoactive component of marijuana.  
In parallel with the discovery, Δ9-THC and other hemp constituents were tested for psychotropic and motor 
effects in man and in animal models, mostly in mice, rats, rabbits, and dogs. Δ9-THC proved to be the most 
effective among all phytocannabinoids being responsible for the vast majority of effects such as motor 
disturbances and catalepsy, corneal areflexia (in rabbits), scratching, euphoria and dysphoria, anxiety, 
drowsiness, altered time and audiovisual perceptions, panic attacks and impaired memory124.  
The underlying mechanisms for these effects were mostly believed to result from “non-specific” 
interactions between the lipophilic Δ9-THC and the cell membranes, changing the fluidity and structure of 
the latter122. However this view of Δ9-THC action is outdated by the discovery of Matsuda and co-workers in 
1990 that cloned the CB1125, a G protein-coupled receptor, which binds cannabinoids and whose activation 
is responsible for the Δ9-THC effects. Three years later another cannabinoid receptor, the CB2, was 
discovered but its expression was found to be restricted mainly to immune tissues126. 
The presence of specific receptors for cannabinoids suggested the existence of endogenous ligands which 
could mimic Δ9-THC effects: in 1992 Devane and colleagues described the chemical structure of the lipid 
molecule N-arachidonoylethanolamine also called anandamide (AEA), the first EC, isolated from brain and 
determined by mass spectrometry and nuclear magnetic resonance spectroscopy127. The name anandamide 
takes origin from the Sanskrit word “ananda”, which means “bliss”. In 1995 a second endogenous ligand for 
CB1 was discovered, the 2-arachidonyl glycerol (2AG), which was isolated from the gut 128. In the figure 3.1 
the cannabinoid system time-line is represented.  
Cannabinoid receptors, endocannabinoids and the enzymatic complexes for their synthesis and 
degradation represent together the endogenous signaling system, the ECS. In the last twenty years, it has 
become evident the ECS involvement in numerous mammalian physiological processes ranging from 
memory to stress response, from pain perception to reproduction: this evidence triggered an increasing 
number of studies in many medical research fields exploring all the functions and alterations of the ECS in 
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physiological and pathological conditions. Amongst all the regulatory functions attributed to ECS, its 
involvement in the food intake and energy balance mechanisms seems to be crucial11-14. ECs regulate many 
essential mechanisms in this context, for instance hunger, nutrients metabolism, regulation of body weight 
and rewarding proprieties of food14. The ECS system seems to be one of the principal candidates for the 
future therapeutic strategies against obesity. However, despite the increasing number of studies carried 
out so far aimed to discover the basic mechanisms underlying the actions of ECs in the human metabolism, 
further studies are required in order to further expand our knowledge in the field.  
 
 
Figure 3.1: Cannabinoid system time-line. 
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Ib. Cannabinoid receptors  
CB1 and CB2 are G protein-coupled receptors, mainly of the Gi/o inhibitory subtype
107. They are constituted 
by seven transmembrane domains connected by three extracellular and three intracellular loops and two 
hydrophilic tails: an extracellular N-terminal tail (shorter in the type 2 receptor) and an intracellular C-
terminal tail that interact with the G-protein. The receptor activation leads to the activation of the Gi/o 
protein, inhibiting adenylate cyclase with consequent decrease of cytosolic levels of the second messenger 
cyclic adenosine monophosphate (cAMP). In the CNS the activation of these receptors leads to the 
inhibition of the transmembrane ionic conductance, activating K+A channels and inhibiting N and P/Q type 
Ca+ channels. Furthermore, their activation can stimulate intracellular kinases such as the focal adhesion 
kinase (FAK), phosphatidyl-inositol 3-kinases (PI3-K), ERK kinases and the p38 MAP kinase. The kinases 
activation can mediate the CB1-induced expression of the immediate early genes (IEG), such as the 
transcription factors c-fos, c-jun, zif268 and the brain-derived neurotrophic factor (BDNF)14. These pathways 
are summarized in figure 3.2 (adapted from Pagotto U. et al. 200614).  
The distribution of the cannabinoid receptors has been extensively studied using some different 
approaches, such as the autoradiography in brain sections129, in situ hybridization130 and 
immunohistochemistry131. According to receptor expression studies, CB1 receptor is the most abundant G-
coupled receptor in the mammalian brain and it’s highly expressed in hippocampus, neocortex, amigdala, in 
some region of the basal ganglia, thalamic and hypothalamic nuclei, cerebellar cortex and brainstem nuclei 
and the olfactory bulb14. Furthermore, last year Benard and co-workers found CB1 expression also in 
membranes of neuronal mitochondria, evidencing its direct involvement in cellular respiration and energy 
production132.Originally, CB1 was defined as the “brain type” receptor because of its high expression in the 
CNS; however, additional studies concerning its expression have confirmed also the presence of this 
receptor in many peripheral organs such as for instance the thyroid, the adrenal glands and the testicles. 
Importantly CB1 is expressed in peripheral tissue involved in the energy metabolism: almost ten years ago, 
CB1 was found in human and animal adipocytes15-133 and later expression of this receptor was found also in 
the liver134, pancreas135 and skeletal muscle14. CB1 is also present in the gastro-intestinal tract (GI)136, where 
it modulates many important functions, such as gastric emptying, intestinal motility and secretions137. In 
addition, CB1 is expressed in vagal nerve terminal of the GI involved in the modulation of food intake136. 
The CB2 receptors, conversely, are expressed almost only in immune cells138.  
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Figure 3.2: CB1 intracellular signalling. 
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Ic. Endocannabinoids 
ECs are lipids, polyunsaturated fatty acids derivatives of arachidonic acid. Five ECs have been described so 
far, but only two of them are present at appreciable physiological concentrations and bind CB1 with 
considerable affinity: AEA and 2AG (figure 3.3). For this reason, these two ECs are the more studied and 
best characterized. 
Given their lipophilic nature, ECs are not stored after their production, but released as soon after their 
synthesis exerting their biological functions on neighboring cells or on the same cell which produced them, 
following an “on demand” production mechanism139. Therefore, since they are local mediators, it has been 
hypothesized that ECs found in plasma represents a “spill-over” from tissues rather than a biologically 
active fraction140. 
Moreover, it has been shown that in the brain ECs behave as retrograde messengers: they are first 
synthesized in the postsynaptic cell and then they activate the CB1 receptor expressed on the presynaptic 
cell139. 
 
 
 
 
Figure 3.3: Anandamide and 2AG chemical structure. 
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1. AEA 
As mentioned before, AEA was the first endogenous molecule binding cannabinoid receptors identified. It 
binds CB1 receptor with appreciable affinity and, when injected in the rat brain, induces the same effects of 
THC127. The AEA biosynthesis occurs on demand and it is a two steps process: first, the AEA precursor N-
arachidonoyl- phosphatidylethanolamine (NAPE) is synthesized by a reaction catalyzed by the enzyme N-
acyltransferase (NAT) consisting in the intermolecular passage of an arachidonic acid group from the Sn-1 
position of phosphatidylcholine to the head group of phosphatidylethanolamine. The second reaction is a 
stimulus-dependent cleavage of the NAPE mediated by a phospholipase D141 (NAPE-PLD) producing AEA and 
phosphatidic acid. The reactions of the AEA biosynthesis are represented in figure 3.4 (adapted from 
Piomelli D., 2003142). NAPE-PLD is widely distributed in mammalian tissues; expression studies revealed the 
high content of this enzyme in mice brain, kidney and testicles141. A moderate expression of NAPE-PLD was 
also found in organs directly involved in energy metabolism, such as the large intestine and the skeletal 
muscle141.  
 
 
Figure 3.4: AEA biosynthesis. 
 
 
Two kinds of second messengers control the NAT activity: Ca2+ and cAMP142. Ca2+ is directly required for 
NAT activity, since NAT is inactive without it. cAMP activ NAT indirectly through the NAT phosphorylation 
by a protein kinase A-dependent mechanism. It was shown that AEA is produced and released from 
cultured rats brain neurons in a calcium ion-dependent manner: incubating the cultured neurons with [3H]-
ethanolamine, Ca2+ ionophores, such as the ionomycin, stimulate the [3H]-AEA accumulation143. There is 
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also some evidence of regulation of AEA biosynthesis through G protein-coupled receptor: Giuffrida and 
colleagues found an increase of AEA concentration after administration of quinpirole, a D2 like dopamine 
receptor agonist, in rat dorsal striatum that can be prevented by raclopride, a D2 like receptor 
antagonist144.  
AEA was isolated for the first time from brain extracts127; several studies suggested that AEA content varies 
across different brain regions, but quantitative analyses are not always consistent145. A high AEA amount 
has been found in hippocampus and striatum; appreciable quantities in midbrain, cortex, hypothalamus 
and cerebellum145. In the periphery, a particularly important production of AEA has been found in tissues 
involved in the control of energy homeostasis, such as the gut, the liver, the WAT, the skeletal muscles and 
the pancreas140.  
AEA action is regulated by a two steps process: after its biological actions, it is first internalized into the cell 
and then hydrolyzed by the fatty acid amide hydrolase (FAAH)146. FAAH is an intracellular membrane-bound 
serine hydrolase with an N-terminal transmembrane domain, which is the principal catabolic enzyme of 
AEA, generating arachidonic acid and ethanolamine. This enzyme is widely expressed in the rat brain with a 
main presence in principal neurons of the cortex, the hippocampus, the cerebellum and the olfactory 
bulb147, but moderate FAAH expression was found in almost all the major brain areas148. Concerning the 
periphery, FAAH expression was found in different organs, some of which involved in the energy balance 
regulation such as the liver148, the pancreatic beta-cells and the white adipocytes17. 
Furthermore, AEA neuronal breakdown is mainly a post-synaptic process142. The AEA removal from the 
extracellular space and the transport of it into the cytosol is still unclear; an interesting mechanism was 
proposed by Piomelli and co-workers, finding a FAAH like anandamide transporter (FLAT) which lacks the 
catabolic action typical of FAAH but can bind anandamide with lower affinity, transporting it into cells149.  
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2. 2AG 
2AG is a monoacylglycerol, omega6 fatty arachidonic acid and glycerol ester. Two possible synthesis 
pathways were described. First, it can derive from the conversion of phosphatidylinositol in 1,2-
diacylglycerol (DAG) mediated by the enzyme phospholipase C (PLC) and the consequent hydrolysis of DAG 
in 2AG trough the enzyme diacylglycerol-lipase (DAGL)150. An abundant expression of DAGL was found in 
the rodent hypothalamus, while a mild expression of this enzyme was found in the majority of extra-
hypothalamic brain areas150. In periphery, the most copious presence of DAGL was found in human 
pancreas, however the presence of this enzyme was observed in many other human peripheral tissues, 
such as for instance the adipose tissue or the liver150. 
The second pathway proposed is the synthesis of a 2-arachydonoyl-lysophospholipid mediated by the 
enzyme phospholipase A1 (PLA1); the 2-arachydonoyl-lysophospholipid is then hydrolyzed by a lyso-PLC142. 
The synthesis pathways of 2AG are summarized in figure 3.5 (adapted from Piomelli D., 2003142). The 2AG is 
the most abundant endocannabinoid in the brain: its concentration is about 170 fold higher than 
anandamide151.  
 
 
 
Figure 3.5: 2AG biosynthesis. 
 
 
2AG was isolated for the first time in the gut128, a tissue directly involved in the energy balance. Similarly to 
AEA, 2AG production seems to be important also in the WAT, the liver and the skeletal muscle140. 2AG 
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concentrations in brain areas are not different as for AEA145: this EC has been found in considerable amount 
in almost all the major brain regions, in particular the hypothalamus, the hippocampus and the midbrain145.  
The principal enzyme responsible for the 2AG degradation is the monoacylglycerol lipase (MAGL) a 
membrane-bound serine hydrolase that catalyzes the 2AG break-down generating fatty acid and glycerol. 
Like FAAH, also MAGL is widely diffused in many brain areas, with higher expression in the cerebellum, the 
cortex, and the hippocampus, but while the FAAH distribution is principally post-synaptic, MAGL was found 
mainly presynaptically152. The 2AG re-uptake mechanism is still unclear. 
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II. Endocannabinoids and obesity 
 
IIa. Animal studies and early evidences 
Since ancient times it was known that the consumption of cannabis in different forms was able to stimulate 
appetite, particularly for palatable foods153. The identification of THC as main psychoactive component of 
marijuana allowed investigating the appetite stimulatory effect of this molecule. Indeed, several animal 
studies demonstrated the ability of THC to promote appetite, although significant effects were shown only 
with low doses154. After the discovery of cannabinoids receptors and the introduction of selective 
antagonists, the increased appetite induced by THC was clearly linked to the activation of the CB1 receptor, 
since its effect was inhibited by the CB1 selective antagonist SR141617 (Rimonabant) but not by the CB2 
selective antagonist SR144528155. After the identification of ECs as endogenous ligands of the CB1 receptor, 
it was demonstrated that low AEA doses, injected systemically156 or in the ventro-medial nucleus of 
hypothalamus157, stimulate the appetite. A similar increase of food intake was produced also injecting 2AG 
systemically or in the nucleus accumbens158. Moreover, orexigenic sites of action of ECs in the 
hypothalamus and limbic forebrain suggested their involvement in both homeostatic and reward-related 
control of appetite159.  
The investigations carried out using CB1 antagonists have provided a direct support to the hypothesis by 
which ECs have a regulatory role on food intake. AM251, a CB1 antagonist, reduced appetite in rats fed ad 
libitum160. However, the most important evidence of the ECS involvement in the control of food intake was 
provided by the development of knock-out mice lacking the CB1 receptor. Indeed, knock-out mice eat less 
compared to wild-type littermates, and their food intake cannot be further modulated by Rimonabant, 
while wild-type mice treated with this CB1 antagonist showed a decreased food intake108. In addition, CB1 
knock-out mice are resistant to the orexigenic action of neuropeptide Y (NPY) as well as wild-type mice 
treated with Rimonabant161. Recently, Bellocchio et al. demonstrated an opposite role of CB1 in regulating 
food intake in the brain: while modulation of glutamatergic transmission by CB1 exerts the well-known 
cannabinoid-induced orexigenic effect, CB1 expressed on GABAergic neurons mediate a surprising 
hypophagic effect, suggesting a central opposite regulation of food intake by the ECS162. In the interesting 
work carried out in 2001 by Di Marzo and colleagues, the authors showed an inverse relationship between 
levels of leptin , an anorexigenic hormone produced primarily by the adipose tissue, and hypothalamic ECs 
levels. In particular, they showed an increase in hypothalamic ECs levels linked to a defective leptin 
signaling in obese db/db and ob/ob mice, while acute leptin intravenous injections were able to decrease 
hypothalamic ECs108.  
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In a study carried out in 2003, Cota and co-workers described in detail the phenotype of CB1 knock-out 
mice showing hypophagia and reduced body weight and fat mass compared to CB1 wild-type littermates, 
and evidencing the crucial role of the ECS in the energy homeostasis balance15. Moreover, authors 
proposed for the first time a food intake-independent mechanism contributing to the leaner phenotype of 
CB1 knock-out mice, suggesting that the reduced body fat in these mice could result from both central and 
peripheral mechanisms, such as hypothalamic alterations and deregulations of the adipocytes functions, 
since they first reported a role for CB1 receptors in the modulation of the adypocite metabolism15. 
Consequently, it was shown that CB1 knock-out mice were resistant to metabolic modifications induced by 
chronic exposure to a high-fat diet, such as high levels of circulating triglycerides and elevated plasma 
concentrations of leptin and insulin, a clue of leptin and insulin resistance16-163. Interestingly, changes of 
AEA concentrations were also found in the small intestine of mice related to fasting and re-feeding 
conditions164. AEA levels were higher in duodenum and liver following food deprivation and decreased after 
food intake, suggesting a possible peripheral mechanism involving ECs and food intake164. 
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IIb. Human studies: circulating endocannabinoids in obesity 
The studies carried out in animals have highlighted the important role of the ECS in the modulation of food 
intake and in the development of obesity. Despite the fact that the ECS is very well characterized in animal 
models, experimental evidence about its physiopathological role in humans is still lacking. 
The detection of ECs in human plasma could contribute to better understand the relationship between ECs 
and human obesity. Although some ECs functions have been very well characterized, the role of the 
circulating ECs is still unclear. It has been found an up-regulation of circulating ECs in obese patients, and in 
some studies also a correlation between their levels and several parameters altered by obesity, such as 
waist circumference and BMI19-20. In 2005 it was first published the up-regulation of AEA circulating levels 
(but not 2AG) in obese women presenting binge eating disorders (BED) compared to normo-weight 
women165 while in another study of the same year, both AEA and 2AG plasma levels resulted higher in 
obese post-menopausal women compared to lean women133. In the second study it was further found a 
positive correlation between AEA and BMI, 2AG and waist circumference. In 2006 Matias and co-workers 
found increased levels of both AEA and 2AG also in overweight diabetic subjects17. Studies about circulating 
ECs evidenced also the existence of a relationship between their plasma levels, insulin levels and the 
development of insulin resistance. In 2006 Bluher and colleagues found that 2AG circulating levels 
positively correlated with fasting plasma insulin concentrations and negatively correlated with glucose 
infusion rate during clamp, suggesting a direct relation between 2AG levels and glucose metabolism19. In 
2009 it was proposed that insulin is as negative regulator of circulating levels of ECs: authors found an AEA 
decrease induced by glucose oral load inversely correlated to fasting levels of insulin and glucose, 
suggesting that the ability of insulin to negatively regulate plasma ECs is lost in the presence of insulin 
resistance166.  
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i. Endocannabinoids and weight loss 
Few studies have been carried out so far about modifications in circulating ECs levels after weight loss. In 
the first study in obese post-menopausal women a 5% of total body weight loss obtained in 13-15 weeks 
133. Moreover, in this study also CB1 and FAAH mRNA levels in adipose tissues were evaluated, and neither 
resulted significantly influenced by the weight loss133. In another study, authors investigated changes in 
circulating ECs in twenty randomized non-diabetic obese patients treated with sibutramine, an inhibitor of 
neurotransmitters reuptake used as anorexigenic drug, withdrawn from the market in 2010. Patients were 
first treated with 15mg/day of the drug or placebo for 5 days (acute treatment) and then they were treated 
with open-label 15mg/day of sibutramine (chronic treatment). Neither the acute treatment nor the chronic 
treatment caused significant changes in circulating AEA and 2AG after a body weight loss of 6.0 ± 0.8 kg 
obtained after three months167. On the contrary, in another study in 2009 significant changes were 
observed in plasma ECs after a weight loss induced by life style modifications21. 49 asymptomatic non-
diabetic obese men followed a life-style modification program including a diet and physical activity exercise 
during 1 year. At the end of this period, subjects presented reduced body weight (-6.4kg), BMI (-2.1kg/m2) 
and waist circumference (-8.0cm) and also ameliorated parameters implicated in obesity co-morbidities, 
such as triglycerides (−0.74 mmol/l), HDL-cholesterol (+0.13 mmol/l) and fasting insulin levels (−51.9 
pmol/l). Both AEA and 2AG levels were decreased after the weight loss (AEA: -0.54 pmol/l, p<0.005; 2AG: -
0.98 pmol/l, p<0.005)21.  
Since different results were achieved by different studies, it is still unclear whether the weight loss can 
directly lead to variations of circulating ECs levels. Noteworthy, experimental parameters and procedures 
of the three studies discussed above were not the same, such as weight loss strategies, patients 
characteristics and ECs measurement time-point: therefore, is likely that these experimental discrepancies 
are the reasons behind the inconsistency of the obtained results. In particular, it is possible that in the first 
two studies some weeks of pharmacologic and life-style treatment were insufficient to achieve significant 
changes. The latter study was carried out after one year, during which patients achieved an adequate 
weight loss that led to physiological ECs changes.  
Summarizing, in obese patients circulating ECs levels are higher compared to normo-weight subjects; and 
after weight loss obtained with life-style modifications plasma ECs tend to decrease. Studies carried on so 
far clarifying the meaning and alteration mechanisms of circulating ECs are still insufficient; starting from 
what has been found so far, further data are required to elucidate the role played by these molecules in the 
framework of the human obesity. 
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ii. Endocannabinoids and food intake  
Several studies in animals showed changes of ECs levels in tissues such as the hypothalamus and limbic 
forebrain in the CNS168 or in peripheral tissue, such as the duodenum164 related to the animal feeding 
status. In 2006, comparable changes of ECs were found also in human plasma by Matias and co-workers: 
they described a significant post-prandial decrease of AEA in plasma after the consumption of a meal with 
high content of fat in normo-weight subjects17.  
These results were further confirmed in 2012, when a precise kinetics of plasma AEA levels related to the 
food intake was described. In normo-weight subjects, AEA presented an increase in pre-prandial blood 
concentrations and a post-prandial decrease of almost the 40%, displaying a circulating profile of a hunger 
signal. Obese patients, while retaining the pre-prandial AEA peak, have a blunted post-prandial decrease in 
plasma AEA (approximately 10% of post-prandial change) after the consumption of a calorically balanced 
meal (figure 3.6 A-B modified from Gatta-Cherifi et al., 2012)22. Concerning  2AG, it was confirmed what 
was previously found in 2006: its circulating levels are not modified by the feeding status, suggesting a 
different role for 2AG in the context of food intake (figure 3.6 C).  
 
 
 
 
Figure 3.6: AEA circulating concentrations changes related to the feeding status in normal-weight and obese people (A). 
Circulating AEA post-prandial percentage of change in normal-weight and obese people (B). 2AG circulating concentrations 
changes related to the feeding status in normal weight and obese people (C). 
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Similarly, the authors also reported a meal-related kinetics of the anorexigenic peptide YY (PYY) that 
showed in normo-weight subjects opposite changes compared to AEA, significantly increasing after the 
meal consumption. While PYY levels did not change in obese subjects in response to the meal (figure 3.7 A-
B modified from Gatta-Cherifi et al., 201222), suggesting an obesity-dependent deregulation of the levels of 
this hormone, as previously reported169.  
 
 
 
 
Figure 3.7: PYY circulating concentrations changes related to the feeding status in normal-weight and obese subjects (A). 
Circulating PYY post-prandial percentage of change in normal-weight and obese subjects (B).  
 
 
At this stage, it is still not clear where AEA changes originate from. A natural candidate could be the gastro-
intestinal tract: the presence of the ECS has been extensively documented in the gastrointestinal tract, 
where CB1 and CB2 receptors have been found, and ECs and enzymes involved in both their production and 
degradation have been quantified. Furthermore, as mentioned before, ECs in gastrointestinal tract tissues 
are increased during fasting and a decreased after refeeding in rodents136-164.       
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IIc. The emerging role of endocannabinoids related compounds  
In addition to the well characterized AEA, other N-acylethanolamines (NAEs) could be involved in food 
intake and obesity mechanisms: oleoyl-ethanolamine (OEA), amide of oleic acid and ethanolamine, and 
palmitoyl-ethanolamine (PEA), amide of palmitic acid and ethanolamine. Since they belong to the same 
chemical class and share the same biosynthetic and degradative pathway, PEA and OEA are structurally 
very similar to AEA (figure 3.8).  
 
 
 
 
Figure 3.8: PEA and OEA chemical structure. 
 
 
Despite these similarities, PEA and OEA are inactive on cannabinoid receptors170. Both these compounds 
exert their biological proprieties binding the nuclear receptor peroxisome proliferator-activated receptor 
alpha (PPAR-α)170. Some studies suggested a link between the action of these two compounds and AEA: 
OEA and especially PEA can be an alternative substrate for FAAH, the AEA catabolic enzyme, reducing in 
this way the degradation rate of AEA and enhancing its action171. For this reason, PEA and OEA are defined 
as “entourage” compounds. Giving their structural similarities and related actions with AEA, an involvement 
of these molecules in the energy homeostasis and food intake has been supposed172. 
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i. Animal studies 
Given the actions exerted by AEA and 2AG in energy balance and obesity development in animals, studies 
were carried out also to assess whether OEA and PEA were involved in the same mechanisms. 
In 2001, Rodriguez de Fonseca and co-workers found decreased concentrations of OEA in the small 
intestine in rats after food deprivation. OEA administration caused reduction of food intake, suggesting an 
anorexic effect of this molecule, mostly at peripheral levels, while PEA was significantly less potent than 
OEA in exerting this action173. Two years later, it was demonstrated by the same group that the anorexic 
action and the reduction of body weight gain induced by OEA required PPAR-α receptors, since this effect is 
lost in PPAR- α knock-out mice170. Furthermore, it was shown that OEA injection is able to enhance lipolysis 
in wild-type mice but not in PPAR-α knock-out mice174. In a recent study, Schwartz and colleagues found 
increased OEA mobilization after fat injection in the duodenum, but not after proteins or carbohydrates 
infusion. They hypothesized a specific link between ingestion of fats and satiety induced by intestinal OEA 
mobilization175.  
Unlike OEA, PEA functions concerning food intake and obesity pathophysiology are less characterized. PEA 
seems to exert its main biological role as anti-inflammatory molecule. This peculiar effect was shown to be 
carried out through PPAR-α receptors, since is lacking in PPAR-α knock-out mice176. Likely, PEA could have a 
role in obesity-induced inflammation. 
 
ii. Human studies 
As for AEA and 2AG, the role of circulating PEA and OEA in human obesity is not clear. Few studies were 
carried out so far measuring these ethanolamines in the plasma of obese subjects. In one of the first human 
studies investigating expressly these molecules172, PEA and OEA were measured in visceral fat and 
subcutaneous fat of two groups of subjects: obese patients and normo-weight controls. No significant 
differences between the two groups were found in visceral fat content of PEA and OEA; on the contrary, 
significantly lower PEA concentrations were found in subcutaneous fat of obese subjects compared to 
visceral fat172.  In the same study, fasting PEA and OEA were quantified in blood of diabetic over-weight 
patients compared to healthy volunteers finding higher concentrations of both the NAEs in diabetic over-
weight patients. Furthermore, they found a decrease of post-prandial circulating PEA and OEA in healthy 
volunteers after a meal with high-fat content172.  In 2010, increased OEA concentrations were found in 20 
subjects affected by sleep apnea compared with over-weight healthy controls; also a correlation between 
OEA circulating levels and BMI was found in the sleep apnea group177. Last year, Matias et al. measured PEA 
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and OEA, in association with endocannabinoids AEA and 2AG, in saliva and they found elevated 
concentrations of the four analytes in obese subjects compared to normal-weight people178.  
Further knowledge is therefore required to better understand the physiological role of these circulating 
compounds in relation to obesity and food intake, measuring them in different conditions. 
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III. Anti-obesity approaches 
Nowadays, in case of severe obesity (BMI>30 kg/m2) when life-style modifications are not sufficiently 
effective, two kinds of therapeutic strategies are currently available, drug therapies and bariatric surgery. 
 
IIIa. Drug therapies  
Three drugs developed so far have proved to be successful in decreasing significantly body weight: 
Sibutramine, Orlistat and Rimonabant, a CB1 antagonist. 
Sibutramine is an inhibitor of neurotransmitters serotonin and norepinephrine reuptake, which has an 
effect on both food intake and energy expenditure179. In 1997, this drug was approved by FDA and in 1999 
its use was authorized in the European Union (EU)180. Unfortunately, data from the Sibutramine 
Cardiovascular Outcomes Trial (SCOUT)181 proved an increased risk of myocardial infarction and stroke, and 
consequently, this drug was withdrawn from the market in 2010, first in EU and then in USA and other 
countries180. 
Orlistat is the first anti-obesity drug that is not acting as an appetite-suppressant; indeed, it causes an 
inhibition of pancreatic and gastric lipases, by which 30% of ingested dietary fat remains undigested and 
unabsorbed leading in particular to ameliorations of lipid profile parameters182. This drug was approved by 
FDA in 1999, and it is still on the market in approximately 100 countries all over the world, despite its 
gastro-intestinal side effects180. Noteworthy, Orlistat is less effective than other anti-obesity drugs; 
however, it is the only one currently available on the market 180. 
Given the scarce availability of anti-obesity drugs, based on the studies carried out on animals, in 1994 the 
pharmaceutical company Sanofi-Aventis developed a CB1 antagonist, the Rimonabant (commercialized as 
Acomplia®)183. Despite it was at the beginning tested as a smoking cessation agent184, evidence about the 
efficacy of this CB1 antagonist in animal studies led Sanofi-Aventis to test it as pharmacological strategy 
against obesity in humans at the beginning of 2000s.  
Several studies evaluated the efficacy of Rimonabant in the treatment of obesity: in August 2001 a wide 
phase III study called185 the RIO program (Rimonabant in Obesity) started, including more than 6600 
patients all over the world. The study was constituted by 4 controlled randomized trials: RIO-Europe, RIO-
Lipids, RIO-North America and RIO-Diabetes. RIO-Lipids and RIO-Diabetes were more focused on the 
amelioration of specific obesity co-morbidities (hyper-lipidemia and diabetes mellitus type II, respectively), 
while RIO-Europe and RIO-North America recruited obese and over-weight patients with or without co-
morbidities14. All the patients involved (1507 for RIO-Europe, 1036 for RIO-Lipids, 3045 for RIO-North 
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America and 1045 for RIO-Diabetes) were treated for two years with Rimonabant 5 mg/day or 20 mg/day 
or placebo. Furthermore, subjects followed also a life-style modification program and a hypo-caloric diet 
together with the drug therapy. The primary end-point of RIO-North America was the evaluation of the 
body weight loss during the first year and the prevention of weight regain after a further patients 
randomization at the beginning of the second year of the study. On the other hand, the main end-point of 
RIO-Europe was the evaluation of body weight loss14.  Similar results were obtained at the end of each trial: 
data from RIO-Lipids showed a weight loss of more than 10% of the initial body weight in the 44.3% of 
patients included in the Rimonabant 20mg group (p:0.001 vs placebo), 16.3% of patients included in the 
Rimonabant 5mg group and 10.3% of placebo group patients. The Rimonabant 20mg group showed also 
substantial and significant reduction of waist circumference, circulating triglycerides, C-reactive protein and 
a significant increase of HDL cholesterol compared to the placebo group186. Moreover, during this trial 
Rimonabant resulted generally well tolerated, reporting the main side-effect regarding the gastro-intestinal 
tract (nausea) or upper respiratory tract infections186. Similarly, data from RIO-Europe showed a weight loss 
significantly greater in patients treated with Rimonabant 20mg (-6.6kg) and Rimonabant 5mg (-3.4kg) 
compared to patients treated with placebo (-1.8kg) after one year. Also the improvement of waist 
circumference, HDL-cholesterol, triglycerides and insulin resistance was greater in the Rimonabant 20mg 
group. Transient and mild side effects were reported by a similar percentage of patients in all the groups187-
188. Thanks to these positive results obtained by the RIO program, in June 2006 the European Medicines 
Agency (EMEA) approved the sale of Acomplia® for the treatment of obesity and related co-morbidities in 
Europe for patients with a BMI ≥ 30 or BMI > 27 with severe co-morbidities, such as diabetes type II or 
dyslipidemia. However, the side effects induced by Rimonabant therapy were higher than expected: 
patients under therapy described side effects on their mood such as depressive and anxiety symptoms. 
Thus, in the 2009 Acomplia ® was withdrawn from the market189. The withdrawal of this compound from 
the market also highlighted the necessity to improve the knowledge about the role of the ECS in the human 
physiology to better define future therapeutic strategies.  
Currently new anti-obesity drugs are under investigation, some of them based on gut hormones-like 
molecules180. Indeed, the development of new anti-obesity drugs possibly having mild central and 
peripheral side effects is strongly needed in order to help tackle the obesity epidemic. 
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IIIb. Bariatric surgery: Roux-en-Y gastric bypass  
Currently, the most effective long-term treatment for severe obesity is bariatric surgery, a variety of 
surgical procedures aimed at the obtainment of weight loss, mostly reducing the stomach size, to reach 
satiety more quickly, or bypassing an intestine part, reducing in this way the nutrients absorption. Different 
bariatric surgeries were developed and proved to be the best long-term treatment for obesity, successfully 
reducing body weight and obesity related co-morbidities. Among them, RYGB is the most performed 
(approximately 90% of bariatric surgeries23), since it achieves the best weight loss results and several 
metabolic ameliorations. This surgery provides a substantial and durable weight loss: 37% of total body 
weight after 1 year and the regain of the 7% of the body weight loss after 14 years. Furthermore, another 
interesting aspect of this bariatric surgery is the high percentage of patients with complete type II diabetes 
(T2DM) remission: approximately 80%111.  
 
i. Surgical procedure 
RYGB is a malabsorptive and restrictive surgical procedure described for the first time in the early 1990s. It 
is performed creating a stomach restriction (“pouch”) and an intestine bypass: the stomach capacity is 
reduced to 30 ml111 allowing the patient to feel quickly sated with a less amount of food, while the intestine 
bypass reduces the nutrients absorption bypassing the duodenum and the jejunum. The intestine is 
rearranged with the typical “Y” shape in the new anatomical configuration and in this way the nutrients are 
directly carried to the distal gut. The operation is represented in figure 3.9. 
 
Figure 3.9: RYGB surgery. The stomach restriction leads to the formation of the “pouch”. Bypassed intestinal parts are the 
duodenum and jejunum. Arrows indicate the ingested food route determined by the new anatomy. 
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ii. Roux-en-Y gastric bypass anti-diabetic effect 
Several clinical studies have described a direct anti-diabetic effect of the RYGB. The first study was carried 
out in 1995: in 82.9% of patients with T2DM and 98.7% of patients with glucose impairment undergone this 
surgery ameliorations were observed for all the parameter relative to the glucose metabolism111. In 2005 
another study was performed monitoring fasting glucose and glycated hemoglobin (HbA1C) plasma levels 
before, 6 months after and 12 months after the RYGB intervention. Significant decrease of both the 
analyzed parameters was observed one year after, with T2DM resolution in 74% of 177 included 
patients112.  The high percentage of complete remission of T2DM after RYGB was further confirmed by 
other studies verifying also the anti-diabetic efficiency of the RYGB compared to the classic weight loss 
strategy: the diet190. This year a study was published in which the anti-diabetic efficacy of the RYGB was 
compared with sleeve gastrectomy and medical therapies, such as incretin analogues combined with a diet. 
All these three strategies achieved a better glycemic control after one year, but the RYGB showed the 
highest percentage of improvements: 12% of the patients with medical therapy, 37% with sleeve 
gastrectomy and 42% of patients with RYGB reached the first study end-point, the decrease of the HbA1C 
level of 6%191. Despite the number of published works about the relationship between this surgery and the 
diabetes remission, the precise physiological mechanism underlying this effect is still unclear. Noteworthy, 
it is now well accepted that the T2DM remission obtained after the RYGB is weight loss independent: firstly 
because 30% of patients present normal glucose levels approximately 3 days after the surgery192-193 before 
the weight loss occurs; secondly because this anti-diabetic effect is not obtained with other types of 
bariatric surgery, although providing the same amount of weight loss194.  
Several hypotheses possibly explaining the specific RYGB anti-diabetic effect have been proposed. In 2002, 
Cummings and colleagues suggested the ghrelin hypothesis. Ghrelin is an orexigenic peptide produced 
mainly by the stomach and duodenum, both organs altered after RYGB. The authors measured circulating 
ghrelin in post-RYGB patients, finding extremely low levels of this hormone195. Their findings were due to 
the specific anatomical changes provided by the RYGB. The compromised ghrelin secretion after the 
operation can improve the glucose tolerance, since ghrelin inhibits insulin secretion, hepatic insulin 
signaling and secretion of adiponectin, a peptide involved in the glucose regulation and fatty acid break-
down196.  
Another interesting hypothesis was suggested by Morinigo et al. in 2006. They found increased levels of 
glucagon-like peptide1 (GLP-1), a hypo-glycemic hormone enhancing glucose-dependent insulin secretion, 
and PYY in patients six weeks after RYGB when subjects were still obese, suggesting that this increased 
secretion was not dependent on the weight loss. They hypothesized that this increased hormonal secretion 
is due to the early direct contact between unabsorbed nutrients and intestinal L-cells, responsible of the 
production of these two hormones197. This way, insulin action is enhanced by GLP-1 and PYY increased 
122 
 
secretion. Also animal studies provided some hypotheses about the RYGB anti-diabetic effect. Troy et al. 
found increased levels of gluconeogenesis enzymes in the intestine of mice undergone a murine-
counterpart of the human RYGB. The increased intestinal gluconeogenesis seems to activate a pathway 
through the portal vein and the glucose transporter GLUT-2, which is able to decrease glucose hepatic 
production and therefore increase hepatic insulin sensitivity198. 
All the proposed hypotheses described above are not exclusive. It is possible that some of the mechanisms 
discussed so far and some undiscovered pathways participate to the general anti-diabetic effect of the 
RYGB. At this stage, new target systems and clinical data are required to better address future research to 
understand the underlying physiological mechanisms of this effect.  
 
 
IIId. Roux-en-Y gastric bypass, endocannabinoids and androgens: previous studies  
Since more knowledge is needed about the modifications induced by RYGB surgery on different 
physiological systems to explain its metabolic effects, in the last years some clinical and animal studies 
were carried on investigating the alterations that RYGB could have on ECs and steroids. 
Only one study so far investigated the relationship between metabolic changes induced by RYGB and ECs 
levels. In this study, performed in 2008 by Guijarro et al., they investigated the role of the ECS in three 
groups of diet-induced obese rats: RYGB rats, sham-operated rats and sham-operated pair fed rats199. They 
measured ECs in skeletal muscle and liver 14 and 28 days after the operation, corresponding approximately 
to one year and three years in humans respectively. They found a non significant increase of AEA 
concentration in both liver and skeletal muscle 14 days after the RYGB operation, despite the greater 
weight loss achieved compared to the other two groups. At the day 28, they found a significant decrease of 
AEA in both the analyzed tissues, following a further weight loss. A significant decrease of 2AG was also 
found at the day 28 only in the liver. The authors hypothesized that the decreased ECs concentrations were 
a consequence of all the improved metabolic parameters and the ECS could be implicated in the 
assessment of the physiological changes occurred after the RYGB199.  
On the contrary, several studies were carried out about the relationship between androgens functionality 
and RYGB. As described in the former chapter, obesity is characterized by decreased levels of androgens in 
men, likely due to a deregulation of the HPG axis, and different authors described the recovery of normal 
androgens levels in patients undergoing RYGB115-117. Hammoud et al measured total testosterone 
circulating levels in 22 obese men before and two years after RYGB. The average total testosterone was 
doubled after two years (before: 3,15 ± 2,01 ng/ml; two years after: 6,26 ± 1,85 ng/ml), furthermore they 
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found increases of free testosterone and SHBG; all these parameters were coherent with improvements in 
the sexual quality of life116. In another study, testosterone and DHEA levels were measured in obese men 
before, 3 months after, 6 months after and 1 year after a RYGB intervention. Testosterone levels increased 
significantly at all the study’s time points, while no significant changes of DHEA concentrations were 
observed117.  
Taking into account all the clinical data discussed so far, RYGB seems to ameliorate androgens functions by 
increasing their circulating levels and, consequently, improve the sexual functions in RYGB patients. 
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IV. Aim of the project 
Data discussed so far indicate that the ECS is strongly involved in the regulation of food intake and energy 
balance. Despite a meticulous characterization of this system in animals, human ECS has been not so 
accurately studied. To extend our understanding about the role of this system in human physiology and, in 
particular, its influence on the regulation of energy balance and the pathophysiology of obesity, recent 
studies are now focusing on the quantification of ECs in plasma.  
So far, three main evidences have been found regarding the relationship between circulating ECs and 
obesity. First, plasma ECs levels are higher in obese patients compared to normo-weight patients, indicating 
an up-regulation of this system related to obesity. Second, after a diet-induced body weight loss, these 
circulating levels decrease, confirming that this up-regulation is directly linked to the obesity condition. 
Third, plasma AEA presents a pre-prandial peak and a post-prandial decrease, behaving as an orexigenic 
molecule.  
Thus, in the second part of the thesis project we investigated the changes induced by RYGB intervention on 
ECS in obese patients. For this purpose, we used a sensitive and specific LC-MS/MS method previously 
validated following FDA guidelines for bioanalytical method validation45 to quantify plasma levels of two 
endocannabinoids, AEA and 2AG, and two endocannabinoids related compounds, PEA and OEA, in 12 
obese patients (BMI > 40 kg/m2 or BMI > 35 kg/m2 with obesity associated complications) undergoing 
RYGB. First, we measured fasting ECs in these patients before the surgery, one month after the surgery and 
six months after the surgery to assess variations of these levels in relation to different percentages of body 
weight loss obtained after the surgery. Second, performing blood withdrawals all over the day before and 
after a standardized meal at the three stages of the study, we assessed whether the ECs kinetics related to 
the food intake is subject to alterations.  
Potential variations in ECs levels after RYGB, and therefore after a weight loss, can give significant clues 
about ECs functions and their involvement in the physiopathology of human obesity. Furthermore, some of 
the data discussed so far strongly suggest that ECs, particularly AEA, produced in the gastrointestinal tract 
could play an important role in the regulation of food intake and energy homeostasis in humans. Since this 
surgery is generating important and specific changes in the anatomy of the gastro-intestinal tract, the ECs 
levels variations related to food intake could be in part elucidated. In addition, in this study we looked at 
the correlations between circulating ECs levels and anthropometric parameters relative to visceral obesity.  
Furthermore, in the same group of patients, we have been also interested in androgen measurement 
because obesity causes hypogonadism in men and in particular an important decrease of these circulating 
molecules likely due to HPG deregulation, as discussed in the former chapter. The decrease of circulating 
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androgens, and especially of testosterone, can lead impairment of the sexual function and obesity is one of 
the principal chronic pathological conditions characterized by this dysfunction. It is still not clear the direct 
link between obesity development and testosterone decrease, especially because the obesity-related 
deregulation of the HPG is sex-specific causing, on the contrary, increased circulating levels of testosterone 
in women. Furthermore, some clinical studies were carried out so far to investigate the recovery of 
androgens circulating normal levels and therefore an improved sexual function after a weight loss. Almost 
all the studies reported a significant increase of total testosterone after a weight loss obtained by both diet 
and bariatric surgery.  
In order to better understand the beneficial effects of the RYGB and consequently of a weight loss on male 
sex steroids, we measured also fasting androgens, in particular testosterone and DHEA, in male patients. As 
well as ECs, androgens were evaluated at three different time point of the study: before, one month after 
and six months after the RYGB in relation to different percentage of weight loss, using a GC/MS method 
previously developed and validated. 
Data resulting from testosterone and DHEA quantification will help to better characterized the androgen 
functions recovery after a weight loss induced by a specific surgery and therefore the recuperation of HPG 
functionality. Despite the existence of some data about this recovery, the underlying mechanisms are 
unclear. Resulting data from both ECs and androgens quantification at the three different time points of the 
study could be finally correlated, to assess if a direct link exists between these two kinds of circulating 
molecules. Indeed, animal and molecular studies showed that the ECS and the steroid system are 
interconnected, since important components of the ECS localize at all the three levels of the HPG and both 
systems have a key role in reproduction and sexual arousal. Moreover, it has been demonstrated in animals 
and humans a decrease of circulating testosterone under chronic THC treatments, results that were also 
confirmed in animals by chronically administering AEA.  
With our study it will be possible to find out whether a correlation exists between circulating androgens 
and ECs, and if this correlation can be altered by body weight loss or other obesity-related parameters.  
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V. Materials and Methods 
 
Va. Chemicals 
Pure standards of endocannabinoids AEA, 2AG, PEA and OEA and ISTD d4-AEA, d5-2AG, d4-PEA and d2-OEA 
were from Cayman Chemical, Ann Arbor, MI. Pure standard and ISTD of testosterone and DHEA were from 
Sigma-Aldrich, St. Louis, MO. 
 
Vb. Patients 
i. Recruitment 
So far, 12 obese patients (4 males and 8 females) out of 20 have completed the study. Subjects were 
recruited, after previous informed consent, at the CHU Haut Leveque in Pessac. The inclusion criteria were 
the following: 
- Age between 18 and 60 years; 
- Severe obesity with a BMI > 40 kg/m2 or BMI > 35 kg/m2 with associated obesity complications; 
- Commitment for a prolonged post-operative follow-up; 
- Effective contraception for pre-menopausal women. 
The exclusion criteria were the following: 
- Psychosis, severe depression or anxiety; 
- Drugs addiction, tobacco addiction or chronic alcoholism; 
- Associated pathologies involving a short-term prognosis; 
- Patients without an adequate family or social support; 
- Short-term pregnancy purpose; 
- Presence of THC in urine. 
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For the inclusion, the metabolic phenotype was evaluated measuring weight and height for BMI 
assessment, waist circumference, concentration of fasting insulin, HbA1C, lipid profile (HDL cholesterol, 
triglycerides and LDL cholesterol) and liver enzymes. Visceral adiposity was measured with computed 
tomography (CT scan). Pre-operative patient characteristics are summarized in table 3.1. 
 
 
Sex 8 Females/4 Males 
Age (years) 39,92 ± 3,20 
Body weight (kg) 136,8 ± 7,09 
BMI (kg/m2) 47,67 ± 1,65 
 
 
Table 3.1: Pre-operative patients characteristics. 
 
Behavioral phenotype was evaluated for each patients before the surgery, one month after the surgery and 
six months after the surgery using the French version of the Beck depression questionnaire to measure and 
exclude severity of depression, the Three Factor Eating Questionnaire to assess the eating behavior, the 
Orwell 1997 questionnaire for the quality of life and the Temperament and Character Inventory for the 
personality evaluation.  
 
ii. Hospitalization 
Based on inclusion and exclusion criteria, 12 patients have been so far selected. These patients have been 
hospitalized, pre-operative parameters were assessed and the surgery was scheduled. 48 hours before the 
surgery, the blood withdrawals for the first time point of the study were carried on. Patients were 
hospitalized again one week, three weeks, one month and six months after the surgery to receive routine 
post-operative controls. One month and six months after the surgery were carried out other blood 
withdrawal for the second and third time point of the study. 
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Vc. Blood sampling  
Blood withdrawals for ECs measurement were performed during different hours of the day at three 
different stages of the study: before the RYGB, one month after the surgery and six months after the 
surgery (figure 3.10). The first blood withdrawal (h: 9:00) was used to assess fasting circulating ECs and 
androgens concentrations. Following blood withdrawals were performed at 10:00, 11:00, and 11:30. At 
12:00 patients were exposed to the food. At 12:20 the meal started and finished at 12:40. Other blood 
withdrawals were performed at the end of the first portion, at the end of the meal and 60, 120 and 180 
minutes after the meal. The food was standardized for all the patients: each portion was 150gr of pasta 
served with 5gr of butter and 10 gr of grated cheese (265 kcal/portion). Blood was collected in heparin 
tubes and directly centrifuged at 2000 x g for 10 minutes at 4°C immediately after the withdrawal. Plasma 
was stored at -80° until the analysis. 
 
    
 
 
Figure 3.10: Design of the study. In three different stages (before the surgery, one month after the surgery and six 
months after the surgery) ten blood withdrawal were performed all over the day. Arrows indicate the phases of the 
meal: exposure to the food (1), meal start (2), end of the first portion (3) and end of the meal (4).  
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Vd. Endocannabinoids measurements  
ECs measurement still represents an analytical challenge. These molecules are present at very low 
concentrations, especially in plasma, and their lipid nature makes the extraction and quantification even 
more problematic. Early quantification methods were developed between the end of 90s and the beginning 
of 2000s using GC/MS mainly to quantify these compounds in mice brain regions200-201, but these methods 
were often laborious, since lipid molecules require derivatization to be analyzed with GC, and time 
consuming. In the last years, giving the increasing importance of the ECS in different clinical and research 
fields and particularly the emerging role of circulating ECs in human obesity, several more sensitive, fast 
and specific quantification methods were developed using LC-MS/MS202-203. This technique offers the best 
versatility, reliability, sensitivity and specificity required to measure these lipid analytes at very low 
concentrations. However, a dramatic discrepancy currently still exists between plasma ECs values found 
from different authors and research laboratories. It was shown that several different conditions could 
influence ECs concentrations and probably they represent the reasons behind the inconsistency of the 
values described so far203-204. Therefore, a precise standardization of blood withdrawal parameters, samples 
storage, laboratory materials, analytes extraction and LC-MS/MS analysis conditions, as well as a highly 
experienced staff, is required to avoid pitfalls that can affect ECs concentrations and to preserve the 
accuracy of the analytic method. 
The LC-MS/MS method used for the ECs quantification in this thesis was previously developed at the 
Analytical Chemistry Platform of the Neurocentre Magendie INSERM U862 in Bordeaux.  This method was 
validated following the FDA guidelines for bioanalytical method validation45 for four analytes: AEA, 2AG, 
PEA and OEA, providing an adequate sensitivity and specificity to obtain accurate and precise ECs 
quantification in human plasma22. 
Endocannabinoids extraction. Lipids extraction was performed with a liquid-liquid method (LLE) modified 
from the Folch method. 1 ml of plasma was homogenized with chloroform/methanol/Tris-HCl 50 mM pH 
7.5 (2:1:1, v/v) containing ISTD. After liquid-liquid extraction, the organic phase was transferred in screw-
cap Pyrex tubes and dried under a gentle stream of nitrogen. The dried lipid extracts were then pre-purified 
by open bed chromatography on silica columns. After the sample load, a first washing step was performed 
with chloroform/methanol 99:1 while the eluting step was with chloroform/methanol 9:1. The eluted 
fractions transferred in 1,5 ml eppendorf were finally dried under nitrogen, reconstituted in 65 l of 
methanol and transferred in autosampler vials for the LC-MS/MS analysis22. 
Liquid chromatography. Chromatographic analysis was performed with a Surveyor LC Pump Plus apparatus 
(Thermo-Scientific, Waltham, MA, USA). Analytes separation was achieved using an analytic column 
Supelco Discovery C18 15 cm x 4,6 mm x 5 m, a reverse phase analytic column with a non-polar stationary 
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phase suitable for lipid analytes such as ECs, equipped with a column-guard Phenomenex Analytical Guard 
Cartridge C18 4 x 3 mm; both analytic column and guard-column were kept in the column oven set at 40°C. 
The chromatographic separation for AEA, 2AG, PEA and OEA was achieved using 1ml/min polar mobile 
phases (A: H2O 100% and B: methanol with 0,1% of acetic acid) usually adequate for reverse phase 
chromatography, and an isocratic gradient (15% A, 85% B), suitable for compounds with similar polarity, 
with excellent resolution. The overall chromatographic run was 25 minutes.  
Mass spectrometry. Mass spectrometry analysis was performed with a TSQ Quantum Access triple 
quadrupole instrument (Thermo-Scientific, Waltham, MA, USA). Eluted analytes carried from the analytical 
column outflow were ionized using an APCI ionization source, the most suitable to ionize analytes in this 
range of molecular weight and to use a mobile phase flow of 1 ml/min, operating in positive ion mode at a 
temperature of 350°C. The ionization nebulizer gas was nitrogen, while the collision gas for analytes 
fragmentation during the MS/MS analysis was pure argon. All the precursor ions, product ions and collision 
energy previously optimized for each analyte are summarized in table 3.2. Mass spectrometer operated in 
SRM mode. 
Quantification. Stock solutions and working solution were prepared for each analyte in methanol and 
stored at -20°C. A linear six-points calibration curve was prepared from the working solutions ranged from 
0.15 pmol to 7,5 pmol for AEA and from 1,5 pmol to 75 pmol for 2AG, PEA and OEA. The isotopic dilution 
quantification method by linear regression, described in the former chapter, was the chosen quantification 
mode. 
Compound Molecular 
weight 
Precursor 
ion (m/z) 
Product ion 
(m/z) 
Collision 
energy (eV) 
AEA 347,5 348,2 287,05 13 
d4-AEA 351,6 352,2 287,12 14 
2AG 378,6 379,2 287,01 14 
d5-2AG 383,6 384,2 287 16 
PEA 299,5 300,2 62,35 16 
d4-PEA 303,5 304,2 62,32 16 
OEA 325,5 326,2 62,2 18 
d2-OEA 327,5 328,2 62,29 18 
 
Table 3.2: Molecular parameters used for the LC-MS/MS analysis. 
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Ve. Androgens measurements  
Androgen quantification was performed with a GC/MS method previously developed and validated205-206 
and routinely used at the Analytical Chemistry Platform of the Neurocentre Magendie INSERM U862 in 
Bordeaux. Despite LC-MS/MS is becoming more used in clinical and research laboratories for steroids 
quantification, GC/MS represents still the gold standard technique for these hormones in the clinical 
routine. 
Steroids extraction. Extraction of steroid was performed with a SPE followed by derivatization. ISTD were 
added to 300 l of plasma then mixed with 500 l of methanol/H2O (75/25, v/v) and 500 l of pure 
methanol. After centrifugation (10000 rpm, 10 min, 4°C) supernatants were transferred in glass tubes, 
partially dried under a stream of nitrogen and diluted in 2,5 ml of methanol/H2O (5/95, v/v). Steroids were 
extracted with SPE using reverse-phase Bond Elut C18 100mg 3 ml cartridges (Agilent, France) with 
following steps:  
- activation of C18 cartridges with 2 ml of methanol; 
- washing with 2 ml of methanol/H2O (5/95, v/v); 
- samples loading; 
- washing with 2 ml of methanol/H2O (5/95, v/v); 
- second washing with 2 ml of methanol/H2O (50/50, v/v) 
The steroid fraction was finally eluted with methanol (2 ml) into screw-cap pyrex tubes and evaporated to 
dryness at 50°C under a nitrogen stream to prepare for derivatization205-206. 
Derivatization. The derivatization phase, as explained in the former chapter, is required in GC/MS analysis 
to make compounds more volatile. Plasma dried extracts were derivatized by a two-step procedure. First, 
pentafluorobenzyloxime was added to favor the negative chemical ionization detection. After 1 hour 
incubation at 70°C, trimethylsilyl was added to each sample to reach sensitivity, selectivity and 
reproducibility for the simultaneous detection of the analytes. Samples were incubated at 70°C for 20 
minutes, transferred in autosampler vials and then injected in the GC/MS system205-206 (figure 3.11). 
GC/MS analysis. 1 l of derivatized samples were injected into a GCMS-QP2010 mass spectrometer 
(Shimadzu Corporation, Kyoto, Japan) through an autosampler. Analytes separation was achieved using a 
15 m Rtx-5Sil MS W/Integra Guard capillary column (Restek, France) with a 0.25 mm inside diameter and 
0.1 m film thickness. The carried gas was ultra-high pure helium (Linde Gas, France) at linear velocity (60 
cm/s). The employed injector temperature was 260°C and splitless mode was used for 0,5 minutes after the 
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injection. Capillary column temperature was maintained at 160°C for 1 minute. One minute after the 
samples injection column oven was warmed at 230°C with a rate of 60°C/min; temperature was then raised 
to 260° at a rate of 4°C/min and then to 290°C at 60°/min. Transfer-line temperature was kept at 290°C. 
The total chromatographic run was 15 minutes. 
Analytes ionization was performed with negative ion chemical ionization mode. Ion source temperature 
was 200°C and the ion source pressure was 0,7-0,8 Torr; methane (research grade 5.0, 99.9995%; Air 
Products, France) was used as reactant gas. Emission current was set at 60 μA and electron energy was 70 
eV. Mass spectrometer operated in SIM mode.  
Quantification. Stock solutions and working solution were prepared for each analyte in methanol and 
stored at -20°C. BSA 4% was used as matrix for a seven-point calibration curve ranging from 0,5 to 32 pg for 
each analytes. The pure BSA solution represented the “zero point”. SPE procedure described above was 
performed for each calibration curve point and the zero point. The isotopic dilution quantification method 
by linear regression was the chosen quantification mode.  
 
 
 
Figure 3.11: Steroids derivatization model. 
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Vf. Anthropometric and biochemical measurements  
Patients weight was controlled with a balance having a precision of 0,1 kg and height with a stadiometer 
with an accuracy of 0,5 cm. Waist circumference was measured between the upper iliac spines and the last 
ribs with a measuring tape.  
 
Vg. Statistics  
Data analysis was performed with GraphPad Prism 5 program. Results are expressed by mean ± SEM. Area 
under the curve (AUC) was calculated using the trapezoidal method to quantify changes of ECs levels in the 
kinetics. Data were analyzed with One Way ANOVA (fasting ECs, fasting androgens, AUC) or Two Way 
ANOVA (kinetics); performed post-test was Tukey. Mean differences were considered statistically 
significant when p<0,05 (*p<0,05; **p<0.005; ***p<0.0005).  
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VI. Preliminary results 
The initial project was designed to include 20 patients. Considering surgery, hospitalization and follow-up 
duration, estimated project time was two years. At the present moment, the results presented in this thesis 
concerning ECs measurements are relative to 12 patients out of 20 who completed the study, while 
androgens measurements were carried out so far for 2 out of 4 male patients. 
 
VIa. Patients weight loss achievement 
Pre-surgery patients body weight was on average 136,79 ± 7,09 kg; one month after the surgery patients 
body weight on average was 125,3 ± 6,60 kg while six months after the surgery it was 106,7 ± 7,01 kg 
(figure 3.12). 
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Figure 3.12: Body weight changes for each patient, in detail (A). Changes of patients weight on average (B).  
 
Patients achieved a body weight loss of the 8,39 ± 0,42% of total body weight one month after the surgery 
and 22,38 ± 1,27% of total body weight six months after the surgery (figure 3.13). Different literature data 
concerning RYGB showed a body weight loss of 37% on average one year after the surgery111; therefore, 
since our patients lost more than 20% of the total body weight six months after the surgery, they are 
responding as expected to the treatment. 
                                                                                                                            
 
 
Figure 3.13: Patients body weight loss in percentage of total body weight. 
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As well as the body weight also the BMI was markedly reduced after the RYGB. Pre-operative BMI on 
average was 47,67 ± 1,65 kg/m2. After the surgery BMI was significantly reduced: 43,90 ± 1,51 kg/m2 one 
month after and 37,22 ± 1,56 kg/m2 six months after (figure 3.14).   
                                                                                                                                                             
 
 
 
 
 
Figure 3.14: BMI changes for each patient, in detail (A). Changes of patients BMI on average (B).  
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VIb. Circulating endocannabinoids levels in obese RYGB patients 
 
AEA. We observed that plasma AEA fasting levels showed a tendency to increase one month after the 
RYGB. Conversely, six months after, AEA circulating levels tend to decrease (figure 3.15).  
 
 
 
 
Figure 3.15: Overnight fasting AEA levels. 
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Analyzing AEA meal related kinetics we found the same tendency. One month after the RYGB subjects 
tended to have higher levels of circulating AEA. Differently, six months after the surgery AEA levels went 
back to pre-surgery values (figure 3.16 A-B), as demonstrated from the significant differences observed 
between the AUC (figure 3.16 C). At this time-point we observed also a tendency for AEA to increase 
right before the meal and decrease after the meal, showing kinetics similar to the normal weight 
subjects (figure 3.16 D). No correlations have been found between circulating AEA levels and BMI (figure 
3.17). 
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Figure 3.16: Whole daily dynamic AEA concentrations (A). In detail, AEA dynamic levels during the meal and relative AUC. 
Arrows indicate the phases of the meal 1: exposure to the food; 2: meal start; 3: end of the first portion; 4: end of the meal 
(B). Complete kinetics AUC (C). Meal window kinetics AUC (D). 
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Figure 3.17: Correlation between AEA circulating levels and BMI. 
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2AG. 2AG circulating fasting levels are not affected one month after the surgery; however, we observed a 
tendency of these values to increase six months after the surgery (figure 3.18). 
 
 
 
 
Figure 3.18: Overnight fasting 2AG levels. 
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We did not observe significant variations in the 2AG kinetics (figure 3.19 A-B-C-D), similarly to findings 
previously published21. Similarly, no correlation has been found between circulating 2AG and BMI (figure 
3.20). 
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Figure 3.19: Whole daily dynamic 2AG concentrations (A). In detail, 2AG levels during the meal and relative AUC. Arrows 
indicate the phases of the meal 1: exposure to the food; 2: meal start; 3: end of the first portion; 4: end of the meal (B). 
Complete kinetics AUC (C). Meal window kinetics AUC (D). 
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Figure 3.20: Correlation between 2AG circulating levels and BMI. 
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PEA. We did not observe significant differences one month after the surgery for fasting levels of PEA. 
Six months after the surgery there is a tendency to a decrease (figure 3.21). 
 
 
 
 
Figure 3.21: Overnight fasting PEA levels. 
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Circulating PEA levels are overall lower after 6 months compared to 1 month after the RYGB (figure 3.22 A-
B), as we found significant differences in the AUC (figure 3.22 C-D). No significant variations related to the 
feeding status have been observed as well as no correlation between plasma PEA levels and patients BMI 
was found (figure 3.23). 
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Figure 3.22: PEA concentrations across the day (A). In detail, PEA levels during the meal and relative AUC. Arrows indicate the 
phases of the meal 1: exposure to the food; 2: meal start; 3: end of the first portion; 4: end of the meal (B). Complete kinetics 
AUC (C). Meal window kinetics AUC (D). 
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Figure 3.23: Correlation between PEA circulating levels and BMI. 
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OEA. Differently from AEA, fasting circulating OEA levels showed a tendency to increase both one and six 
months after the RYGB compared to pre-operative levels (figure 3.24).  
 
 
 
 
Figure 3.24: Overnight fasting OEA levels. 
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Concerning the kinetics, while we did not find significant differences between before and 1 month after the 
GYBP, at 6 months subjects tend to have increased OEA levels, which decrease after the meal (figure 3.25). 
No correlation has been found between OEA levels and BMI (figure 3.26). 
 
 
 
 
 
151 
 
 
 
 
 
 
 
Figure 3.25: OEA concentrations across the day (A). In detail, OEA levels during the meal and relative AUC. Arrows indicate the 
phases of the meal 1: exposition to the food; 2: meal start; 3: end of the first portion; 4: end of the meal (B). Complete kinetics 
AUC (C). Meal window kinetics AUC (D). 
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Figure 3.26: Correlation between OEA circulating levels and BMI. 
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VIc. Circulating androgens levels in obese RYGB patients 
Testosterone. Testosterone overnight fasting circulating levels tend to increase one month after the 
surgery. Six months after the surgery we observed a further increase, at this time point testosterone 
plasma levels are significantly different from testosterone levels before the surgery (figure 3.27). 
 
 
 
Figure 3.27: Overnight fasting testosterone levels. 
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DHEA. Similarly, DHEA overnight fasting concentrations tend to increase after the surgery (figure 3.28). 
 
 
 
 
Figure 3.28: Overnight fasting DHEA levels. 
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VII. Discussion, conclusion and future perspective 
 
Currently, obesity is an important health threat worldwide since it leads to fatal co-morbidities and a 
consequent reduction of life-span4. Apart from the behavioral therapy, including diet, exercise and 
psychological support, two therapeutic approaches are available for the management of obesity: drug 
therapy and bariatric surgery. However, only one drug is currently available for the pharmacological 
therapy of this condition180. Bariatric surgery is currently the most effective anti-obesity long-term 
treatment in reducing body weight and obesity related co-morbidities. The most performed type of 
bariatric surgery is the RYGB23, since it ensures the best body weight loss results and the less amount of 
body weight regain. Furthermore, patients undergoing this surgery present a surprisingly high percentage 
of T2DM remission, approximately the 80% of subjects111. Despite this phenomenon has been extensively 
examined, the molecular and physiological mechanisms underlying this remission are still poorly 
understood207. To improve the knowledge about effects of anatomical and physiological changes induced 
by RYGB, new target systems must be investigated207.  
For this purpose, we analyzed for the first time potential changes induced by RYGB on circulating ECs and 
also the recovery of normal androgens concentrations after this surgery, already shown by some authors115-
117.  
It is well known that the ECS is directly involved in food intake and energy balance11-14; this relationship has 
been widely investigated in animals15-16 while few studies were carried out so far in humans. After the 
withdrawn from the market of the CB1 antagonist anti-obesity drug Rimonabant189, it was clear that 
knoweldge about the role of the ECS in human physiology was lacking. Approximately twenty years ago the 
first methods were developed to measure ECs in animal tissues200 with chromatography coupled mass 
spectrometry. At that time, development of this technique was an epochal change for the emerging field of 
ECS research. Traditional analytical techniques so far employed were not suitable to accurately measure 
these molecules, since they are present at very low concentrations and their lipid nature make their 
isolation and precise quantification even more complicated. This revolutionary technical progress allowed 
improving new knowledge about ECS. 
Chromatography tandem mass spectrometry methods were recently optimized to measure circulating ECs 
in human plasma208-209. During the last decade, several methods were developed and validated, becoming 
more sensitive and accurate22-202-203. So far, three main evidences have been found regarding circulating ECs 
in humans: first, their levels are higher in obese patients than in normo-weight subjects, suggesting that 
this up-regulation is related to obesity17-18. Second, after diet-induced weight loss, plasma ECs levels are 
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reduced21, further confirming the direct relationship between high ECs in plasma and obesity. Third, the EC 
AEA shows a preprandial rise and a postprandial decrease in plasma, therefore it is likely that this molecule 
is involved in mechanisms underlying food intake22. However the role of plasma ECs is still not clear; some 
authors hypothesized that since ECs are local mediators, this circulating fraction, widely less abundant than 
ECs found in tissues, represents a “spill-over” from tissues rather than a biologically active fraction140.  
We therefore designed a project to analyze the involvement of the ECS in weight loss induced by the RYGB. 
We measured plasma concentrations of AEA, 2AG, PEA and OEA, with a previously developed and validated 
LC-MS/MS method22 at the analytical chemistry platform of the Neurocentre Magendie in Bordeaux, in 12 
obese patients (BMI > 40 kg/m2 or BMI > 35 kg/m2 with obesity associated complications) recruited at the 
CHU Haut Leveque in Pessac, undergoing a RYGB intervention. Blood withdrawals were performed at three 
different stages of the study: before the surgery, one month after the surgery and six months after the 
surgery. To evaluate both basal and dynamic ECs levels, a first blood withdrawal was performed in the 
morning during fasting state; other blood withdrawals were performed at h. 10:00, 11:00, 11:30. At h. 
12:00 patients were exposed to the food and another blood sampling was performed. At h. 12:20 the meal 
started and further blood withdrawals were performed at the end of the first portion, at the end of the 
meal and 60, 120 and 180 minutes after the meal.  
Our results confirm data reported in literature concerning the efficacy of the RYGB. Our patients lost on 
average 8,39 ± 0,42% of total initial body weight one month after the surgery and 22,38 ± 1,27% of their 
total initial body weight six month after the surgery. Several authors reported an average weight loss of 
approximately 37% of total initial body weight after one year111. Considering the percentage of body weight 
loss reached by our patients six month after the intervention, we can confirm that they are responding very 
well to the surgery. Similarly, average BMI decreased from a pre-surgery 47,67 ± 1,65 kg/m2 to 37,22 ± 1,56 
kg/m2 six months after.  
Concerning circulating ECs, one month after the surgery we observed a tendency of AEA fasting 
concentrations to increase, despite the weight loss. Six months after, when patients achieved a further 
weight loss, AEA fasting levels tended to decrease as compared to measurements carried out one month 
after the RYGB. In addition, found that plasma AEA changes were statistically significant across the day. We 
observed also a tendency for plasma AEA to increase right before the meal and decrease after the meal 6 
months after RYGB, showing a profile more similar to normal weight subjects. These AEA changes may 
seem in contrast with the documented ECs decrease after diet-induced weight loss21. The different method 
used to achieve the weight loss may explain this difference: RYGB generates a new anatomy of the GI 
system in which the stomach is reduced and some parts of the intestine, such as duodenum and part of 
jejunum111, are excluded in order to completely avoid contact with nutrients. Evidence from animal studies 
highlighted an increase of AEA exactly in the duodenum during fasting164, suggesting a different regulation 
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of AEA peripheral production during this condition. It is therefore likely that the duodenum exclusion 
induced by the surgery can be considered as a continuous fasting state, leading to local AEA production.  
Another hypothesis that could explain AEA increased concentrations one month after the surgery is an 
increased lipid mobilization after gastric bypass, which was found by Kullberg and co-workers210. In this 
study, the authors analyzed two groups of patients achieving a similar weight loss with two different 
strategies: RYGB or life-style modifications. They measured visceral and abdominal subcutaneous fat depots 
finding an increased percentage of fat loss in the surgery group. Similarly, the percentage of total body fat 
in the surgery group was lower than in the life-style modifications group210. Giving that ECs are derived 
from lipids, it is likely that the increased lipid mobilization could lead to increased circulating ECs. However, 
if this was true, all ECs should change in a comparable manner. While, we observed that the RYGB did not 
lead to significant alterations in 2AG, neither under fasting nor during the meal, confirming results 
previously published22.  
We found a tendency to decreased PEA concentrations six months after the RYGB. Similarly, a significant 
difference between in the AUC one and six months after the RYGB was observed. The involvement of PEA in 
mechanisms underlying food intake and obesity development has never been confirmed; on the other 
hand, it has been shown that PEA is involved in inflammatory states176. It is possible that decrease observed 
six months after the surgery depends on a decreased inflammatory state. Further analysis, such as the 
evaluation of inflammatory markers at the three study time-points, will elucidate the observed altered 
concentration.   
On the other hand, several animal studies confirmed the involvement of OEA in food intake173-175. Similar to 
AEA, OEA concentrations increase one month after RYGB; conversely, its plasma levels further rise also six 
months after the surgery. Furthermore, as well as AEA, OEA presents a pre-prandial peak and a more 
evident post-prandial decrease after weight loss, six months after the surgery. First studies identified OEA 
as a potential anorexic molecule, decreasing food intake when injected in animals173-175. Our data, on the 
contrary, shows that OEA may have an opposite role in human plasma, increasing during a fasting condition 
and decreasing after a meal. Noteworthy, in both the two studies carried out so far investigating OEA in 
plasma, higher concentrations were found in diabetic over-weight172 patients and over-weight sleep apnea 
patients177; moreover, in the first study the authors found also an OEA post-prandial decrease172, consistent 
with our data. 
Probably, OEA has a different regulation and a different role in plasma and in tissues; further studies are 
required to confirm the role of plasma OEA in food intake regulation in humans.  
In conclusion, body weight loss achieved with bariatric surgery may have a different impact on the ECS 
compared to diet-induced weight loss, likely due to specific anatomic and metabolic changes induced by 
158 
 
the surgery. An accurate analysis of these changes and further studies are required to relate these 
alterations to important peripheral mechanisms in which the ECS has been shown to have a role. 
 
The relationship between low androgens circulating levels and obesity in men is still not clear. Low 
testosterone is predictive of visceral obesity development87 while, on the other hand, it has been clearly 
shown that visceral obesity leads to hypogonadism and consequently to low androgens circulating levels10-
87. In the study described in the former chapter, we found highly statistical significant differences between 
testosterone concentrations in three populations: normo-weight, over-weight and obese, confirming that 
testosterone levels are inversely proportional to BMI. In this second part of the project, we measured 
testosterone and DHEA in two male obese patients to test whether normal circulating values of these two 
steroid hormones are improved after the weight loss surgery-induced. Few studies have been carried out 
so far to verify the recovery of sexual steroid hormones in men after RYGB. One reason could be the fact 
that patients undergoing bariatric surgery are mainly women211. Data obtained so far are sufficiently 
consistent to affirm that RYGB induces an increase in androgen plasma concentrations. However, they will 
need to be further confirmed and strengthened by increasing the number of studied subjects. 
We found a significant increase of testosterone plasma levels six months after the surgery, when patients 
lost approximately 20% of the initial body weight. The same tendency has been confirmed for DHEA, 
although without statistical significance. At this point, we can confirm what was previously observed by 
other authors: weight loss induced by RYGB leads to increased androgens circulating levels and possibly to 
an amelioration of the HPG functionality. 
 
Concerning both ECs and androgens measurements, we found several changes but few of them reached 
the statistical significance. In this case, the determining factor could be the relative small number of 
subjects (12 for ECs measurements, 2 for androgen measurements). When recruitment, follow-up and 
measurements will be completed and we will analyze data from 20 patients, we may have more robust 
results and therefore provide also a correlation between the circulating levels of these two molecules 
groups. 
Furthermore, we are also recruiting another group of obese subjects who will undergo life-style 
modifications in order to reach the same body weight loss than our RYGB patients. We will then compare 
ECs and androgens circulating changes in the two groups of patients to better distinguish the specific role 
of the surgery in these modifications. 
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In conclusion, the RYGB is currently one of the most effective anti-obesity therapies, achieving a fast and 
durable weight loss and generating considerable ameliorations on obesity related co-morbidities. The new 
anatomy may contribute to the particular effects of this surgery, influencing different biological systems, 
such as the ECS and the HPG, that are known to play a role in the pathophysiology of obesity. Further 
studies are required to further characterize the underlying mechanisms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
160 
 
GENERAL DISCUSSION 
The development of LC-MS/MS has been a remarkable turning point in the history of analytical chemistry, 
allowing the precise identification and quantification of molecules with great improvements in 
experimental and clinical practice. This technique can be easily introduced in the clinical routine to improve 
worth and credibility of quantitative tests, essential for accurate diagnoses and follow-up of a high number 
of pathologies. Similarly, LC-MS/MS may improve different fields of medical research, allowing us to better 
understand the molecular mechanisms underlying physiological and pathological processes still unclear.  
The first study carried out in this thesis has been the comparison between our LC MS/MS method 
developed for steroids quantification and classic immunoassays. This study put in evidence the already 
known limits of the traditional techniques. Furthermore, we provided a preliminary redefinition of steroids 
circulating intervals in healthy subjects. The need to redefine normal ranges is urgent for several classes of 
molecules, since the intervals currently used in the clinical practice have been defined more than 50 years 
ago with quantification methods that nowadays show analytical limits. The employment of LC-MS/MS can 
be precious also to correctly review reference intervals, since the short analysis times allow to easily 
perform large population screening. 
In this thesis this technique has been also used to clarify changes of two important classes of compounds, 
steroid hormones and ECs, in relation to obesity, currently one of the worldwide relevant health issues. 
Alterations of these two systems related to obesity are still poorly understood. Especially the precise 
relationship “cause-effect” is not clear: experimental evidence so far led to highlight a bidirectional link, 
which must be elucidated. In the study carried out in the first part of the thesis we found significantly lower 
circulating levels of testosterone in obese patients compared to normo-weight patients. Testosterone can 
be the classic example of a bidirectional link with obesity: low testosterone is predictive of visceral obesity 
development and, on the other hand, visceral obesity leads to decreased testosterone levels. In the second 
part of the thesis we measured testosterone in obese patients before and after a weight loss induced by 
gastric bypass surgery: six months after the surgery circulating levels of this hormone increase, suggesting 
that the weight loss is able to restore them. In these patients we evaluated also plasma levels of ECs, lipid 
molecules circulating at very low concentrations, problematic to measure until the development of LC-
MS/MS. Our preliminary data showed a particular effect of the RYGB surgery on the ECS giving us important 
clues about the modulation of this system in the periphery. 
An accurate and trustworthy quantification of these compounds, especially for ECs and steroids circulating 
at very low concentrations, can lead to better understand the role of these two groups of molecules in the 
development of obesity or to address future therapeutic strategies. The advantages that this technique 
may produce for the whole scientific progress were unimaginable only fifty years ago. 
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